<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005016.pub2" GROUP_ID="RENAL" ID="432704022920394619" MERGED_FROM="" MODIFIED="2016-02-01 02:35:47 +0000" MODIFIED_BY="Narelle Willis" REVIEW_NO="004" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2016-02-01 13:33:46 +1100" MODIFIED_BY="Narelle Willis">
<TITLE>High-flux versus low-flux membranes for end-stage kidney disease</TITLE>
<CONTACT>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>giovanni.strippoli@uniba.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-02-01 13:33:46 +1100" MODIFIED_BY="Narelle Willis">
<PERSON ID="19787" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Suetonia</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Palmer</LAST_NAME>
<SUFFIX>MBChB</SUFFIX>
<POSITION/>
<EMAIL_1>suetonia.palmer@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2>PO Box 4345</ADDRESS_2>
<CITY>Christchurch</CITY>
<ZIP>8140</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 3 364 0903</PHONE_1>
<PHONE_2/>
<FAX_1>+64 3 3253368</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19790" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kannaiyan</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Rabindranath</LAST_NAME>
<SUFFIX>MRCP</SUFFIX>
<POSITION>Consultant Nephrologist</POSITION>
<EMAIL_1>ksrabi@yahoo.co.uk</EMAIL_1>
<EMAIL_2>samuelrabi@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Renal Unit</DEPARTMENT>
<ORGANISATION>Waikato District Hospital</ORGANISATION>
<ADDRESS_1>Pembroke Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP>3240</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4552" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1>
<EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2>
<URL>http://kidneyandtransplant.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Edward Ford Building A27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8062" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Roderick</LAST_NAME>
<SUFFIX/>
<POSITION>Reader in Public Health</POSITION>
<EMAIL_1>pjr@soton.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Medicine, Community Clinical Sciences</DEPARTMENT>
<ORGANISATION>University of Southampton</ORGANISATION>
<ADDRESS_1>Level C, South Academic Block</ADDRESS_1>
<ADDRESS_2>Southampton General Hospital</ADDRESS_2>
<CITY>Southampton</CITY>
<ZIP>S016 6YD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 01703 796532</PHONE_1>
<PHONE_2/>
<FAX_1>+44 01703 796530</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2E96EA8782E26AA2000C5DBB29655CBD" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Francesco</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Locatelli</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Department</POSITION>
<EMAIL_1>nefrologia@ospedale.lecco.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Nephrology and Dialysis Department</DEPARTMENT>
<ORGANISATION>Ospedale A Manzoni</ORGANISATION>
<ADDRESS_1>Via Dell'eremo 9/11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lecco</CITY>
<ZIP>23900</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 0341 489850</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>giovanni.strippoli@uniba.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-11-12 14:21:48 +1100" MODIFIED_BY="Gail Higgins">
<UP_TO_DATE>
<DATE DAY="18" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2012"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2016-01-20 15:32:36 +1100" MODIFIED_BY="Gail Y Higgins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-01-20 15:32:36 +1100" MODIFIED_BY="Gail Y Higgins">
<DATE DAY="20" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>Amended study name House 2000 to House 1999</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-05-02 14:08:37 +1000" MODIFIED_BY="Narelle S Willis"/>
<SOURCES_OF_SUPPORT MODIFIED="2011-03-23 13:39:48 +1100" MODIFIED_BY="Suetonia Palmer">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2011-03-23 13:39:48 +1100" MODIFIED_BY="Suetonia Palmer">
<SOURCE>
<NAME>National Kidney Research Fund</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-03-23 13:39:48 +1100" MODIFIED_BY="Suetonia Palmer">
<NAME>Consorzio Mario Negri Sud unrestricted grant from Amgen Dompe</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-02-01 13:34:38 +1100" MODIFIED_BY="Narelle Willis">
<SUMMARY MODIFIED="2012-04-24 15:28:55 +1000" MODIFIED_BY="Suetonia Palmer">
<TITLE MODIFIED="2012-03-27 12:32:43 +1100" MODIFIED_BY="Narelle S Willis">Does haemodialysis membrane type influence outcomes in people with kidney disease?</TITLE>
<SUMMARY_BODY MODIFIED="2012-04-24 15:28:55 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Haemodialysis removes excess fluid and metabolic products from the blood in people who have limited kidney function. Haemodialysis membranes are classified as high-flux or low-flux based on their ability to remove fluid and molecules. It has been suggested that removal of larger solutes across high-flux haemodialysis membranes may better reflect normal kidney function and improve clinical outcomes. To investigate this issue, we analysed 33 studies that involved 3820 people which directly compared haemodialysis using high-flux or low-flux membranes.</P>
<P>We found that high-flux dialysis membranes reduced deaths from heart and circulatory (cardiovascular) causes by 17%, but did not reduce overall risk of death. This means that if 100 people were treated with high-flux dialysis for approximately two years, three deaths from cardiovascular causes may be prevented in people who need long-term haemodialysis.</P>
<P>Based on the available evidence, we could not be certain that the type of membrane flux involved had any effect on deaths from infection, hospital admissions, joint problems due to long term dialysis, quality of life, or kidney function in people on long-term haemodialysis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-08-15 14:45:01 +1000" MODIFIED_BY="Suetonia Palmer">
<ABS_BACKGROUND MODIFIED="2012-03-16 12:07:25 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Clinical practice guidelines regarding the use of high-flux haemodialysis membranes vary widely. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-07-18 16:32:52 +1000" MODIFIED_BY="Suetonia Palmer">
<P>We aimed to analyse the current evidence reported for the benefits and harms of high-flux and low-flux haemodialysis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-08-15 14:45:01 +1000" MODIFIED_BY="Suetonia Palmer">
<P>We searched the Cochrane Renal Group's Specialised Register (July 2012) through contact with the Trials Search Co-ordinator using search terms relevant to this review. The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from the following sources:Quarterly searches of the Cochrane Central Register of Controlled Trials CENTRAL, weekly searches of MEDLINE OVID SP, handsearching of renal-related journals and the proceedings of major renal conferences, searching of the current year of EMBASE OVID SP, weekly current awareness alerts for selected renal journals and searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-03-28 15:45:46 +1100" MODIFIED_BY="Suetonia Palmer">
<P>We included randomised controlled trials (RCTs) that compared high-flux haemodialysis with low-flux haemodialysis in people with end-stage kidney disease (ESKD) who required long-term haemodialysis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-07-26 11:19:01 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Data were extracted independently by two authors for study characteristics (participants and interventions), risks of bias, and outcomes (all-cause mortality and cause-specific mortality, hospitalisation, health-related quality of life, carpal tunnel syndrome, dialysis-related arthropathy, kidney function, and symptoms) among people on haemodialysis. Treatment effects were expressed as a risk ratio (RR) or mean difference (MD), with 95% confidence intervals (CI) using the random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-07-26 11:18:13 +1000" MODIFIED_BY="Suetonia Palmer">
<P>We included 33 studies that involved 3820 participants with ESKD. High-flux membranes reduced cardiovascular mortality (5 studies, 2612 participants: RR 0.83, 95% CI 0.70 to 0.99) but not all-cause mortality (10 studies, 2915 participants: RR 0.95, 95% CI 0.87 to 1.04) or infection-related mortality (3 studies, 2547 participants: RR 0.91, 95% CI 0.71 to 1.14). In absolute terms, high-flux membranes may prevent three cardiovascular deaths in 100 people treated with haemodialysis for two years. While high-flux membranes reduced predialysis beta-2 microglobulin levels (MD -12.17 mg/L, 95% CI -15.83 to -8.51 mg/L), insufficient data were available to reliably estimate the effects of membrane flux on hospitalisation, carpal tunnel syndrome, or amyloid-related arthropathy. Evidence for effects of high-flux membranes was limited by selective reporting in a few studies. Insufficient numbers of studies limited our ability to conduct subgroup analyses for membrane type, biocompatibility, or reuse. In general, the risk of bias was either high or unclear in the majority of studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-07-18 16:38:52 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux haemodialysis may reduce cardiovascular mortality in people requiring haemodialysis by about 15%. A large well-designed RCT is now required to confirm this finding.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-02-01 13:34:38 +1100" MODIFIED_BY="Narelle Willis">
<BACKGROUND MODIFIED="2016-02-01 13:34:38 +1100" MODIFIED_BY="Narelle Willis">
<P>Dialysis is the mainstay of treatment for people with end-stage kidney disease (ESKD). Mortality rates relating to both cardiovascular and non-cardiovascular causes for people commencing haemodialysis is nearly 30 to 50 times that of the general population (<LINK REF="REF-de-Jager-2009" TYPE="REFERENCE">de Jager 2009</LINK>). However, recent evidence suggests that the high rates of mortality and hospital admission in people who need dialysis may be improving (<LINK REF="REF-USRDS-Annual-Report-2010" TYPE="REFERENCE">USRDS Annual Report 2010</LINK>). Numerous interventions, including statin therapy (<LINK REF="REF-_x0034_D-2005" TYPE="REFERENCE">4D 2005</LINK>; <LINK REF="REF-AURORA-2009" TYPE="REFERENCE">AURORA 2009</LINK>), epoetins targeting higher haemoglobin levels (<LINK REF="REF-Besarab-1998" TYPE="REFERENCE">Besarab 1998</LINK>), and dialysis dose (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>) have not been shown to improve all-cause mortality in people who need dialysis. Frequent haemodialysis (six times weekly) may offer improved survival rates compared with the current standard of three times weekly (<LINK REF="REF-Chertow-2010" TYPE="REFERENCE">Chertow 2010</LINK>); however, interventions that clearly reduce mortality in people on haemodialysis are urgently required.</P>
<P>In the absence of sufficient kidney function, haemodialysis removes accumulated water and metabolites from the blood across a semi-permeable dialysis membrane. The earliest haemodialysis membranes consisted of cellulose that was associated with an inflammatory response and had a small pore size, only allowing clearance of molecules smaller than 5000 Daltons into the dialysate. As dialysis membrane technology has improved, high-flux membranes with larger pore sizes have been developed to allow greater clearances of larger retention molecules with reduced induction of inflammatory mediators (improved biocompatibility) (<LINK REF="REF-Clark-1999" TYPE="REFERENCE">Clark 1999</LINK>; <LINK REF="REF-Woffindin-1988" TYPE="REFERENCE">Woffindin 1988</LINK>). The larger &#8220;middle&#8221; molecules cleared by high-flux membranes include the amyloidogenic beta-2 microglobulin and advanced glycation end products. While observational studies suggest high-flux haemodialysis is associated with lower mortality (<LINK REF="STD-Koda-1997" TYPE="STUDY">Koda 1997</LINK>; <LINK REF="REF-Port-2001" TYPE="REFERENCE">Port 2001</LINK>; <LINK REF="STD-Woods-2000" TYPE="STUDY">Woods 2000</LINK>) and dialysis-related amyloidosis (<LINK REF="STD-Chanard-1989" TYPE="STUDY">Chanard 1989</LINK>; <LINK REF="STD-Koda-1997" TYPE="STUDY">Koda 1997</LINK>; <LINK REF="REF-van-Ypersele-de-Strihou-1991" TYPE="REFERENCE">van Ypersele de Strihou 1991</LINK>) individual randomised controlled trials (RCTs) have not confirmed that high-flux haemodialysis improves clinical outcomes (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>). High-flux dialysis membranes have larger pore sizes that may increase transportation of dialysate impurities or contaminants from the dialysate to the bloodstream even when the dialysate quality complies with acceptable standards (<LINK REF="REF-Schiffl-2011" TYPE="REFERENCE">Schiffl 2011</LINK>), although some evidence suggests that high-flux membranes may actively absorb endotoxins and impede their back-transfer from dialysate into the bloodstream (<LINK REF="REF-Jaber-1998" TYPE="REFERENCE">Jaber 1998</LINK>; <LINK REF="REF-Lonnemann-1992" TYPE="REFERENCE">Lonnemann 1992</LINK>).</P>
<P>Clinical practice guidelines on dialysis membrane flux are variable (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The <LINK REF="REF-EBPG-2002" TYPE="REFERENCE">EBPG 2002</LINK> strongly recommend that high-flux haemodialysis should be used in all high risk patients, and given the small incremental cost, should be considered for people with ESKD starting haemodialysis (<LINK REF="REF-Tattersall-2010" TYPE="REFERENCE">Tattersall 2010</LINK>). The <LINK REF="REF-Renal-Association-2009" TYPE="REFERENCE">Renal Association 2009</LINK> guidelines suggest that high-flux dialysers be used instead of low-flux dialysers, and the Kidney Disease Outcomes Quality Initiative (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>) recommends that using poorly biocompatible, unmodified cellulose dialyser membranes for haemodialysis be discouraged. The Australasian guidelines make no recommendations about membrane flux, citing insufficient evidence (<LINK REF="REF-CARI-2005" TYPE="REFERENCE">CARI 2005</LINK>).</P>
<P>While individual studies suggest benefits for high-flux membranes on clinical outcomes in subgroups of patients on haemodialysis, particularly those with longer times on haemodialysis (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>) or higher comorbidity (<LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>), the overall efficacy and safety of high-flux compared with low-flux membranes for dialysis in all available RCTs remains uncertain.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-07-18 15:25:21 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Our objective was to determine if high-flux membranes improved clinical outcomes compared with low-flux membranes in people with ESKD who require long-term haemodialysis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-08-09 11:09:11 +1000" MODIFIED_BY="Suetonia Palmer">
<SELECTION_CRITERIA MODIFIED="2012-07-26 11:05:30 +1000" MODIFIED_BY="Suetonia Palmer">
<CRIT_STUDIES MODIFIED="2012-03-27 13:37:17 +1100" MODIFIED_BY="Suetonia Palmer">
<P>We sought randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) that compared high-flux with low-flux dialysis membranes for inclusion in this systematic review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-03-16 15:07:39 +1100" MODIFIED_BY="Suetonia Palmer">
<P>We included studies that enrolled adults who required long-term haemodialysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-06-26 15:45:12 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Our study inclusion criteria specified any (or several) high-flux haemodialysis membranes versus any (or several) low-flux haemodialysis membranes for one month or longer.</P>
<P>Where unspecified, membrane flux was classified as high- or low-flux based on ultrafiltration coefficient (kUF) (the rate at which water crosses the membrane at a given trans-membrane pressure) or beta-2 microglobulin clearance (<LINK REF="REF-FDA-1998" TYPE="REFERENCE">FDA 1998</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>). High-flux was defined as an ultrafiltration coefficient greater than 12 mL/h/mm Hg or beta-2 microglobulin clearance greater than 20 mL/min; and low-flux haemodialysis membranes were defined as having an ultrafiltration coefficient less than 12 mL/h/mm Hg or beta-2 microglobulin clearance less than 10 mL/min.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-07-26 11:05:30 +1000" MODIFIED_BY="Suetonia Palmer">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-06-26 18:59:16 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>All-cause mortality</LI>
<LI>Cause-specific mortality (cardiovascular mortality, infection-related mortality)</LI>
<LI>Hospitalisation (number of patients who were admitted to hospital, number of hospital admissions/patient/year, length of hospital stay (days)).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-07-26 11:05:30 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Infection requiring hospitalisation, parenteral antibiotic treatment or described as 'significant' in the included studies</LI>
<LI>Health-related quality of life</LI>
<LI>Predialysis (that is, from blood obtained before a dialysis session) beta-2 microglobulin concentration</LI>
<LI>Adequacy of dialysis measured either by Kt/V<SUB>urea</SUB> or urea reduction ratio (URR)</LI>
<LI>Dialysis-associated amyloid-related complications (carpal tunnel syndrome, dialysis-related arthropathy)</LI>
<LI>Withdrawal due to treatment inadequacy</LI>
<LI>Kidney function (e.g. residual renal function (RRF))</LI>
<LI>Lipid profile.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-08-09 11:06:55 +1000" MODIFIED_BY="Suetonia Palmer">
<ELECTRONIC_SEARCHES MODIFIED="2012-08-09 11:06:55 +1000" MODIFIED_BY="Suetonia Palmer">
<P>We searched the Cochrane Renal Group's Specialised Register (July 2012) through contact with the Trials Search Co-ordinator using search terms relevant to this review. The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from the following sources.</P>
<OL>
<LI>Quarterly searches of the Cochrane Central Register of Controlled Trials CENTRAL</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the specialised register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the 'Specialised Register' section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-06-09 14:38:10 +1000" MODIFIED_BY="Suetonia Palmer">
<OL>
<LI>Authors of studies identified as potentially eligible for inclusion were contacted both to clarify missing data or methodological details and to ask for additional published or unpublished studies.</LI>
<LI>Studies presented in conference proceedings were included.</LI>
<LI>Reference lists of previous reviews (including systematic reviews) and previous studies were included</LI>
<LI>Papers in languages other than English were included and translation facilities available from the Cochrane Collaboration were used as required.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-08-09 11:09:11 +1000" MODIFIED_BY="Suetonia Palmer">
<STUDY_SELECTION MODIFIED="2012-03-16 15:21:16 +1100" MODIFIED_BY="Suetonia Palmer">
<P>All titles and abstracts were independently assessed by two or more authors (KSR, AMM, SCP). Full papers were then obtained for those studies that might fulfil the inclusion criteria. At least two authors (KSR, AMM, SCP) independently assessed these studies to determine if they were eligible for inclusion. Disagreements were resolved by discussion with another author (GFMS).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-03-16 15:22:21 +1100" MODIFIED_BY="Suetonia Palmer">
<P>At least two authors (KSR, CB, SCP) extracted data independently. Discrepancies were resolved by discussion with another author (GFMS). When data were not reported or incomplete, study authors were contacted for clarification. When more than one report of a study was identified, reports were grouped and the publication providing the most data was designated as the primary reference. We took care not to duplicate data from multiple published sources of the same study.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-03-27 13:43:16 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Two authors assessed the risk of bias in the included studies using a standard checklist developed by the Cochrane Collaboration (including the domains of sequence generation, allocation concealment, blinding of patients, investigators and outcome assessors, analysis by intention-to-treat, whether incomplete data were addressed, freedom from selective reporting, and other biases). We did not use a summary scoring system to assess study risks of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-08-09 11:09:11 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Treatment effects were summarised as risk ratios (RR) for dichotomous outcomes or mean differences (MD) for continuous outcomes, together with 95% confidence intervals (CI), using a random-effects model to pool data (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). For dichotomous data (all-mortality, cardiovascular mortality, infection-related mortality, hospital admission, symptoms during dialysis, carpal tunnel syndrome, dialysis-related arthropathy, withdrawal due to treatment inadequacy) the RR was used together with 95% CI. For continuous data (Kt/V<SUB>urea</SUB>, URR, beta-2 microglobulin levels, serum cholesterol and triglycerides, health-related quality of life, and RRF), the MD was used.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2012-03-28 15:51:23 +1100" MODIFIED_BY="[Empty name]">
<P>Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. Additional unpublished data for outcomes or risks of bias were provided by the investigators of five studies and included in the analyses (<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>).</P>
<P>Evaluation of important numerical data, such as numbers of participants screened and randomised; intention-to-treat; as-treated and per-protocol population analyses were performed. Rates of attrition due to drop-out, loss to follow-up and withdrawal, were investigated. Issues of missing data and imputation methods (such as last-observation-carried-forward) were critically appraised (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-03-27 16:04:19 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-07-18 15:35:11 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Insufficient numbers of randomised studies were available to assess for publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-03-16 14:41:27 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Data were pooled using a random-effects model, but the fixed-effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-06-09 14:43:22 +1000" MODIFIED_BY="Suetonia Palmer">
<P>We could not perform additional planned subgroup analysis and random effects meta-regression to explore how study characteristics (membrane biocompatibility or reuse; comorbid conditions; and time on dialysis) might have influenced treatment effects due to the insufficient number of identified trials reporting each outcome (generally fewer than four).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-07-11 14:54:07 +1000" MODIFIED_BY="[Empty name]">
<P>We performed sensitivity analyses to explore the influence of the following factors on effect size:</P>
<UL>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis taking account of risk of bias, as specified;</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results; and</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<STUDY_DESCRIPTION MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<P>
<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2012-11-12 15:27:44 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Our search identified 1034 unique citations, of which 682 were excluded because they evaluated interventions that were not relevant to the review, were not clinical studies, or were not RCTs (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Full-text assessment of 352 potentially eligible citations identified 33 eligible studies (3820 participants) reported in 81 publications that were included in this systematic review. We identified one ongoing study which we will include in a future update (<LINK REF="STD-NCT00004285" TYPE="STUDY">NCT00004285</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<P>We could include 16 studies in the meta-analyses that involved 3221 participants (<LINK REF="STD-Ayli-2005" TYPE="STUDY">Ayli 2005</LINK>; <LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>; <LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>; <LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>; <LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>). The 17 remaining, generally smaller studies (total of 599 participants) were included, but not meta-analysed, because of a number of factors: relevant outcomes were not reported; studies were cross-over designs and did not provide data for the end of the first phase of treatment; or did not report data in an extractable format (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>; <LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>; <LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>; <LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>; <LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>; <LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>).</P>
<P>All 33 included studies compared high-flux with low-flux dialysis membranes in people who required chronic haemodialysis and were published between 1989 and 2010 (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Study size varied from 12 to 1846 participants; and follow-up ranged from one month to six years. Median follow-up was three months (interquartile range 2 to 12 months). Nearly two-thirds of studies (20/33) conducted follow-up over fewer than six months (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>; <LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>; <LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>; <LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>). A third of included studies (12/33) applied cross-over study designs (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>; <LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>; <LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>; <LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>). Overall, 28 studies focused on the effects of dialysis membrane flux on dialysis tolerance (4) (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>); beta-2 microglobulin, advanced glycation end product, or urea clearance (4) (<LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>); biocompatibility (3) (<LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>; <LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>); oxidative stress (2) (<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>); lipids (3) (<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>); haemoglobin (6) (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>; <LINK REF="STD-Ayli-2005" TYPE="STUDY">Ayli 2005</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>); homocysteine levels (2) (<LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>); RRF (2) (<LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>); visual-evoked potentials (1) (<LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>); or C-reactive protein (1) (<LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>).</P>
<P>Five studies (13%) evaluated patient-level clinical outcomes. Of these, <LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK> and <LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK> assessed dialysis-related arthropathy for six months and six years of follow-up respectively. Three studies primarily evaluated treatment effects on mortality: <LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK> followed up 54 participants for 12 months; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK> (1846 participants) was conducted over a mean of 4.48 years; and <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK> (Membrane Permeability Outcome) (738 participants) followed up participants for a minimum of three years.</P>
<P>High-flux membranes used in the studies generally consisted of polysulfone, polyacrylonitrile, polyamide, or polymethylmethacrylate (PMMA), although three studies evaluated high-flux cellulose or cuprammonium membranes (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>). Low-flux membranes were cuprophane or cellulose, although 12 generally more recent studies used low-flux polysulfone (<LINK REF="STD-Ayli-2005" TYPE="STUDY">Ayli 2005</LINK>; <LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>; <LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>); or polyamide (<LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>). Participants in the <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK> study were assigned to a variety of membrane types for both high-flux and low-flux treatment. The ultrafiltration coefficient or beta-2 microglobulin clearances of the high-flux and low-flux membranes were specified in 12 studies (<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>). <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK> specifically defined high-flux membrane as an ultrafiltration coefficient &gt; 14 mL/h/mm Hg and a mean beta-2 microglobulin clearance of &gt; 20 mL/min; and low-flux membrane as a mean beta-2 microglobulin clearance of &lt; 10 mL/min; whereas <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK> defined high-flux as a sieving coefficient for beta-2 microglobulin &gt; 0.6 and ultrafiltration coefficient &#8805; 20 mL/h/mm Hg and low-flux as a sieving coefficient of beta-2 microglobulin of 0 and an ultrafiltration coefficient &#8804; 10 mL/h/mm Hg. We identified seven studies that reported reuse of dialysis membranes (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>; <LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>); and 10 studies that permitted single use of dialysis membranes only (<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>; <LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>). The other included studies did not clearly report if membrane reuse was practised (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>Studies generally enrolled patients with a mean age of between 50 and 65 years. In the two larger studies (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>), participants were on average aged 57.6 and 59.8 years, respectively, which is similar to the average ages of US and European dialysis populations (<LINK REF="REF-Miskulin-2009" TYPE="REFERENCE">Miskulin 2009</LINK>). <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK> enrolled incident patients (on dialysis &#8804; 2 months).</P>
<P>The remaining studies included patients if they had been on dialysis for at least two months (<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>); three months (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>); six months (<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>) and 12 months (<LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>). Time on dialysis was not an eligibility criterion in the remaining 18 studies. The actual time on dialysis before enrolment varied widely: from 151 months reported by <LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK> in a study evaluating dialysis arthropathy; 44.4 months in <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; and one month in <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>. Patients with diabetes mellitus contributed to nearly half the population in two studies (1886 participants) (<LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>); from 25% to 50% of participants in two studies (69 participants) (<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>) between 0% and 25% in two studies (784 participants) (<LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>) and were specifically excluded in six small studies (177 participants) (<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>; <LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>). <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK> (30 participants) included only participants with diabetes mellitus.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-07-18 17:29:28 +1000" MODIFIED_BY="[Empty name]">
<P>After detailed full-text review we excluded 225 studies (270 reports) (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>) because:</P>
<UL>
<LI>was a description of a proposed study (1);</LI>
<LI>they were not an appropriate intervention (56);</LI>
<LI>did not include people who had chronic kidney disease (3);</LI>
<LI>did not measure a prespecified outcome (75);</LI>
<LI>were not randomised (72);</LI>
<LI>were of short duration (6), or</LI>
<LI>were reviews or commentaries (12).</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<P>Assessments of the risk of bias in the included studies are reported in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. In general, the risk of bias was either high or unclear in most studies.</P>
<ALLOCATION MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<UL>
<LI>Allocation concealment was adequate in only five studies (<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>); inadequate in two (<LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>) and unclear in the remainder.</LI>
<LI>Sequence generation methods were adequate in five studies (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>); inadequate in two (<LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>) and unclear in the remainder.</LI>
</UL>
</ALLOCATION>
<BLINDING MODIFIED="2012-07-11 14:02:36 +1000" MODIFIED_BY="[Empty name]">
<P>Participants were blinded to treatment allocation in one study (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>), investigators were blinded to treatment allocation in two studies (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>), and outcome assessors were blinded to treatment allocation in two studies (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-11-12 15:11:07 +1100" MODIFIED_BY="[Empty name]">
<P>Data were complete in four studies (<LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>); inadequate in 13 (<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>; <LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>; <LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>); and unclear in the remainder.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<P>We found that 25 studies were at high risk of bias due to selective reporting. Reasons included: data not extractable for meta-analysis (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>); insufficient prespecified data or insufficient mortality or adverse event data (<LINK REF="STD-Ayli-2005" TYPE="STUDY">Ayli 2005</LINK>; <LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>; <LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>; <LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>; <LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>; <LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>; <LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>; <LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>; <LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>; <LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>; <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>; <LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>); and selective reporting of quality of life data (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>); or adequacy assessment (<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-11-12 15:11:01 +1100" MODIFIED_BY="[Empty name]">
<P>Analysis was based on intention-to-treat in two studies (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>). Our analysis indicated that four studies were at risk of other sources of bias. These included: unclear methods for selecting participants included in the analyses (<LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>); participants repeating assessments to make up for loss to follow-up (<LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>); not all treatments available at participating sites (<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>); and inconsistency in the number of included subjects in multiple study reports (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>High-flux membranes did not reduce all-cause mortality when compared with low-flux membranes (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (10 studies, 2915 participants): RR 0.95, 95% CI 0.87 to 1.04) or death due to infection (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (3 studies, 2547 participants): RR 0.90, 95% CI 0.71 to 1.14). However, cardiovascular mortality was significantly reduced by 17% in people who received high-flux membrane haemodialysis (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (5 studies, 2612 participants): RR 0.83; 95% CI 0.70 to 0.99) across a median follow-up of 24 months. In absolute terms, treating 100 people with ESKD using high-flux membrane haemodialysis for approximately two years will not reduce deaths from any cause (one death prevented, 95% CI -3 to 4), but may prevent three deaths attributable to cardiovascular causes (95% CI 0 to 6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hospital admissions</HEADING>
<P>In analyses that included two studies or fewer, high-flux membranes were not associated with reduced hospitalisation due to any cause (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.1 (2 studies, 36 events, 74 participants): RR 0.79, 95% CI 0.52 to 1.20); cardiovascular disease (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.2 (1 study, 54 participants): RR 0.92, 95% CI 0.23 to 3.70); or infection (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.3 (1 study, 20 participants): RR 0.33, 95% CI 0.02 to 7.32). The number of hospital admissions was significantly reduced by 0.2/year (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (155 participants): 95% CI -0.37 to -0.03) with high-flux membrane dialysis in one study (<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>). <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK> reported no significant difference between the number of all-cause hospital admissions (527 episodes in the high-flux group versus 518 episodes in the low-flux group) or infection-related admissions (74 episodes in the high-flux group versus 82 episodes in the low-flux group).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Quality of life outcomes were reported in two studies (<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK> evaluated quality of life in 22 people over four months, using the Time Trade Off (TTO) index, Sickness Impact Profile (SIP) and the Haemodialysis Quality of Life Questionnaire (HQoL). In <LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>, quality of life was analysed using three tools: the Index of Well-Being, Kidney Diseases Quality of Life Long-Form Questionnaire, and the Short Form-36 Questionnaire, in 1813 people over three years of follow-up. In general, neither of the studies identified statistical or clinical differences between high-flux and low-flux membranes for effects on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Manifestations of dialysis-related amyloidosis and predialysis serum beta-2 microglobulin</HEADING>
<P>High-flux membranes resulted in higher predialysis beta-2 microglobulin clearance (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (6 studies, 2071 participants): MD -12.17 mg/L, 95% CI -15.83 to -8.51 mg/L) but as expected not urea (equilibrated Kt/V<SUB>urea</SUB>) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (3 studies, 1968 participants): MD -0.00, 95% CI -0.03 to 0.02). One study that included few events, reported the effect of treatment on the clinical complications of beta-2 microglobulin-mediated amyloidosis, finding significant reductions in carpal tunnel syndrome (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.1 (1 study, 20 participants): RR 0.06, 95% CI 0.00 to 0.90) and dialysis-associated arthropathy (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.2 (1 study, 20 participants): RR 0.06, 95% CI 0.00 to 0.90). <LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>, a small study published in abstract form only, reported improvement in shoulder movement, but no differences in walking time, grip strength, or fist closure, in 18 people with established dialysis-arthropathy after six months of high-flux haemodialysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Symptoms related to dialysis (hypotension, nausea, vomiting, and muscle cramps)</HEADING>
<P>One study found no difference between high-flux and low-flux dialysis membranes for intradialytic hypotension (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (1 study, 84 participants): RR 3.00, 95% CI 0.13 to 71.61). <LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK> reported no difference between membrane types in the incidence of symptomatic hypotension, headache, and pruritus among patients in the high-flux and low-flux groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dialysis adequacy</HEADING>
<P>There were no differences between high-flux and low-flux groups with respect to numbers of patients who withdrew due to dialysis inadequacy (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (1 study, 155 participants): RR 0.58, 95% CI 0.13 to 2.71).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Lipids</HEADING>
<P>There were no differences between high-flux and low-flux haemodialysis membranes with respect to total cholesterol levels (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.1 (4 studies, 124 participants): MD &#8211;0.16 mmol/L, 95% CI -0.59 to 0.27 mmol/L); high-density lipoprotein (HDL) cholesterol (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.2 (4 studies, 154 participants): MD -0.04 mmol/L, 95% CI -0.14 to 0.05 mmol/L); low density lipoprotein (LDL) cholesterol (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.3 (4 studies, 154 participants): MD 0.06, 95% CI  -0.20 to 0.31 mmol/L); very low density lipoprotein (VLDL) cholesterol (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.3 (2 studies, 64 participants): MD -0.11 mmol/L; 95% CI -0.39 to 0.17 mmol/L) and serum triglycerides (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.4 (4 studies, 124 participants): MD -0.21 mmol/L; 95% CI -0.48 to 0.05 mmol/L).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Residual renal function</HEADING>
<P>
<LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK> reported that RRF at the end of study period was significantly higher in high-flux group participants (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK> (1 study, 30 participants): MD 1.10 mL/min, 95% CI 0.80 to 1.40) compared with the low-flux group. <LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK> reported data on rate of decline of RRF. Participants in the high-flux group had a significantly slower decline in RRF (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK> (1 study, 20 participants): MD -0.13 mL/min/mo, 95% CI -0.17 to -0.09 mL/min/mo).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Adverse events reported in the included studies are summarised in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>. Generally, adverse events were not systematically sought by investigators in most trials. The reported adverse events were also heterogeneous between included studies. Adverse events were reported by 13 investigators (<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>; <LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>; <LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>; <LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>; <LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>; <LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>; <LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>; <LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>; <LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>; <LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>; <LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>) which included adverse reactions (unspecified), hypotension during dialysis, vomiting, cramping, hospital admissions, infections, graft thrombosis, symptoms during dialysis, treatment inadequacy, reaction to dialysis membrane, arthritis-like symptoms, vascular access failure, and intracranial haemorrhage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup and publication bias analysis</HEADING>
<P>Due to the small number of studies that reported individual outcomes of interest we did not perform a funnel plot analysis of publication bias or subgroup analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-07-18 16:08:45 +1000" MODIFIED_BY="Suetonia Palmer">
<SUMMARY_OF_RESULTS MODIFIED="2012-07-18 15:11:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>We identified 33 studies that evaluated the effects of membrane flux on clinical and biochemical outcomes in people on haemodialysis for this review. Collectively, the 33 studies included nearly 4000 people, and the median follow-up period of participants was three months. Of these, 10 studies that included about 3000 participants, reported mortality data. Although membrane flux had no effect on all-cause mortality, in meta-analyses limited by few studies, cardiovascular mortality was reduced by approximately 17% in people who received high-flux haemodialysis compared to low-flux haemodialysis. In absolute terms, treating 100 people with high-flux haemodialysis membranes for two years may prevent approximately three deaths from cardiovascular causes. We found no evidence that membrane flux altered infection-related mortality; there were insufficient data to understand treatment effects on hospitalisation due to infection; and few studies systematically reported adverse events. There was insufficient information identified to reliably determine the effects of membrane flux on dialysis-related arthropathy; carpal tunnel syndrome; quality of life; or admission to hospital for any cause. As expected, high-flux dialysis was found to remove beta-2 microglobulin better than low-flux dialysis, but it had no clinical effect on lipid clearance.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-07-18 15:15:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>The strengths of the current analysis include the comprehensive and systematic review of randomised studies, a published and peer-reviewed protocol, and a systematic search strategy of MEDLINE, EMBASE, and the Cochrane Renal Group's Specialised Register. Despite the strengths of the current review, several limitations should be noted.</P>
<P>First, most studies were small and had heterogeneous enrolment criteria. Particularly, there were few studies that reported the effects of membrane flux on important patient-relevant outcomes, including mortality, symptoms, and functional status. Data for treatment effects on mortality relied heavily on a single study (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>) that dominated (contributed over 80% of the weight) these meta-analyses. Based on the cardiovascular death rate of approximately 9%/year observed in the low-flux membrane group, we calculated that a study of approximately 4000 participants followed for two years would be necessary to achieve 80% power needed to confirm the 17% risk reduction in cardiovascular mortality observed with high-flux dialysis.</P>
<P>Second, data were particularly sparse for risks of adverse events. Most studies did not report adverse events systematically. As a consequence, the relative safety of high-flux compared to low-flux dialysis is incompletely understood.</P>
<P>Third, to provide summary estimates, we combined a study with participants commencing dialysis (incident) with studies in which participants were already on dialysis (prevalent). Although we found no heterogeneity in the analyses for mortality, which suggested that the findings were generalisable among different dialysis populations regardless of time already on dialysis at enrolment, the small number of studies meant we could not be sure that important differences in treatment effects were not influenced by treatment effects carried over from previous dialysis modalities or survivor bias. Insufficient study data for mortality also precluded subgroup analyses to understand the effects of other specific study and participant characteristics on outcomes. It is unclear if membrane type (synthetic versus modified and unmodified cellulose), or biocompatibility, modified the effects of flux on cardiovascular mortality. It was however observed that membranes were synthetic and generally more biocompatible in both the high-flux and low-flux treatment groups in recent, larger studies. Additionally, the effects of membrane reuse on treatment effects or duration of follow-up could not be explored.</P>
<P>Consistency in the treatment effect between studies suggests that the findings may be generalisable to all people on haemodialysis. However, the small number of studies in the mortality analyses, combined with the dominance of two large studies (<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>; <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>), means that possible differences exist in the effects of membrane flux on people with specific clinical characteristics.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-04-24 09:50:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Importantly, data from individual studies in the review combined with the number of studies reporting specified outcomes indicate that evidence for the benefits and safety of high-flux and low-flux dialysis has marked limitations that should be taken into account when interpreting the results of this review. Nearly all studies were at high risk of bias from most elements considered essential in the conduct of a randomised trial that may have unpredictable effects on the summary treatment effects. </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-04-24 09:51:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>While the review was completed according to standardised Cochrane methodology, potential biases in the review process should be considered. We completed a formal search designed by a specialist information manager including data from wide sources including handsearching, to limit the potential for omission of potentially relevant studies. There were insufficient studies included in most meta-analyses to allow us to examine for potential publication bias. Inspection of the funnel plot for mortality indicated asymmetry suggesting smaller studies with smaller treatment effects for high-flux membranes were not available for analysis. Most studies did not systematically report all relevant patient-centred outcomes, suggesting that data for mortality and other clinical outcomes were incomplete, and summary estimates were potentially unreliable. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-07-18 16:08:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>Larger membrane pore sizes in high-flux dialysis membranes may increase back-transport of dialysis impurities, including endotoxin fragments, from dialysate to bloodstream. Accordingly, high-flux membranes may theoretically increase adverse effects in the event of dialysate contamination, although contrasting data suggests that reduced transport of endotoxins occurs across synthetic high-flux membranes (<LINK REF="STD-Schindler-2003" TYPE="STUDY">Schindler 2003</LINK>).</P>
<P>The mechanism for lowering cardiovascular mortality by high-flux membrane dialysis was unclear. Larger membrane pore size resulted in increased transport of retention solutes by both diffusion and convention, and may enable greater clearance of circulating molecules and fluid that are potentially pathogenic for cardiovascular disease. However, the identity of such cleared molecules has not been determined. Alternatively, high-flux membranes may reduce cardiovascular deaths because of greater biocompatibility or reduced pro-inflammatory properties, although these hypotheses could not be tested using the current data. </P>
<P>We noted that in the dialysis population, cardiovascular, but not all-cause mortality was improved by high-flux haemodialysis. There are two possible main reasons for this discrepancy between cardiovascular mortality (which was reduced by 17%) and all-cause mortality (no effect). First, due to the small number of studies, a type II statistical error may have occurred (that is, not finding a difference between treatment groups when a difference exists) due to insufficient statistical power. This is despite inclusion of over 1000 fatal events in nearly 3000 individuals in our analysis, making this possibility less likely. Alternatively, high-flux membrane dialysers may specifically reduce deaths due to cardiovascular disease (such as atherosclerotic vascular occlusion, heart failure, or sudden death) in people on haemodialysis, but not deaths from non-vascular causes, about which we have little information. Because cardiovascular deaths accounted for approximately 50% of deaths in the included studies, a reduction in cardiovascular events may not have been sufficient to reduce the mortality rate for high-flux membranes overall.</P>
<P>RCTs of membrane flux analysed in this review do not confirm the large reductions in all-cause mortality associated with high-flux dialysis in observational cohort studies (<LINK REF="STD-Hornberger-1992" TYPE="STUDY">Hornberger 1992</LINK>; <LINK REF="REF-Port-2001" TYPE="REFERENCE">Port 2001</LINK>; <LINK REF="STD-Woods-2000" TYPE="STUDY">Woods 2000</LINK>). The discrepancy in the magnitude of mortality benefit for high-flux dialysis membranes between observational data and RCTs is most likely due to the risks of bias by confounding that are present in uncontrolled cohort analyses that may exaggerate treatment effects. High-flux dialysis membranes enable greater clearance of larger retention molecules than standard flux membranes, including the potentially amyloidogenic beta-2 microglobulin. While observational analyses suggest evidence that high-flux dialysis is associated with fewer complications related to beta-2 microglobulin accumulation (<LINK REF="STD-Chanard-1989" TYPE="STUDY">Chanard 1989</LINK>; <LINK REF="STD-Koda-1997" TYPE="STUDY">Koda 1997</LINK>; <LINK REF="REF-van-Ypersele-de-Strihou-1991" TYPE="REFERENCE">van Ypersele de Strihou 1991</LINK>) only two RCTs have so far reported the effects of membrane flux on the incidence of carpal tunnel syndrome or dialysis-related arthropathy (<LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>; <LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>). Current randomised data are therefore insufficient to reliably inform clinicians and patients about the effects of high-flux membrane dialysis on amyloid-related complications. Assessing dialysis technologies with respect to beta-2 microglobulin amyloidosis is especially problematic due to the requirement for a long follow-up duration to allow for appearance of clinical manifestations. Observational studies show that amyloid-related complications occur in only in 5% to 10% of patients by 5 years, and in 15% to 30% by 10 years (<LINK REF="REF-Schwarz-1984" TYPE="REFERENCE">Schwarz 1984</LINK>) making randomised studies evaluating these outcomes arduous and expensive. Despite the paucity of data, it should be noted that the lack of evidence that high-flux membranes reduce amyloid-related complications does not necessarily indicate a lack of efficacy. A beneficial effect for high-flux haemodialysis on arthropathy and carpal tunnel syndrome is possible, but remains unproven.</P>
<P>The current meta-analyses support, in part, clinical guideline statements for membrane flux (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), although the <LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK> and <LINK REF="REF-CARI-2005" TYPE="REFERENCE">CARI 2005</LINK> guidelines now predate the release of results from <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>, and the latter are currently being updated. Although the present meta-analysis supports the suggestion by the <LINK REF="REF-EBPG-2002" TYPE="REFERENCE">EBPG 2002</LINK> to consider use of high-flux membranes for haemodialysis patients to reduce cardiovascular risk, and that high-flux membranes might be considered in all patients who need haemodialysis, the data cannot confirm that membrane flux is an important factor when considering prevention of beta-2 microglobulin amyloidosis, as suggested by <LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK> and <LINK REF="REF-EBPG-2002" TYPE="REFERENCE">EBPG 2002</LINK>.</P>
<P>To our knowledge, this is the first systematic review of RCTs that has specifically evaluated membrane flux for haemodialysis. A previous systematic review evaluated the effects of types of dialysis membrane (synthetic versus cellulose (modified and unmodified)) on outcomes and found no evidence of clinical benefit for synthetic membranes, despite including 32 studies (<LINK REF="REF-MacLeod-2005" TYPE="REFERENCE">MacLeod 2005</LINK>). Insufficient data for health-related outcomes, including mortality, were available in that review. Similarly, a systematic review that compared haemodiafiltration, haemofiltration, and acetate-free biofiltration, which are potentially more effective processes than haemodialysis in removing high molecular weight solutes, did not find evidence indicating any benefit of convective strategies on mortality, hospitalisation, or dialysis-related hypotension (<LINK REF="REF-Rabindranath-2005" TYPE="REFERENCE">Rabindranath 2005</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-18 16:09:23 +1000" MODIFIED_BY="Suetonia Palmer">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-18 16:09:23 +1000" MODIFIED_BY="Suetonia Palmer">
<P>The currently available trial evidence has not demonstrated superiority of high-flux membranes with respect to important clinical outcomes such as all-cause mortality, quality of life and hospital admission. It is not possible to recommend the use of these membranes in preference to low-flux membranes. A larger confirmatory RCT is required before high-flux membranes can be recommended to reduce cardiovascular mortality. Current RCT data cannot confirm that high-flux dialysis prevents amyloid-related arthropathy or carpal tunnel syndrome in people on long-term haemodialysis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-07-18 15:25:32 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Further evidence from larger RCTs is needed to confirm the benefit of high-flux membranes with respect to dialysis-related amyloidosis. The <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK> study has reported that the use of high-flux membranes are associated with significantly lower mortality in patients with both diabetes and low albumin (&lt; 4 g/dL). A larger study conducted specifically in people with ESKD and higher comorbidities (diabetes, low serum albumin, pre-existing cardiovascular disease) is necessary to confirm these findings.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-08-09 11:02:07 +1000" MODIFIED_BY="Suetonia Palmer">
<P>This review was funded by the National Kidney Research Fund (UK). We gratefully acknowledge the support provided by the Cochrane Renal Group for the assistance in the preparation of this systematic review, and particularly the assistance of Narelle Willis and Gail Higgins. We also thank Drs Blankestijn, Bonomini, Churchill, Harun-ur-Rashid, Hoenich, Jeloka, Krieter, Locatelli, Munger, Rocco, and the National Institutes of Health for providing additional unpublished data. We would also like to especially thank the Cochrane Renal Group for providing generous financial assistance to sponsor KSR to visit their editorial base in Sydney for training in the conduct of systematic reviews.</P>
<P>We would like to acknowledge the contributions of Prof Alison MacLeod and Dr Conal Daly who conceived the review with input from the Renal Association (UK), Standards and Audit sub-committee, and Dr Sheila Wallace who were all co-authors of this review's protocol; and Dr Carmen Bonifati who assessed the risk of bias and extracted data.</P>
<P>We thank the referees for their comments and feedback during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-08-09 10:57:30 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>KSR received funding from the National Kidney Research Fund (UK) to conduct this systematic review.</LI>
<LI>GFMS is the scientific director for Diaverum, a global provider of renal services</LI>
<LI>SCP receives an unrestricted fellowship from the Consorzio Mario Negri Sud, provided by Amgen Dompe.</LI>
<LI>FL was principal investigator of the MPO trial supported by an unrestricted grant by Fresenius Medical Care; has received lecture fees from Bellco, Fresenius Medical Care, and Gambro-Hospal.</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-08-09 11:02:17 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>KSR and SCP screened search results.</LI>
<LI>GFMS and SCP advised about the review methodology.</LI>
<LI>KSR and SCP assessed the risks of bias in the included studies and extracted data.</LI>
<LI>PR gave advice on outcome measures, study inclusion criteria and will help with resolving differences in study inclusion and data extraction.</LI>
<LI>SCP wrote the review.</LI>
<LI>GFMS, PR, FL reviewed and approved the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-07-26 11:08:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Risk of bias assessment tool has replaced the quality checklist.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-03-29 10:22:59 +1100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-02-01 13:32:06 +1100" MODIFIED_BY="Narelle Willis">
<STUDIES MODIFIED="2016-02-01 13:32:06 +1100" MODIFIED_BY="Narelle Willis">
<INCLUDED_STUDIES MODIFIED="2016-02-01 13:32:06 +1100" MODIFIED_BY="Narelle Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Acchiardo-1989" MODIFIED="2011-03-22 11:18:13 +1100" MODIFIED_BY="[Empty name]" NAME="Acchiardo 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-03-22 11:18:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Acchiardo SR, Quinn BP, Burk LB, Moore LW</AU>
<TI>Are high flux dialysis and erythropoietin treatment in a collision course?</TI>
<SO>ASAIO Transactions</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>3</NO>
<PG>308-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2688711"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayli-2005" MODIFIED="2011-03-23 18:34:59 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Ayli 2005" YEAR="2004">
<REFERENCE MODIFIED="2009-04-17 09:17:32 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayli D, Ayli M, Azak A, Yuksel C, Kosmaz GP, Atilgan G, et al</AU>
<TI>The effect of high-flux hemodialysis on renal anemia</TI>
<SO>Journal of Nephrology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>5</NO>
<PG>701-6</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:17:26 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15593038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-23 18:34:59 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ayli M, Ayli D, Azak A, Yuksel C, Atilgan G, Dede F, et al</AU>
<TI>The effect of high-flux hemodialysis on dialysis-associated amyloidosis</TI>
<SO>Renal Failure</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>1</NO>
<PG>31-4</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:17:44 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15717632"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blankestijn-1995" MODIFIED="2009-04-17 09:21:13 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Blankestijn 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-04-17 09:21:13 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA</AU>
<TI>High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>9</NO>
<PG>1703-8</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:21:10 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7780060"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1989" MODIFIED="2011-03-23 18:35:38 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Brown 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-03-23 18:35:38 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown EA, Sethi D, Perkin GD, Maini RN, Gower PE</AU>
<TI>High flux haemodialysis: optimal treatment for dialysis arthropathy? [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<PG>241</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 19:15:07 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sethi D, Brown EA, Perkin GD, Maini RN, Gower PE</AU>
<TI>High-flux haemodialysis: optimal treatment for dialysis arthropathy? [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>4</NO>
<PG>318</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2006" MODIFIED="2012-11-12 14:57:35 +1100" MODIFIED_BY="[Empty name]" NAME="Chu 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-07-11 17:26:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu P, Chiu Y, Lin J, Chen S, Wu K</AU>
<TI>The effect of low-flux and high-flux dialysers on endothelial dysfunction, oxidative stress and insulin resistance [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>738A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-28 16:04:32 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD</AU>
<TI>Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance. [see comment]</TI>
<SO>Blood Purification</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>2</NO>
<PG>213-20</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:04:32 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:04:32 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18285698"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Churchill-1993" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Churchill 1993" YEAR="1992">
<REFERENCE MODIFIED="2011-03-23 18:35:56 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Bird DR, Taylor DW, Beecroft ML, Gorman J, Wallace JE</AU>
<TI>Effect of high-flux hemodialysis on quality of life and neuropsychological function in chronic hemodialysis patients</TI>
<SO>American Journal of Nephrology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>6</NO>
<PG>412-8</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:24:40 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="1292340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN, Taylor DW, Tomlinson CW, Beecroft ML, Gorman J,Stanton E</AU>
<TI>Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure</TI>
<SO>Nephron</SO>
<YR>1993</YR>
<VL>65</VL>
<NO>4</NO>
<PG>573-577</PG>
<IDENTIFIERS MODIFIED="2009-04-17 11:57:28 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 11:57:28 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="8302412"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-1993" MODIFIED="2011-03-23 18:36:18 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Collins 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-04-17 09:26:09 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins D, Lambert M, Tannenbaum J, Oliverio M, Schwab S</AU>
<TI>Tolerance of hemodialysis: a randomized prospective trial of high flux vs. conventional high efficiency hemodialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>360</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:26:09 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 09:26:09 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00460571"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-23 18:36:18 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collins DM, Lambert MB, Tannenbaum JS, Oliverio M, Schwab SJ</AU>
<TI>Tolerance of hemodialysis: a randomized prospective trial of high-flux versus conventional high-efficiency hemodialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>2</NO>
<PG>148-54</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:26:18 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8400077"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Vriese-2003" MODIFIED="2012-03-28 16:06:30 +1100" MODIFIED_BY="[Empty name]" NAME="De Vriese 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-03-28 16:06:30 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Vriese AS, Langlois M, Bernard D, Geerolf I, Stevens L, Boelaert JR, et al</AU>
<TI>Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>12</NO>
<PG>2596-600</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:06:30 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:06:30 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14605283"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fishbane-1997" MODIFIED="2011-03-22 11:22:17 +1100" MODIFIED_BY="[Empty name]" NAME="Fishbane 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-03-22 11:22:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fishbane S, Bucala R, Pereira BJG, Founds H, Vlassara H</AU>
<TI>Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia</TI>
<SO>Kidney International</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>6</NO>
<PG>1645-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="1998021792"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardinali-1994" MODIFIED="2009-04-17 09:27:21 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Gardinali 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-04-17 09:27:21 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardinali M, Calcagno A, Conciato L, Agostoni A, Rosti A, Cori P, et al</AU>
<TI>Complement activation in dialysis: effects on cytokines, lymphocyte activation and beta 2 microglobulin</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>6</NO>
<PG>337-44</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:27:21 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7806419"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1996" MODIFIED="2011-03-23 18:36:35 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Goldberg 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-03-23 18:36:35 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW</AU>
<TI>High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>104-7</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:28:28 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8804007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:29:05 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman AM, Goldberg IJ, Lavarias VA, Vanni-Reyes T, Levin NW</AU>
<TI>High flux properties, not biocompatibility of dialysis membranes, improve cholesterol (chol) and triglyceride (tg) levels in patients with end stage renal disease (esrd) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>580</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:28:49 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 09:28:49 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00484602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-1997" MODIFIED="2011-03-23 18:36:46 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Hartmann 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-03-23 18:36:46 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann J, Fricke H, Schiffl H</AU>
<TI>Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>3</NO>
<PG>366-73</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:30:04 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="9292565"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 12:25:59 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffl H, Hartmann J, Lang S</AU>
<TI>Bicompatible membranes slow the decline of residual renal function in patients undergoing regular hemodialysis [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S415</PG>
<IDENTIFIERS MODIFIED="2009-04-17 12:25:59 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 12:25:59 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00461676"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HEMO-2002" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]" NAME="HEMO 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-03-16 12:05:19 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benz RL, Pressman MR, Brown J</AU>
<TI>Does membrane flux (F) or dialysis eKT/V dose (K) affect ESRD-related sleep disorders in hemodialysis (HD) patients (Pts): an ancillary study of the HEMO trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>September, Program and Abstracts</NO>
<PG>20a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chelamcharla M, Yan G, Rocco M, Schulman G, Teehan B, Toto R, et al</AU>
<TI>Effect of hemodialysis dose and flux on lipoproteins (LP) in the HEMO study [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A285</PG>
<IDENTIFIERS MODIFIED="2011-03-07 15:41:36 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-18 16:30:41 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, et al</AU>
<TI>Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group</TI>
<SO>Journal of the Amercian Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>117-27</PG>
<IDENTIFIERS MODIFIED="2009-04-17 11:05:33 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 11:05:33 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9890317"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:48:55 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, et al</AU>
<TI>Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>12</NO>
<PG>3251-63</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:48:55 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="14638924"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 11:33:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung AK, Levin NW, HEMO Study Group</AU>
<TI>Effect of high flux (HF) hemodialysis (HD) membranes on clinical outcomes: results from the HEMO study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>Program &amp; Abstracts</NO>
<PG>432A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:49:10 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al</AU>
<TI>Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>6</NO>
<PG>2380-9</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:49:08 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15149351"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 14:06:44 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chumlea WC, Dwyer J, Bergen C, Burkart J, Paranandi L, Frydrych A, et al</AU>
<TI>Nutritional status assessed from anthropometric measures in the HEMO study</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>1</NO>
<PG>31-8</PG>
<IDENTIFIERS MODIFIED="2010-05-02 14:06:44 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 14:06:44 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12563621"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:27:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daugirdas JT, Greene T, Cheung AK, Beck GJ, Levin NW, Kusek JW, et al</AU>
<TI>Effect of membrane flux intervention in HEMO study patients when grouped by months on dialysis at randomization, serum albumin, diabetes, and b2-M clearance [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>698A</PG>
<IDENTIFIERS MODIFIED="2011-03-07 15:42:08 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:27:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmez J, Beck G, Beddhu S, Levey A, Sarnak M, Yan G, et al</AU>
<TI>Effect of high flux hemodialysis (HD) on cerebrovascular (CBV) deaths: results from the HEMO study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>609A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-07 15:54:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Depner T, Beck G, Daugirdas J, Kusek J, Eknoyan G</AU>
<TI>Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>33</VL>
<NO>1</NO>
<PG>142-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9915282"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 17:04:36 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Depner TA, Gotch FA, Port FK, Wolfe RA, Lindsay RM, Blake PG, et al</AU>
<TI>How will the results of the HEMO study impact dialysis practice?</TI>
<SO>Seminars in Dialysis</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1</NO>
<PG>8-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12535292"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 11:21:31 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al</AU>
<TI>Effect of dialysis dose and membrane flux in maintenance hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>25</NO>
<PG>2010-9</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:49:30 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12490682"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 17:32:27 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, et al</AU>
<TI>Design and statistical issues of the hemodialysis (HEMO) study</TI>
<SO>Controlled Clinical Trials</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>5</NO>
<PG>502-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11018567"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:35:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leypoldt JK, Cheung AK, Clark WR, Daugirdas JT, Gotch FA, Greene T, et al</AU>
<TI>Characterization of low and high flux dialyzers with reuse in the HEMO study: interim report [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1518</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-07 15:55:44 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F</AU>
<TI>Effect of dialysis dose and membrane flux in maintenance hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>384</VL>
<NO>15</NO>
<PG>1491-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12691051"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 11:33:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F</AU>
<TI>Effect of dialysis dose and membrane flux in maintenance hemodialysis.[comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>15</NO>
<PG>1491-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 11:33:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maroni B, Burkhart J, Burrowes J, Dwyer J, Henry R, Kusek J, et al</AU>
<TI>Relationship between dialysis dose, membrane flux and indices of nutritional status at baseline in the HEMO study: an interm report [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>Program &amp; Abstracts</NO>
<PG>288A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 11:33:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocco M, Dwyer J, HEMO Study Group</AU>
<TI>Effect of dose and flux interventions on nutritional parameters: results from the hemodialysis study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>Program &amp; Abstracts</NO>
<PG>421A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-28 16:08:41 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocco MV, Dwyer JT, Larive B, Greene T, Cockram DB, Chumlea WC, et al</AU>
<TI>The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>6</NO>
<PG>2321-34</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:08:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:08:41 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15149346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:50:04 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unruh M, Benz R, Greene T, Yan G, Beddhu S, DeVita M, et al</AU>
<TI>Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>1</NO>
<PG>355-66</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:50:02 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15200444"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-House-1999" MODIFIED="2016-02-01 13:32:06 +1100" MODIFIED_BY="Narelle Willis" NAME="House 1999" YEAR="2000">
<REFERENCE MODIFIED="2012-03-28 16:09:06 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>House A, Freeman D</AU>
<TI>Larger intradialytic effect of high flux vs low flux polysulfone on homocysteine levels, but not on lipids or apo AI/CIII ratio [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>209A</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:09:06 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-01 13:32:06 +1100" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>House AA, Donnelly JG</AU>
<TI>Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis</TI>
<SO>ASAIO Journal</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>1</NO>
<PG>94-7</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:09:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="9952016"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:54:25 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC</AU>
<TI>Effect of high flux vs low flux hemodialysis on homocysteine, lipoprotein(a) and lipid profiles: a prospective randomized trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>211A</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:54:25 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00401331"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-23 18:37:17 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC</AU>
<TI>Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>7</NO>
<PG>1029-34</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:51:36 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="10862642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INFLUX-2008" MODIFIED="2012-07-11 17:28:25 +1000" MODIFIED_BY="Suetonia Palmer" NAME="INFLUX 2008" YEAR="2006">
<REFERENCE MODIFIED="2012-07-11 17:28:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combe C, Beck W, Argiles A, Brunet P, Chauveau P, Choukroun G, et al</AU>
<TI>Influence of hemodialysis (HD) membrane (Mb) permeability (Perm) in patients (Pts) with mild chronic inflammation: results from INFLUX, a randomized controlled multicenter clinical trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>485A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:28:25 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Combe C, Beck W, Argiles A, Brunet P, Chauveau P, Choukroun G, et al</AU>
<TI>Influence of hemodialysis (HD) membrane permeability (perm) in patients (Pts) with mild chronic inflammation: Intermediate results from INFLUX, a randomized controlled multicenter study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>517A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="ISRCTN" VALUE="7228763"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeloka-2001" MODIFIED="2012-03-28 16:12:36 +1100" MODIFIED_BY="[Empty name]" NAME="Jeloka 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-03-28 16:12:36 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeloka T, Mathur MD, Kaur R, Kohli R, Singh NP, Rizvi SNA</AU>
<TI>I2 microglobulin in chronic renal failure and effect off different dialyzer membrane on its clearance</TI>
<SO>Indian Journal of Nephrology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>4</NO>
<PG>160-4</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:09:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00663574"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klemm-2004" MODIFIED="2012-03-28 16:11:36 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Klemm 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-03-28 16:11:36 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klemm A, Franke C, Busch M, Muller A,Franke S, Lang D, Passlick-Deetjen J, Stein G</AU>
<TI>Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites</TI>
<SO>Clinical Nephrology</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>3</NO>
<PG>191-7</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:11:36 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:11:36 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15077870"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krieter-2002" MODIFIED="2012-07-11 17:28:43 +1000" MODIFIED_BY="[Empty name]" NAME="Krieter 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-11 17:28:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krieter DH, Sauer N, Reinhardt B, Lemke HD, Foitzik-Kisseler M, Hartwig M, et al</AU>
<TI>No evidence for pyrogen transfer in haemodialysis (hd) with low-and high-flux dialyzers [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuchle-1996" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]" NAME="Kuchle 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-04-24 09:42:48 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kuchle C, Fricke H, Held E, Schiffl H</AU>
<TI>High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis</TI>
<SO>American Journal of Nephrology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>6</NO>
<PG>484-8</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:55:43 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8955759"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:56:01 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuchle C, Fricke H, et al</AU>
<TI>High-flux hemodialysis postpones clinical manifestation of dialysis associated amyloidosis [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>6</NO>
<PG>A232</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:56:01 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 09:56:00 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00261301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuchle C, Lang SM, Held E, Schiffl H</AU>
<TI>Biocompatibility, b2-microglobulin and dialysis-associated amyloidosis [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S404</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:10:07 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-04 15:58:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mrowka CH, Schiffl H</AU>
<TI>Comparative evaluation of beta-2 microglobulin removal by different hemodialysis membranes: a six year follow-up</TI>
<SO>Nephron</SO>
<YR>1993</YR>
<VL>63</VL>
<NO>3</NO>
<PG>368-9</PG>
<IDENTIFIERS MODIFIED="2010-04-13 21:44:52 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-04-13 21:44:52 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8446285"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:56:19 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffl H, D'Agostini B, Held E</AU>
<TI>Removal of beta 2-microglobulin by hemodialysis and hemofiltration: a four year follow up</TI>
<SO>Biomaterials, Artificial Cells, &amp; Immobilization Biotechnology</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1223-32</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:56:19 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="1457695"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:56:50 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffl H, Kuchle C, Held E</AU>
<TI>Beta-2-microglobulin removal by different hemodialysis membranes</TI>
<SO>Contributions to Nephrology</SO>
<YR>1995</YR>
<VL>112</VL>
<PG>156-63</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:56:50 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7554987"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lang-2001" MODIFIED="2009-04-17 09:57:50 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Lang 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-17 09:57:50 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lang SM, Bergner A, Topfer M, Schiffl H</AU>
<TI>Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>52-7</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:57:50 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11280496"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007a" MODIFIED="2012-11-12 15:11:20 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Li 2007a" YEAR="2007">
<REFERENCE MODIFIED="2011-03-22 11:32:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li M, Jiang GR</AU>
<TI>High- versus low-flux hemodialysis in removing solutes</TI>
<SO>Journal of Clinical Rehabilitative Tissue Engineering Research</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>31</NO>
<PG>6207-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="2007458081"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2010" MODIFIED="2012-07-11 17:29:01 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Li 2010" YEAR="201">
<REFERENCE MODIFIED="2012-03-16 14:22:43 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li PK, Cheng YL, Leung CB, Szeto CC, Chow KM, Kwan BC, et al</AU>
<TI>Effect of membrane permeability on inflammation and arterial stiffness: a randomized trial</TI>
<SO>Clinical Journal of the American Society of Nephrology</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>4</NO>
<PG>652-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20203165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:29:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li PKT, Cheng YL, Leung CB, Szeto CC, Chow KM, Kwan BCH, et al</AU>
<TI>A randomized cross-over trial comparing low-flux polyamide membrane to high-flux polyamide membrane on inflammatory indices and arterial stiffness [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>452A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-1996" MODIFIED="2012-11-12 15:11:01 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-07-04 15:45:34 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Italian Cooperative Dialysis Study Group</AU>
<TI>Effect of hemodialysis membranes on serum albumin</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>2</NO>
<PG>455-6</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:59:28 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11157397"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:59:05 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, et al</AU>
<TI>Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group</TI>
<SO>Kidney International</SO>
<YR>1996</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1293-302</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:59:05 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8887291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:59:44 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, et al</AU>
<TI>The effects of different membranes and dialysis technologies on the treatment tolerance and nutritional parameters of hemodialysis patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1454</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:59:44 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 09:59:54 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, Orlandini G</AU>
<TI>The effects of different membranes and dialysis technologies on the treatment tolerance and nutritional parameters of hemodialysed patients. Design of a prospective randomised multicentre trial</TI>
<SO>Journal of Nephrology</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>2</NO>
<PG>123-9</PG>
<IDENTIFIERS MODIFIED="2009-04-17 09:59:54 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="EMBASE" VALUE="1994156257"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2000" MODIFIED="2012-11-12 15:11:07 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-02 16:31:40 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Andrulli S, Pecchini F, Pedrini L, Agliata S, Lucchi L, et al</AU>
<TI>Effect of high-flux dialysis on the anaemia of haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>9</NO>
<PG>1399-409</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:01:21 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="10978398"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohini-1989" MODIFIED="2012-07-11 17:35:46 +1000" MODIFIED_BY="[Empty name]" NAME="Mohini 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-07-11 17:35:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohini R, Michaels R, Trost C, Gron D, Zasuwa G, Dumler F, et al</AU>
<TI>Comparison of effect of recombinant human erythropoietin (rHEPO) in patients on high flux (HF) vs conventional (C) hemodialysis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>1</NO>
<PG>256</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MPO-2009" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" NAME="MPO 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hannedouche T, Jacobson SH, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, et al</AU>
<TI>Relationship of residual renal function (RRF) to serum b2-microglobulin and advanced glycation end products in patients starting hemodialysis (HD) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>356A</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:13:43 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00445636"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobson SH, Czekalski S, Hannedouche T, Loureiro A, Martin-Malo A, Papadimitriou M, et al</AU>
<TI>Modifiable cardiovascular risk factors: baseline results of the MPO study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>614A</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:14:00 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, et al</AU>
<TI>The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial</TI>
<SO>Journal of Nephrology</SO>
<YR>1999 Mar</YR>
<VL>12</VL>
<NO>2</NO>
<PG>85-8</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:15:09 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2012-03-28 16:15:09 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10378663"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, et al</AU>
<TI>Effect of Membrane Permeability on Survival of Hemodialysis Patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>3</NO>
<PG>645-54</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:33:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:33:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19092122"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Pozzoni P, Di Filippo S</AU>
<TI>What are we expecting to learn from the MPO study?</TI>
<SO>Contributions to Nephrology</SO>
<YR>2005</YR>
<VL>149</VL>
<PG>83-9</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:15:21 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15876831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-28 16:15:37 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Malo A, Czekalski S, Hannedouche T, Jacobson SH, Loureiro A, Papadimitriou M, et al</AU>
<TI>Patient and treatment patterns at start of dialysis: analysis of the effect of age [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>196-7</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:15:37 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanholder R, Hannedouche T, Jacobson SH, La Greca G, Loureiro A, Martin-Malo A, et al</AU>
<TI>Male gender as risk factor to be underdialysed: baseline data from the MPO study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>250</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:16:21 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanholder R, Hannedouche T, Jacobson SH, Ronco C, Loureiro A, Martin-Malo A, et al</AU>
<TI>Protein catabolic rate (PCR) normalised to ideal body weight (BW) as indicator of protein intake: data from the MPO study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>389A-90A</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:16:34 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-04-25 21:44:36 +1000" MODIFIED_BY="Narelle S Willis"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opatrny-2002" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Opatrny 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opatrny K Jr, Reischig T, Eiselt J, Vienken J, Opatrna S, Sefrna F, et al</AU>
<TI>Does treatment with biocompatible 'high-flux' (HF) and 'low-flux' (LF) hemodialysis (HD) differ in it's effect on renal anemia? [abstract]</TI>
<SO>Kidney &amp; Blood Pressure Research</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>2</NO>
<PG>131</PG>
<IDENTIFIERS MODIFIED="2009-04-17 12:34:28 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00509397"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-23 18:42:51 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Opatrny K, Reischig T, Vienken J, Eiselt J, Vit L, Opatrna S, et al</AU>
<TI>Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis</TI>
<SO>Artificial Organs</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>2</NO>
<PG>181-8</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:03:29 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11879248"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ottosson-2001" MODIFIED="2009-04-17 10:05:01 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ottosson 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-04-17 10:05:01 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ottosson P, Attman PO, Knight C, Samuelsson O, Weiss L, Alaupovic P</AU>
<TI>Do high-flux dialysis membranes affect renal dyslipidemia?</TI>
<SO>ASAIO Journal</SO>
<YR>2001</YR>
<VL>47</VL>
<NO>3</NO>
<PG>229-34</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:05:01 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="11374763"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizvi-1995" MODIFIED="2012-03-27 17:07:29 +1100" MODIFIED_BY="[Empty name]" NAME="Rizvi 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-03-27 17:07:29 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rizvi SNA, Sawlani KK, Kohli R</AU>
<TI>Comparative study of high flux haemodialysis versus conventional haemodialysis: Initial Indian experience [abstract]</TI>
<SO>6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong</SO>
<YR>1995</YR>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawaya-1989" MODIFIED="2012-03-16 14:21:04 +1100" MODIFIED_BY="[Empty name]" NAME="Sawaya 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-03-16 14:21:04 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawaya B, Provenzano R, Simkins R, Barkley G, Levin NW</AU>
<TI>Long term effect of conventional and high flux membranes on electrophysiologic (EP) indices in hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>1</NO>
<PG>262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1993" MODIFIED="2012-03-16 14:20:36 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Simon 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-16 14:20:36 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon P, Ang KS, Cam G, Benziane A, Bonn F</AU>
<TI>Indices of adequate dialysis in patients hemodialyzed with AN 69 membrane</TI>
<SO>Kidney International</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>Suppl 41</NO>
<PG>S291-5</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:05:57 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8320940"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skroeder-1993" MODIFIED="2011-03-23 18:42:29 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Skroeder 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-03-23 18:42:29 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Skroeder NR, Jacobson SH, Holmquist B, Kjellstrand P, Kjellstrand CM</AU>
<TI>Beta 2-microglobulin generation and removal in long slow and short fast hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>5</NO>
<PG>519-26</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:07:14 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8488820"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 10:08:54 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM</AU>
<TI>Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis</TI>
<SO>Artificial Organs</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>12</NO>
<PG>880-7</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:08:54 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7887824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takasawa-2005" MODIFIED="2012-07-11 17:30:30 +1000" MODIFIED_BY="[Empty name]" NAME="Takasawa 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-11 17:30:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takasawa K, Takaeda C, Nakagen M, Kawai K, Nakaya I, Kitagawa K, et al</AU>
<TI>Effect of high-flux dialysis on the anemia-prospective randomized crossover study [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-11-12 15:31:00 +1100" MODIFIED_BY="Suetonia Palmer">
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-2008" MODIFIED="2010-07-15 14:22:30 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Abe 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-02 16:22:25 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abe M, Kikuchi F, Kaizu K, Matsumoto K</AU>
<TI>The influence of hemodialysis membranes on the plasma insulin level of diabetic patients on maintenance hemodialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>5</NO>
<PG>354-60</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:26:55 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:26:55 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18538098"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-2009" MODIFIED="2010-07-15 14:22:37 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Abe 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-02 13:19:49 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Abe M, Okada K, Maruyama T, Ikeda K, Kikuchi F, Kaizu K, et al</AU>
<TI>Comparison of the effects of polysulfone and polyester-polymer alloy dialyzers on glycemic control in diabetic patients undergoing hemodialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>2009</YR>
<VL>71</VL>
<NO>5</NO>
<PG>514-20</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:19:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:19:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19473611"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alarcon-1994" MODIFIED="2010-05-02 16:42:53 +1000" MODIFIED_BY="Narelle S Willis" NAME="Alarcon 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 16:42:53 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alarcon A, Almaraz M, Alvarez Lipe R, Andres E, Arias M, Belvis JJ, et al</AU>
<TI>A multicentric study on the effectiveness of the cellulose triacetate membrane in haemodialysis patient</TI>
<SO>Nefrologia</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>2</NO>
<PG>195-206</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:42:53 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:42:53 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994188445"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albertazzi-1999" MODIFIED="2009-04-17 10:44:27 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Albertazzi 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-04-17 10:44:27 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albertazzi MM, Bonomini M</AU>
<TI>Clinical experience with PMMA membrane</TI>
<SO>Contributions to Nephrology</SO>
<YR>1999</YR>
<VL>125</VL>
<PG>213-221</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:44:27 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 10:44:27 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9895442"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amadori-1983" MODIFIED="2010-05-02 16:43:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Amadori 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-05-02 16:43:04 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amadori A, Candi P, Sasdelli M, Massai G, Favilla S, Passaleva A, et al</AU>
<TI>Hemodialysis leukopenia and complement function with different dialyzers</TI>
<SO>Kidney International</SO>
<YR>1983</YR>
<VL>24</VL>
<NO>6</NO>
<PG>775-81</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:43:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:43:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6562280"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andreoli-2007" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]" NAME="Andreoli 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreoli MC, Dalboni MA, Watanabe R, Manfredi SR, Canziani ME, Kallas EG, et al</AU>
<TI>Impact of dialyzer membrane on apoptosis and function of polymorphonuclear cells and cytokine synthesis by peripheral blood mononuclear cells in hemodialysis patients</TI>
<SO>Artificial Organs</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>12</NO>
<PG>887-92</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:44:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:44:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17924987"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-14 13:38:21 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andreoli MCC, Dalboni MA, Watanabe R, Sardenberg C, Manfredi SR, Canziani ME, et al</AU>
<TI>A crossover study on the impact of dialyzer membrane selection on apoptosis and function of neutrophils and PBMC in hemodialysis patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>367A</PG>
<IDENTIFIERS MODIFIED="2010-07-14 13:38:21 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arakawa-1991" MODIFIED="2010-05-02 16:44:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Arakawa 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-02 16:44:30 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arakawa M, Gejyo F, Shimotori T, Ei K, Oda M, Obata N, et al</AU>
<TI>Long-term multicentre study of beta2-microglobulin removal by PMMA BK membrane</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>69-74</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:44:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:44:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1991241879"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnadottir-2002" MODIFIED="2009-04-17 10:47:25 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Arnadottir 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-04-17 10:47:25 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnadottir M, Wingren K, Hultberg B, Hegbrant J</AU>
<TI>The postdialytic rise in the plasma total homocysteine concentration is delayed</TI>
<SO>Blood Purification</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>4</NO>
<PG>334-7</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:47:25 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 10:47:25 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="12169841"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1999" MODIFIED="2011-03-22 11:41:42 +1100" MODIFIED_BY="[Empty name]" NAME="Becker 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-03-22 11:41:42 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becker BN, Pintar TJ, Hofmann RM, Abdullah RN, Knechtle SJ, D'Alessandro AM</AU>
<TI>High-flux hemodialysis may improve delayed graft function [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>719A-20A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergamo-1991" MODIFIED="2011-05-24 10:45:08 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Bergamo 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-05-24 10:45:08 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergamo Collaborative Dialysis Study Group</AU>
<TI>Acute intradialytic well-being: results of a clinical trial comparing polysulfone with cuprophan. Bergamo Collaborative Dialysis Study Group</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>40</VL>
<NO>4</NO>
<PG>714-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1745022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonomini-1994" MODIFIED="2010-05-02 16:44:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bonomini 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 16:44:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonomini V, Coli L, Feliciangeli G, Nanni Costa A, Scolari MP</AU>
<TI>Long-term comparative evaluation of synthetic and cellulosic membranes in dialysis</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1984</YR>
<VL>17</VL>
<NO>7</NO>
<PG>392-8</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:44:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:44:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994300741"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonomini-1996" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Bonomini 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-04-24 16:08:13 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonomini M, Fiederling B, Bucciarelli T, Manfrini V, Di Ilio C, Albertazzi A</AU>
<TI>A new polymethylmethacrylate membrane for hemodialysis</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>4</NO>
<PG>232-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8786174"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bonomini M, Fiederling B, Manfrini V, Martella D, Garofalo E, Bucciarelli T, et al</AU>
<TI>Evaluation of the removal capacity during hemodialysis (HD) of a novel polymethylmethacrylate (PMMA) membrane [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid, Spain</SO>
<YR>1995</YR>
<PG>563</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00509097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bordoni-2006" MODIFIED="2012-07-11 17:30:54 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Bordoni 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-03-28 16:20:43 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bordoni V, Piroddi M, Galli F, de Cal M, Bonello M, Dimitri P, et al</AU>
<TI>Oxidant and carbonyl stress-related apoptosis in end-stage kidney disease: impact of membrane flux</TI>
<SO>Blood Purification</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>1</NO>
<PG>149-56</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:20:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:20:43 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16361856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:30:54 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bordoni VV, Brendolan AA, De Cal M, Levin NN, Crepaldi CC, Goepel WW, et al</AU>
<TI>Caspase 3-dependent apoptosis is corrected by high flux and middle flux but not by low flux membranes [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>405A</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:20:56 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosc-1997" MODIFIED="2009-04-17 10:52:12 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Bosc 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-04-17 10:52:12 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosc JY, LeBlanc M, et al</AU>
<TI>Comparison between high flux cellulose triacetate and high flux polysulfone: a clinical study in hemodialysis and hemodiafiltration [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>A150</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:52:12 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-04-17 10:52:12 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00261407"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boudville-2009" MODIFIED="2011-03-22 10:49:04 +1100" MODIFIED_BY="[Empty name]" NAME="Boudville 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-02 13:31:06 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Boudville N, Horner M, McEwan E, Lim WH, Mudge DW, Markus HE</AU>
<TI>Effect of FX dialysers on systemic inflammation and quality of life in chronic haemodialysis patients</TI>
<SO>Blood Purification</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>2</NO>
<PG>187-93</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:31:06 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:31:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19141998"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branger-1988" MODIFIED="2010-05-02 16:45:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Branger 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-02 16:45:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branger B, Deschodt G, Oules R, Balducchi JP, Granolleras C, Alsabadani B, et al</AU>
<TI>Biocompatible membranes and hemodynamic tolerance to hemodialysis</TI>
<SO>Kidney International - Supplement</SO>
<YR>1988</YR>
<VL>33</VL>
<NO>Suppl 24</NO>
<PG>196-7</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:45:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:45:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3163048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-1987" MODIFIED="2011-03-22 11:41:50 +1100" MODIFIED_BY="[Empty name]" NAME="Campbell 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-03-22 11:41:49 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell J, Dumler F, Stalla K, Levin NW</AU>
<TI>High flux short time hemodialysis: initial clinical experience [abstract]</TI>
<SO>Kidney International</SO>
<YR>1987</YR>
<VL>31</VL>
<NO>1</NO>
<PG>229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caramelo-1994" MODIFIED="2010-05-07 17:00:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Caramelo 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-04-17 10:56:53 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caramelo C, Alcazar R, Gallar P, Teruel JL, Velo M, Ortega O, et al</AU>
<TI>Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>6</NO>
<PG>675-7</PG>
<IDENTIFIERS MODIFIED="2009-04-17 10:56:46 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7970095"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-07 17:00:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffl H</AU>
<TI>Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients [letter]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>911-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7566634"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cases-1993" MODIFIED="2011-06-26 17:22:39 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Cases 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-06-26 17:22:39 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cases A, Reverter JC, Escolar G, Sanz C, Lopez-Pedret J, Revert L, et al</AU>
<TI>Platelet activation on hemodialysis: influence of dialysis membrane</TI>
<SO>Kidney International - Supplement</SO>
<YR>1993</YR>
<VL>41</VL>
<PG>S217-20</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:45:45 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:45:45 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8320925"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chanard-1989" MODIFIED="2010-05-02 16:45:59 +1000" MODIFIED_BY="Narelle S Willis" NAME="Chanard 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-02 16:45:59 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chanard J, Bindi P, Lavaud S, Toupance O, Maheut H, Lacour F</AU>
<TI>Carpal tunnel syndrome and type of dialysis membrane</TI>
<SO>BMJ</SO>
<YR>1989</YR>
<VL>298</VL>
<NO>6677</NO>
<PG>867-8</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:45:59 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:45:59 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2497828"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaveau-1992" MODIFIED="2010-05-02 16:46:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Chaveau 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-02 16:46:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chauveau P, Poignet JL, Kuno T, Bonete R, Kerembrun A, Naret C, et al</AU>
<TI>Phosphate removal rate: a comparative study of five high-flux dialysers</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>114-5</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:46:18 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:46:18 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1866059"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005c" MODIFIED="2012-11-12 15:30:02 +1100" MODIFIED_BY="[Empty name]" NAME="Chen 2005c" YEAR="2005">
<REFERENCE MODIFIED="2012-07-11 17:31:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen X, Li Z, Wu P, Zhang D, Shen Q, Yu X</AU>
<TI>b2-microglobulin and iPTH removal in on-line hemodiafiltration versus low- and high-flux hemodialysis [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Churchill-1995" MODIFIED="2010-05-02 16:47:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Churchill 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-02 16:47:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Churchill DN</AU>
<TI>Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: An appraisal of the evidence</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10 Suppl 10</VL>
<PG>52-6</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:47:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:47:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8825434"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Civati-1991" MODIFIED="2010-05-02 16:48:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Civati 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-02 16:48:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Civati G, Teatini U, Guastoni C, Perego A, Perrino ML, Ballerini L, et al</AU>
<TI>Long-term experience with high-flux polysulfone in hemodialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>42 Suppl 1</VL>
<PG>S26-30</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:48:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:48:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7923979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Combe-1994" MODIFIED="2010-05-02 16:49:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Combe 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 16:49:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combe C, Pourtein M, de Precigout V, Baquey A, Morel D, Potaux L, et al</AU>
<TI>Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1994</YR>
<VL>24</VL>
<NO>3</NO>
<PG>437-42</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:49:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:49:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8079969"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CONTRAST-_x0028_Dutch_x0029_-2005" MODIFIED="2012-07-11 17:36:19 +1000" MODIFIED_BY="[Empty name]" NAME="CONTRAST (Dutch) 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-02 17:35:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Gritters-van den Oever M, Grooteman MP, Bartels PC, Blankestijn PJ, Bots ML, van den Dorpel MA, et al</AU>
<TI>Post-dilution haemodiafiltration and low-flux haemodialysis have dissimilar effects on platelets: a side study of CONTRAST</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>11</NO>
<PG>3461-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19561150"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:26:06 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penne EJ, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, et al</AU>
<TI>[New study evaluating online haemodiafiltration for the reduction of cardiovascular morbidity and mortality in patients undergoing chronic haemodialysis]. [Dutch]</TI>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>2006</YR>
<VL>150</VL>
<NO>28</NO>
<PG>1583-5</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:26:01 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16886698"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:36:19 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penne EL, Blankestijn PJ, Bots ML, Ban Den Dorpel MA, Grooteman MP, Nube MJ, et al</AU>
<TI>Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients: design and rationale of the Dutch CONvective TRAnsport STudy (CONTRAST) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>406A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:25:57 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 14:07:36 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, et al</AU>
<TI>Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]</TI>
<SO>Current Controlled Trials in Cardiovascular Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>1</NO>
<PG>8</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:25:49 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15907201"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:25:44 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nube MJ, et al</AU>
<TI>Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study</TI>
<SO>Seminars in Dialysis</SO>
<YR>2005 Jan</YR>
<VL>18</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:25:44 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15663765"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 13:58:36 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, et al</AU>
<TI>Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST)</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>1</NO>
<PG>77-87</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:58:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:58:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19962805"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:31:28 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penne L, Blankestijn P, Bots M, Van den Dorpel MA, Grooteman M, Nube M, et al</AU>
<TI>Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic dialysis patients: design and preliminary baseline characteristics of the CONvective TRAnsport STudy (CONTRAST) [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A189</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:25:38 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:31:44 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penne L, Blankestijn P, Bots M, Van den Dorpel R, Grooteman M, Nube M, et al</AU>
<TI>The CONvective TRAnsport STudy (CONTRAST) is designed to detect differences in mortality and cardiovascular disease between online hemodiafiltration and hemodialysis: preliminary findings on proof of principle [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>734A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:25:33 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:31:55 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Weerd N, Blankestijn P, Bots M, Van den Dorpel R, Grooteman M, Nube M, et al</AU>
<TI>Dose dependent decrease in beta-2-microglobulin (b2M) levels in patients treated with online hemodiafiltration (HDF) in the Dutch CONvective TRAnsport STudy (CONTRAST) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>53A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:25:27 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-07-15 14:26:38 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2010-07-15 14:26:26 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00205556"/>
<IDENTIFIER MODIFIED="2010-07-15 14:26:38 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="ISRCTN" VALUE="38365125"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danielson-1986" MODIFIED="2012-03-28 16:22:46 +1100" MODIFIED_BY="Narelle S Willis" NAME="Danielson 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-03-28 16:22:46 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Danielson BG, Hallgren R, Venge P</AU>
<TI>Patient reactions and granulocyte degranulation during hemodialysis with cuprophane and polycarbonate membranes. A double-blind study</TI>
<SO>Blood Purification</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>1-3</NO>
<PG>147-50</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:50:33 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:50:33 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3524607"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daugirdas-1994a" MODIFIED="2010-07-04 15:55:59 +1000" MODIFIED_BY="Narelle S Willis" NAME="Daugirdas 1994a" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 16:51:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daugirdas JT</AU>
<TI>The possible effects of dialyzer membrane on morbidity and mortality</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9 Suppl 2</VL>
<PG>145-9</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:51:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:51:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8065606"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Francisco-1994" MODIFIED="2010-05-02 16:52:21 +1000" MODIFIED_BY="Narelle S Willis" NAME="De Francisco 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 16:52:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Francisco AL, Amado JA, Prieto M, Sanz de Castro S, Ruiz JC, Morales P, et al</AU>
<TI>Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism</TI>
<SO>Nephron</SO>
<YR>1994</YR>
<VL>66</VL>
<NO>4</NO>
<PG>442-6</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:52:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:52:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8015649"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dellanna-1999" MODIFIED="2011-03-22 11:42:22 +1100" MODIFIED_BY="[Empty name]" NAME="Dellanna 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-03-22 11:42:22 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dellanna F, Lagendijk H, Westhoff A, Kleophas W, van Endert G</AU>
<TI>Superflux-dialyser and the genius system: the effect of internal filtration on beta-2-microglobulin elimination [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demirtas-2002" MODIFIED="2010-05-02 16:58:50 +1000" MODIFIED_BY="Narelle S Willis" NAME="Demirtas 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-02 16:58:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demirtas S, Nergisoglu G, Akbay A, Karaca L</AU>
<TI>The relation between low-density lipoprotein (LDL) oxidation and hemodialysis with respect to membrane types: Protective effects of vitamin E-bonded membrane</TI>
<SO>Turkish Journal of Medical Sciences</SO>
<YR>2002</YR>
<VL>32</VL>
<NO>2</NO>
<PG>93-100</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:58:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:58:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="2002122144"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Precigout-1996" MODIFIED="2010-05-02 16:53:55 +1000" MODIFIED_BY="Narelle S Willis" NAME="De Precigout 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-02 16:53:55 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Precigout V, Higueret D, Larroumet N, Combe C, Iron A, Blanchetier V, et al</AU>
<TI>Improvement in lipid profiles and triglyceride removal in patients on polyamide membrane hemodialysis</TI>
<SO>Blood Purification</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>2</NO>
<PG>170-6</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:53:55 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:53:55 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8785033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Descamps_x002d_Latscha-1991" MODIFIED="2010-05-02 17:07:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Descamps-Latscha 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-02 17:07:04 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Descamps-Latscha B, Goldfarb B, Nguyen AT, Landais P, London G, Haeffner-Cavaillon N, et al</AU>
<TI>Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: A randomized prospective study</TI>
<SO>Nephron</SO>
<YR>1991</YR>
<VL>59</VL>
<NO>2</NO>
<PG>279-85</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:07:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:07:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1956490"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dhakal-1999" MODIFIED="2010-05-02 17:07:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dhakal 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-02 17:07:51 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dhakal MP, Kallay MC, Shelly MA, Talley TE</AU>
<TI>Post-hemodialysis hypoxia occurs with both biocompatible and bioincompatible dialyzers</TI>
<SO>Dialysis &amp; Transplantation</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>11</NO>
<PG>666-72</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:07:51 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:07:51 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1999388080"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-1998" MODIFIED="2012-03-27 17:08:38 +1100" MODIFIED_BY="[Empty name]" NAME="Ding 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-27 17:08:38 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ding F, Lin S, Fan S</AU>
<TI>The clinical effect of high-flux dialysis and it's influence on plasma cytokine level [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>291</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diop-2000" MODIFIED="2010-05-02 17:08:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Diop 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-02 17:08:51 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diop ME, Viron B, Bailleul S, Lefevre G, Fessi H, Maury J, et al</AU>
<TI>Lp(a) is increased in hemodialysis patients according to the type of dialysis membrane: A 2-year follow-up study</TI>
<SO>Clinical Nephrology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>3</NO>
<PG>210-7</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:08:51 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:08:51 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11020019"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Docci-1992" MODIFIED="2010-05-02 17:10:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Docci 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-02 17:10:20 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Docci D, Bilancioni R, Pistocchi E, Baldrati L, Capponcini C, Delvecchio C, et al</AU>
<TI>Evolution of serum prealbumin following hemodialysis: effect of different dialysis membranes</TI>
<SO>Nephron</SO>
<YR>1992</YR>
<VL>62</VL>
<NO>2</NO>
<PG>145-9</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:10:20 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:10:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1436305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Docci-1995" MODIFIED="2010-05-02 17:12:41 +1000" MODIFIED_BY="Narelle S Willis" NAME="Docci 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-02 17:12:41 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C</AU>
<TI>Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients</TI>
<SO>Nephron</SO>
<YR>1995</YR>
<VL>69</VL>
<NO>3</NO>
<PG>323-6</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:12:41 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:12:41 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7753268"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Domrongkitchaiporn-1997" MODIFIED="2010-05-02 17:13:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Domrongkitchaiporn 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-02 17:13:45 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Domrongkitchaiporn S, Chuncharunee S, Archararit N, Atamasirikul K, Vanichakarn S</AU>
<TI>Effect of dialyzer membranes on beta-2 microglobulin production in Thai hemodialysis patients</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1997</YR>
<VL>80 Suppl 1</VL>
<PG>S138-43</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:13:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:13:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9347661"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donovan-1992" MODIFIED="2010-05-02 17:14:42 +1000" MODIFIED_BY="Narelle S Willis" NAME="Donovan 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-02 17:14:42 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donovan KL, Pacholok S, Phillips A, Humes JL, Coles GA, Williams JD</AU>
<TI>Effect of dialyser composition and reuse on neutrophil count and elastase alpha-1 proteinase inhibitor complex formation</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>3</NO>
<PG>139-43</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:14:42 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:14:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1521897"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falkenhagen-1987" MODIFIED="2010-05-02 17:15:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Falkenhagen 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-02 17:15:57 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falkenhagen D, Bosch T, Brown GS, Schmidt B, Holtz M, Baurmeister U, et al</AU>
<TI>A clinical study on different cellulosic dialysis membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>6</NO>
<PG>537-45</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:15:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:15:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3126455"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-1995" MODIFIED="2010-05-02 17:16:48 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ferreira 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-02 17:16:48 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferreira A, Urena P, Ang KS, Simon P, Morieux C, Souberbielle JC, et al</AU>
<TI>Relationship between serum beta 2-microglobulin, bone histology, and dialysis membranes in uraemic patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>9</NO>
<PG>1701-7</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:16:48 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:16:48 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8559492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fourtunas-2001" MODIFIED="2010-05-02 17:17:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="Fourtunas 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-02 17:17:44 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fourtounas C, Kopelias I, Dimitriadis G, Agroyannis B, Locatelli F, Andrulli S</AU>
<TI>The impact of dialyzers on the anaemia of haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1077-8</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:17:44 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:17:44 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11328925"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-1993" MODIFIED="2010-05-02 17:23:40 +1000" MODIFIED_BY="Narelle S Willis" NAME="Fox 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-02 17:23:40 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox SD, Henderson LW</AU>
<TI>Cardiovascular response during hemodialysis and hemofiltration: thermal, membrane, and catecholamine influences</TI>
<SO>Blood Purification</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>4</NO>
<PG>224-36</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:23:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:23:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8297564"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franke-2002" MODIFIED="2011-03-22 11:42:42 +1100" MODIFIED_BY="[Empty name]" NAME="Franke 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-03-22 11:42:42 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franke S, Klemm A, Franke C, Niwa T, Lang D, Passlick-Deetjin J, et al</AU>
<TI>The impact of a new high-flux membrane -helixone- on serum age levels [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>September, Program &amp; Abstracts</NO>
<PG>717A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gasc_x00a2_n-1993" MODIFIED="2012-03-27 17:09:24 +1100" MODIFIED_BY="[Empty name]" NAME="Gasc¢n 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-27 17:09:24 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gascon A, Lerma JL, Orfao A, Lopez Fernandez A, Ciudad J, Tabemero JM</AU>
<TI>Behaviour of natural killer cells and TCR g-d lymphocytes during hemodialysis with different membranes [abstract]</TI>
<SO>12th International Congress of Nephrology; 1993 June 13-18; Jerusalem, Israel</SO>
<YR>1993</YR>
<PG>319</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girndt-1999" MODIFIED="2010-05-02 17:25:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Girndt 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-02 17:25:20 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girndt M, Heisel O, Kohler H</AU>
<TI>Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>23</NO>
<PG>676-82</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:25:20 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:25:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10193818"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonella-1994" MODIFIED="2010-05-02 17:26:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gonella 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 17:26:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonella M, Mazzotta A, Calabrese G, Guaschino R, Vagelli G, Pratesi G</AU>
<TI>Comparison between heparin dose during hemodiafiltration with high flux synthetic membranes</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>1</NO>
<PG>61-2</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:26:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:26:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8188402"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grekas-1985" MODIFIED="2010-05-02 17:34:14 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grekas 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-05-02 17:34:14 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grekas D, Syrganis C, Georgiou T, Zegla O,Tourkantonis A</AU>
<TI>Biocompatibility of cuprophan and cellulose acetate membranes. Prevention of dialysis hypoxemia and leucopenia by ticlopidine</TI>
<SO>Life Support Systems</SO>
<YR>1985</YR>
<VL>3 Suppl 1</VL>
<PG>68-72</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:34:14 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:34:14 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3870624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grooteman-1995" MODIFIED="2012-11-12 15:30:25 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Grooteman 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-02 17:39:42 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Nube MJ, van Limbeek J, van Houte AJ, Daha MR, van Geelen JA</AU>
<TI>Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphon</TI>
<SO>ASAIO Journal</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>2</NO>
<PG>215-20</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:39:42 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:39:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7640431"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grooteman-1995b" MODIFIED="2012-07-11 17:20:59 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Grooteman 1995b" YEAR="1995">
<REFERENCE MODIFIED="2011-06-26 17:48:17 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman M, Nube M, van Houte A, Schoorl M, van Geelen J</AU>
<TI>Dialyser membrane elution yields pmn with degranulative activity and little adherence [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>450</PG>
<IDENTIFIERS MODIFIED="2010-07-19 09:01:47 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-19 09:01:56 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman M, Nube M, van Houte A, Schoorl M, van Geelen J</AU>
<TI>Lymphocyte subsets in dialyser eluates might represent an index of biocompatibility [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>450</PG>
<IDENTIFIERS MODIFIED="2010-07-19 09:01:56 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-19 09:02:25 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Nube MJ, et al</AU>
<TI>Evidence of marked degranulative activity in polymorphonuclear cells (PMN) from dialyzer eluates [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>1034</PG>
<IDENTIFIERS MODIFIED="2010-07-19 09:02:25 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-19 09:02:18 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Nube MJ, et al</AU>
<TI>Lymphocyte subsets in dialyzer eluates represent an index of bio-incompatibility [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>1034</PG>
<IDENTIFIERS MODIFIED="2010-07-19 09:02:18 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 17:37:47 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Nube MJ, van Houte AJ, Schoorl M, van Limbeek J</AU>
<TI>Granulocyte sequestration in dialysers: a comparative elution study of three different membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>10</NO>
<PG>1859-64</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:37:47 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:37:47 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8592594"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 17:43:14 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Nube MJ, van Limbeek J, Schoorl M, van Houte AJ</AU>
<TI>Lymphocyte subsets in dialyser eluates: a new parameter of bioincompatibility</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>6</NO>
<PG>1073-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8671971"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grooteman-1997" MODIFIED="2010-05-02 17:47:25 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grooteman 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-02 17:47:25 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Nube MJ, Daha MR, Van Limbeek J, van Deuren M, Schoorl M, et al</AU>
<TI>Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes</TI>
<SO>Journal of the Amercian Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>11</NO>
<PG>1745-54</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:47:25 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:47:25 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9355078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grooteman-2005" MODIFIED="2012-03-28 16:25:47 +1100" MODIFIED_BY="[Empty name]" NAME="Grooteman 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-03-28 16:25:47 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Gritters M, Wauters IM, Schalkwijk CG, Stam F, Twisk J, et al</AU>
<TI>Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>12</NO>
<PG>2751-8</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:25:47 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:25:47 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16188898"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grooteman-2007" MODIFIED="2012-03-28 16:26:51 +1100" MODIFIED_BY="[Empty name]" NAME="Grooteman 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-03-28 16:26:51 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grooteman MP, Wauters IM, Teerlink T, Twisk JW, Nube MJ</AU>
<TI>Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied</TI>
<SO>Blood Purification</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>3</NO>
<PG>281-9</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:26:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:26:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17622710"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haag_x002d_Weber-1994" MODIFIED="2010-05-02 17:48:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Haag-Weber 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 17:48:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haag-Weber M, Mai B, Deppisch R, Gohl H, Horl WH</AU>
<TI>Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>4</NO>
<PG>245-51</PG>
<IDENTIFIERS MODIFIED="2010-05-02 17:48:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 17:48:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8026120"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakim-1995" MODIFIED="2010-05-07 15:03:49 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hakim 1995" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:03:49 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM</AU>
<TI>Recent advances in the biocompatibility of haemodialysis membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10 Suppl 10</VL>
<PG>7-11</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:03:49 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:03:49 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8825426"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakim-1996" MODIFIED="2012-03-27 17:18:03 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Hakim 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:04:41 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF</AU>
<TI>The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>3</NO>
<PG>472-8</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:04:41 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:04:41 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8704114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:29:37 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Wingard RL, Ikizler TA, Parker RA, Vanholder R, Husni L, et al</AU>
<TI>Effects of biocompatibility on nutritional status in chronic hemodialysis patients (chd) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>451</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:29:37 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-27 17:18:03 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Wingard RL, Parker RA, Vanholder R, Husni L, Parker TF 3rd</AU>
<TI>Effects of biocompatibility on hospitalizations and infectious morbidity in chronic hemodialysis patients (CHD) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>450</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:29:42 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haque-1994" MODIFIED="2010-05-07 15:07:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Haque 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 15:07:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haque SS, Ishaque M, Rashid HU, Rahman D</AU>
<TI>Study of effectivity and patient well being with cupraphan and cellulose acetate membrane dialyzer</TI>
<SO>Bangladesh Renal Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>1</NO>
<PG>24-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:07:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:07:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994252457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardouin-2000" MODIFIED="2010-05-07 15:08:33 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hardouin 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-07 15:08:33 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardouin P, Flipo RM, Foissac-Gegoux P, Dumont A, Duquesnoy B, Delcambre B</AU>
<TI>Dialysis-related beta 2 microglobulin-amyloid arthropathy. Improvement of clinical symptoms after a switch of dialysis membranes</TI>
<SO>Clinical Rheumatology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>1</NO>
<PG>41-5</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:08:33 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:08:33 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3044672"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haufe-2001" MODIFIED="2010-07-15 14:33:28 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Haufe 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-07-15 14:33:23 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haufe CC, Eismann U, Deppisch R, Stein G</AU>
<TI>Is the expression of beta-2-microglobulin messenger-RNA influenced by high-flux or low-flux dialyzer membranes? [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>282A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:33:23 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:33:28 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haufe CC, Eismann U, Deppisch R, Stein G</AU>
<TI>MRNA expression of beta-2-microglobulin (b2-m) and c-fos in patients with chronic renal replacement therapy [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>563A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:33:28 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-07 15:10:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haufe CC, Eismann U, Deppisch RM, Stein G</AU>
<TI>Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high- or low-flux dialyzer membranes?</TI>
<SO>Kidney International - Supplement</SO>
<YR>2001</YR>
<VL>78</VL>
<PG>S177-81</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:10:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:10:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11169006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heisel-1995" MODIFIED="2012-07-11 17:32:31 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Heisel 1995" YEAR="1996">
<REFERENCE MODIFIED="2012-07-11 17:32:31 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heisel O, Girndt M, Kohler H</AU>
<TI>Does a high flux membrane influence the monokine production of chronic dialysis patients? [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>533</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:34:58 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-26 17:48:51 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heisel O, Girndt M, Kohler H</AU>
<TI>Influence of a high flux membrane on the cytokine production of chronic dialysis patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>7</NO>
<PG>1472</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:11:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:11:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00261184"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez-2007a" MODIFIED="2012-11-12 15:30:37 +1100" MODIFIED_BY="[Empty name]" NAME="Hernandez 2007a" YEAR="2007">
<REFERENCE MODIFIED="2012-03-28 16:28:27 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez MR, Palomo M, Fuste B, Carbo C, Collado S, Cases A, et al</AU>
<TI>Effect of two different dialysis membranes on leukocyte adhesion and aggregation</TI>
<SO>Nephron</SO>
<YR>2007</YR>
<VL>106</VL>
<NO>1</NO>
<PG>c1-8</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:28:27 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:28:27 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17347577"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Himmelfarb-1993" MODIFIED="2010-05-02 16:21:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Himmelfarb 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-02 16:21:54 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM</AU>
<TI>Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1993</YR>
<VL>4</VL>
<NO>2</NO>
<PG>178-86</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:21:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:21:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8400081"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Himmelfarb-1998" MODIFIED="2010-07-15 14:31:50 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Himmelfarb 1998" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:05:48 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, et al</AU>
<TI>Effect of the dialysis membrane on mortality of chronic hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>1996</YR>
<VL>50</VL>
<NO>2</NO>
<PG>566-70</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:05:48 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:05:48 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8840287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:31:25 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Tolkoff-Rubin N, Himmelfarb J, Wingard RL, Parker RA</AU>
<TI>A multicenter comparison of bioincompatible (bicm) and biocompatible (bcm) membranes in the treatment of acute renal failure (arf) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>394</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:31:25 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:31:30 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Wingard RL, Lawrence P, Parker RA, Schulman G</AU>
<TI>Use of biocompatible membranes (bcm) improves outcome and recovery from acute renal failure (arf) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>3</NO>
<PG>367</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:31:30 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:31:37 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim RM, Wingard RL, Parker RA</AU>
<TI>Effect of the dialysis membrane in the treatment of patients with acute renal failure.[see comment]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>20</NO>
<PG>1338-42</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:31:34 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="7935703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:31:44 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Himmelfarb J, Tolkoff RN, Chandran P, Parker RA, Wingard RL, Hakim R</AU>
<TI>A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>2</NO>
<PG>257-66</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:31:41 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="9527402"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:31:50 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parker RA, Himmelfarb J, Tolkoff-Rubin N, Chandran P, Wingard RL, Hakim RM</AU>
<TI>Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>3</NO>
<PG>432-43</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:31:48 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="9740160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoenich-1994" MODIFIED="2010-05-07 15:14:15 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hoenich 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 15:14:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J</AU>
<TI>Clinical comparison of high-flux cellulose acetate and synthetic membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>1</NO>
<PG>60-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:14:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:14:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8177478"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoenich-1995" MODIFIED="2010-05-07 15:15:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hoenich 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-07 15:15:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoenich NA, Woffindin C, Mathews JN, Vienken J</AU>
<TI>Biocompatibility of membranes used in the treatment of renal failure</TI>
<SO>Biomaterials</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>8</NO>
<PG>587-92</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:15:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:15:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7548608"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoenich-1997" MODIFIED="2010-05-07 15:15:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hoenich 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 15:15:44 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoenich NA, Woffindin C, Cox PJ, Goldfinch M, Roberts SJ</AU>
<TI>Clinical characterization of Dicea a new cellulose membrane for haemodialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>1997</YR>
<VL>48</VL>
<NO>4</NO>
<PG>253-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:15:44 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:15:44 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9352161"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoenich-2000" MODIFIED="2012-11-12 15:30:55 +1100" MODIFIED_BY="Narelle S Willis" NAME="Hoenich 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-07 15:16:30 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoenich NA, Stamp S</AU>
<TI>Clinical performance of a new high-flux synthetic membrane</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>2</NO>
<PG>345-52</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:16:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:16:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10922313"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoenich-2000a" MODIFIED="2012-11-12 15:31:00 +1100" MODIFIED_BY="[Empty name]" NAME="Hoenich 2000a" YEAR="2000">
<REFERENCE MODIFIED="2011-03-22 11:44:09 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoenich NA, Stamp S, Roberts SJ</AU>
<TI>A microdomain-structured synthetic high-flux hollow-fiber membrane for renal replacement therapy</TI>
<SO>ASAIO Journal</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>1</NO>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hornberger-1992" MODIFIED="2010-05-07 15:17:14 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hornberger 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-07 15:17:14 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornberger JC, Chernew M, Petersen J, Garber AM</AU>
<TI>A multivariate analysis of mortality and hospital admissions with high-flux dialysis</TI>
<SO>Journal of the Amercian Society of Nephrology</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>6</NO>
<PG>1227-37</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:17:14 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:17:14 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1477318"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hornych-1996" MODIFIED="2010-05-07 15:18:02 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hornych 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:18:02 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hornych A, Remy P, Loung N, Aumont J, Bariety J</AU>
<TI>Biocompatibility of haemodialysis membranes: haemodialysis-related leukotriene B4 and C4 generation</TI>
<SO>Nephron</SO>
<YR>1996</YR>
<VL>74</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:18:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:18:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8883014"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huraib-2000" MODIFIED="2012-03-27 17:18:44 +1100" MODIFIED_BY="Narelle S Willis" NAME="Huraib 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-27 17:18:44 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huraib S, Tanimu D, Shaheen F, Hejaili FM, Giles C, Pagayon V</AU>
<TI>Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study</TI>
<SO>American Journal of Nephrology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>5</NO>
<PG>364-8</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:19:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:19:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11092992"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ingram-1998" MODIFIED="2010-05-07 15:19:56 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ingram 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-07 15:19:56 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ingram AJ, Parbtani A, Churchill DN</AU>
<TI>Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins--a cross-over trial</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>6</NO>
<PG>1452-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:19:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:19:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9641175"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iorio-1997" MODIFIED="2012-03-28 16:45:16 +1100" MODIFIED_BY="Narelle S Willis" NAME="Iorio 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-03-28 16:45:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iorio L, Saltarelli G, Nacca RG, Simonelli R, Violi F</AU>
<TI>Hyperlipidemia in dialysis patients: What treatment?</TI>
<SO>Mineral and Electrolyte Metabolism</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>3-6</NO>
<PG>311-3</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:20:45 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:20:45 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9387140"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivanovich-1983" MODIFIED="2010-05-07 15:21:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ivanovich 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-05-07 15:21:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ivanovich P, Chenoweth DE, Schmidt R, KlinkmannH, Boxer L A, Jacob HS, et al</AU>
<TI>Symptoms and activation of granulocytes and complement with two dialysis membranes</TI>
<SO>Kidney International</SO>
<YR>1983</YR>
<VL>24</VL>
<NO>6</NO>
<PG>758-63</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:21:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:21:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6609268"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Josephson-1992" MODIFIED="2012-07-11 17:22:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="Josephson 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-07 15:22:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Josephson MA, Fellner SK, Dasgupta A</AU>
<TI>Improved lipid profiles in patients undergoing high-flux hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1992</YR>
<VL>20</VL>
<NO>4</NO>
<PG>361-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:22:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:22:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1415204"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasama-1996" MODIFIED="2010-05-07 15:23:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kasama 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:23:17 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasama R, Koch T, Canals-Navas C, Pitone JM</AU>
<TI>Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>5</NO>
<PG>680-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:23:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:23:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8629628"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kato-2001" MODIFIED="2010-05-07 15:26:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kato 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 15:26:51 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kato A, Takita T, Furuhashi M, Takahashi T, Watanabe T, Maruyama Y, et al</AU>
<TI>Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha</TI>
<SO>Artificial Organs</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>6</NO>
<PG>441-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:26:51 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:26:51 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11453873"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2009" MODIFIED="2011-03-22 11:48:10 +1100" MODIFIED_BY="[Empty name]" NAME="Kim 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-02 13:41:57 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Kim S, Oh KH, Chin HJ, Na KY, Kim YS, Chae DW, et al</AU>
<TI>Effective removal of leptin via hemodiafiltration with on-line endogenous reinfusion therapy</TI>
<SO>Clinical Nephrology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>6</NO>
<PG>442-8</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:41:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:41:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19954721"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kino-1995" MODIFIED="2010-05-07 15:28:06 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kino 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-07 15:28:06 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kino K, Akizawa T, Koshikawa S</AU>
<TI>Effects of membrane characteristics on cytokine production by mononuclear cells in regular haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10 Suppl 3</VL>
<PG>29-33</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:28:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:28:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7494611"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirschbaum-1994" MODIFIED="2010-07-15 14:36:10 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Kirschbaum 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 15:29:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirschbaum B</AU>
<TI>The decline in serum albumin after conversion to high flux, high efficiency dialysis</TI>
<SO>Artificial Organs</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>10</NO>
<PG>729-35</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:29:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:29:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7832653"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klemm-1997" MODIFIED="2010-05-07 15:30:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Klemm 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 15:30:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klemm A, Sperschneider H, Winnefeld K, Gunther K, Stein G</AU>
<TI>Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients</TI>
<SO>Clinical Nephrology</SO>
<YR>1997</YR>
<VL>47</VL>
<NO>2</NO>
<PG>133-4</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:30:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:30:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9049466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klinkmann-1998" MODIFIED="2010-05-07 15:31:03 +1000" MODIFIED_BY="Narelle S Willis" NAME="Klinkmann 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-07 15:31:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klinkmann H, Buscaroli A, Stefoni S</AU>
<TI>Beta2-microglobulin and low-flux synthetic dialyzers</TI>
<SO>Artificial Organs</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>7</NO>
<PG>585-90</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:31:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:31:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9684696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koda-1997" MODIFIED="2012-03-28 16:45:55 +1100" MODIFIED_BY="Narelle S Willis" NAME="Koda 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 15:32:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, et al</AU>
<TI>Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>4</NO>
<PG>1096-101</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:32:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:32:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9328951"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1992" MODIFIED="2010-05-07 15:32:49 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kramer 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-07 15:32:49 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer BK, Pickert A, Hohmann C, Liebich HM, Muller GA, Hablitzel M et al</AU>
<TI>In vivo clearance and elimination of nine marker substances during hemofiltration with different membranes</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>7</NO>
<PG>408-12</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:32:49 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:32:49 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1516991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krieter-2008" MODIFIED="2011-03-22 11:48:14 +1100" MODIFIED_BY="[Empty name]" NAME="Krieter 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-02 16:25:20 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krieter DH, Lemke HD, Wanner C</AU>
<TI>A new synthetic dialyzer with advanced permselectivity for enhanced low-molecular weight protein removal</TI>
<SO>Artificial Organs</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>7</NO>
<PG>547-54</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:45:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:45:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18638309"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krieter-2010" MODIFIED="2011-03-22 11:48:19 +1100" MODIFIED_BY="[Empty name]" NAME="Krieter 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-05-02 13:49:55 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, et al</AU>
<TI>Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>1</NO>
<PG>212-8</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:49:47 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:49:47 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19755476"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2009b" MODIFIED="2011-03-22 11:48:28 +1100" MODIFIED_BY="[Empty name]" NAME="Lee 2009b" YEAR="2009">
<REFERENCE MODIFIED="2010-05-02 13:52:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Lee D, Haase M, Haase-Fielitz A, Paizis K, Goehl H, Bellomo R</AU>
<TI>A pilot, randomized, double-blind, cross-over study of high cut-off versus high-flux dialysis membranes</TI>
<SO>Blood Purification</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>4</NO>
<PG>365-72</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:52:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:52:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19729908"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leitienne-1991" MODIFIED="2012-03-28 16:48:01 +1100" MODIFIED_BY="[Empty name]" NAME="Leitienne 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-03-28 16:48:01 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leitienne P, Trzeciak MC, Adeleine P, Ville D, Dechavanne M, Traeger J, et al</AU>
<TI>Comparison of hemostasis with two high-flux hemocompatible dialysis membranes</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>4</NO>
<PG>227-33</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:48:01 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:48:01 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1829439"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1993" MODIFIED="2010-07-15 14:37:23 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Levin 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-07-15 14:37:23 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin N, Zasuwa G, Klinkmann H</AU>
<TI>Introduction, demography, and general methods</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>2-7</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:37:23 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="8272247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-07 15:33:49 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin NW, Zasuwa G</AU>
<TI>Relationship between dialyser type and signs and symptoms</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>30-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:33:49 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:33:49 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8272250"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-1996" MODIFIED="2010-05-07 15:34:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lin 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:34:45 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL, et al</AU>
<TI>Cytokine production during hemodialysis: Effects of dialytic membrane and complement activation</TI>
<SO>American Journal of Nephrology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>4</NO>
<PG>293-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:34:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:34:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8739281"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linnenweber-2001" MODIFIED="2010-05-07 15:36:01 +1000" MODIFIED_BY="Narelle S Willis" NAME="Linnenweber 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 15:36:01 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linnenweber S, Lonnemann G</AU>
<TI>Effects of dialyzer membrane on interleukin-1beta (IL-1beta) and IL-1beta-converting enzyme in mononuclear cells</TI>
<SO>Kidney International - Supplement</SO>
<YR>2001</YR>
<VL>78</VL>
<PG>S282-5</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:36:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:36:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11169027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-1996b" MODIFIED="2012-07-11 17:23:48 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 1996b" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 15:37:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F</AU>
<TI>Influence of membranes on morbidity</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>116-20</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:37:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:37:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8804010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-1997" MODIFIED="2010-05-07 15:39:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Locatelli 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 15:39:57 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Di Filippo S, Manzoni C</AU>
<TI>The effect of dialysis membrane on serum beta2-microglobulin in chronic haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>12</NO>
<PG>2804</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:39:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:39:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1997378135"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-1999" MODIFIED="2012-07-11 14:32:14 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-07-11 14:32:14 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Andrulli S, Del Vecchio L</AU>
<TI>Anemia of hemodialysis patients: evaluation of the effect of BK-F polymethylmethacrylate membrane</TI>
<SO>Contributions to Nephrology</SO>
<YR>1999</YR>
<VL>125</VL>
<PG>173-81</PG>
<IDENTIFIERS MODIFIED="2012-07-11 14:32:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2012-07-11 14:32:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9895439"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2000b" MODIFIED="2012-07-11 17:23:01 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 2000b" YEAR="2000">
<REFERENCE MODIFIED="2010-05-07 15:45:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Di Filippo S, Manzoni C</AU>
<TI>Removal of small and middle molecules by convective techniques</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15 Suppl 2</VL>
<PG>37-44</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:45:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:45:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11051036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2001a" MODIFIED="2012-07-11 17:22:37 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 2001a" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 15:49:41 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Andrulli S, D'Amico M</AU>
<TI>Evaluation of dialysis outcomes: experimental versus observational evidence</TI>
<SO>Journal of Nephrology</SO>
<YR>2001</YR>
<VL>14 Suppl 4</VL>
<PG>S101-8</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:49:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:49:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11798140"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2001b" MODIFIED="2012-07-11 17:22:31 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 2001b" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 15:50:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Del Vecchio L, Andrulli S</AU>
<TI>Dialysis: its role in optimizing recombinant erythropoietin treatment</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16 Suppl 7</VL>
<PG>29-35</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:50:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:50:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11590254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2002" MODIFIED="2010-05-07 15:51:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Locatelli 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-07 15:51:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F</AU>
<TI>Optimizing dose and mode of renal replacement therapy in anaemia management</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17 Suppl 5</VL>
<PG>60-5</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:51:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:51:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12091610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2003" MODIFIED="2010-07-15 14:53:31 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Locatelli 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-07 15:52:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loocatelli F</AU>
<TI>Dose of dialysis, convection and haemodialysis patients outcome - What the HEMO study doesn't tell us: The European viewpoint</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>6</NO>
<PG>1061-5</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:52:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:52:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12748335"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lonnenmann-2003" MODIFIED="2010-05-07 15:59:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lonnenmann 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-07 15:59:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonnemann G, Novick D, Rubinstein M, Passlick-Deetjen J, Lang D, Dinarello C</AU>
<TI>A switch to high-flux Helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis</TI>
<SO>Blood Purification</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>3</NO>
<PG>225-31</PG>
<IDENTIFIERS MODIFIED="2010-05-07 15:59:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 15:59:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12784048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundberg-1994" MODIFIED="2010-07-15 14:39:45 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Lundberg 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-02 14:28:06 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundberg L, Stegmayr BG, Wehle B</AU>
<TI>Backdiffusion or bicarbonate may stimulate complement activation during haemodialysis with low-flux membranes</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>3</NO>
<PG>131-6</PG>
<IDENTIFIERS MODIFIED="2010-05-02 14:28:06 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 14:28:06 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8050803"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacGinley-2001" MODIFIED="2010-05-07 16:00:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="MacGinley 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 16:00:36 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacGinley R, Westhuyzen J, Saltissi D, Morgan C, Healy H, Thirlwell GK, et al</AU>
<TI>Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer</TI>
<SO>ASAIO Journal</SO>
<YR>2001</YR>
<VL>47</VL>
<NO>1</NO>
<PG>66-73</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:00:36 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:00:36 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11199319"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahuet-2001" MODIFIED="2010-05-07 16:03:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mahuet 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 16:03:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maheut H, Lacour F</AU>
<TI>Using AN69 ST membrane: a dialysis centre experience</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>7</NO>
<PG>1519-20</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:03:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:03:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11427664"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MAMHEBI-Study-2006" MODIFIED="2012-07-11 17:32:56 +1000" MODIFIED_BY="[Empty name]" NAME="MAMHEBI Study 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-03-28 16:50:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santoro A, Mancini E, Bolzani R, Boggi R, Cagnoli L, Francioso A, et al</AU>
<TI>The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. [see comment]</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>52</VL>
<NO>3</NO>
<PG>507-18</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:50:28 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:50:28 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18617304"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:32:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santoro A, Mancini E, MAMHEBI Study Group</AU>
<TI>Effects of online hemofiltration (OL-HF) versus bicarbonate dialysis (BD) on mortality and morbidity in hemodialysis (HD) patients: a prospective, randomized, multicenter trial (MAMHEBI Study) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>24A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandolfo-2008" MODIFIED="2012-03-28 16:51:29 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Mandolfo 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-03-28 16:51:29 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandolfo S, Borlandelli S, Imbasciati E, Badalamenti S, Graziani G, Sereni L, et al</AU>
<TI>Pilot study to assess increased dialysis efficiency in patients with limited blood flow rates due to vascular access problems</TI>
<SO>Hemodialysis International</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>1</NO>
<PG>55-61</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:51:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:51:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18271842"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mann-2003" MODIFIED="2010-05-07 16:06:58 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mann 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-07 16:06:58 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mann H, Al-Bashir A, Melzer H, Stiller S</AU>
<TI>Diacap alpha-polysulfone HI PS: a new dialysis membrane with optimum beta2-microglobulin elimination</TI>
<SO>International Journal of Artifical Organs</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>6</NO>
<PG>461-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:06:58 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:06:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12866651"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-Ara-1994" MODIFIED="2010-05-07 16:12:33 +1000" MODIFIED_BY="Narelle S Willis" NAME="Martinez Ara 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:12:33 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez Ara J, Sanz Moreno C, Perez Garcia R</AU>
<TI>Cooperative study of nutrition in hemodialysis IV. Hemodialysis techniques and nutritional parameters</TI>
<SO>Nefrologia</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>Suppl 2</NO>
<PG>51-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:12:33 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:12:33 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994230874"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin_x002d_Malo-1991" MODIFIED="2010-05-07 16:07:57 +1000" MODIFIED_BY="Narelle S Willis" NAME="Martin-Malo 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-07 16:07:57 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Malo A, Castillo D, Castro M, Perez R, Rios A, Jaraba M, et al</AU>
<TI>Biocompatibility of dialysis membranes: a comparative study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1991</YR>
<VL>6 Suppl 2</VL>
<PG>55-8</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:07:57 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:07:57 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1866069"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin_x002d_Malo-1993" MODIFIED="2010-05-07 16:10:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Martin-Malo 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-07 16:10:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Malo A, Castillo D, Castro M, Perez R, Rios A, Jaraba M, et al</AU>
<TI>Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon</TI>
<SO>Kidney International - Supplement</SO>
<YR>1993</YR>
<VL>41</VL>
<PG>S213-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:10:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:10:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8320924"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martos-1997" MODIFIED="2010-05-07 16:13:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Martos 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 16:13:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martos MR, Hendry BM, Rodriguez-Puyol M, Dwight J, Diez-Marques ML, Rodriguez-Puyol D</AU>
<TI>Haemodialyser biocompatibility and erythrocyte structure and function</TI>
<SO>Clinica Chimica Acta</SO>
<YR>1997</YR>
<VL>265</VL>
<NO>2</NO>
<PG>235-46</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:13:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:13:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9385465"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthews-1994" MODIFIED="2010-05-07 16:14:21 +1000" MODIFIED_BY="Narelle S Willis" NAME="Matthews 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:14:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthews JN, Hoenich NA</AU>
<TI>Statistical aspects of the design and analysis of studies to compare haemodialysis membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9 Suppl 2</VL>
<PG>176-83</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:14:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:14:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8065612"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matzkies-2000" MODIFIED="2010-05-07 16:16:05 +1000" MODIFIED_BY="Narelle S Willis" NAME="Matzkies 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-07 16:16:05 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matzkies FK, Reinecke H, Tombach B, Kosch M, Hegger K, Milius M, et al</AU>
<TI>Influence of dialysis procedure, membrane surface and membrane material on iopromide elimination in patients with reduced kidney function</TI>
<SO>American Journal of Nephrology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>4</NO>
<PG>300-4</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:16:05 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:16:05 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10970983"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarthy-1997" MODIFIED="2010-05-07 16:16:52 +1000" MODIFIED_BY="Narelle S Willis" NAME="McCarthy 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 16:16:52 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy JT, Jenson BM, Squillace DP, Williams AW</AU>
<TI>Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>4</NO>
<PG>576-83</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:16:52 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:16:52 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9100048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehrotra-2009" MODIFIED="2012-07-11 17:33:13 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Mehrotra 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-11 17:33:13 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehrotra R, Bross R, Konishi T, Appel M, Tsoi L, Kopple JD</AU>
<TI>What is the optimal arterial pH for protein balance in automated peritoneal dialysis (APD) patients' [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>724A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:41:25 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 13:54:31 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Mehrotra R, Bross R, Wang H, Appell M, Tso L, Kopple JD</AU>
<TI>Effect of high-normal compared with low-normal arterial pH on protein balances in automated peritoneal dialysis patients</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>90</VL>
<NO>6</NO>
<PG>1532-40</PG>
<IDENTIFIERS MODIFIED="2010-05-02 13:54:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 13:54:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19846545"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Memoli-2000" MODIFIED="2010-05-07 16:18:39 +1000" MODIFIED_BY="Narelle S Willis" NAME="Memoli 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-07 16:18:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, et al</AU>
<TI>Role of different dialysis membranes in the release of interleukin-6- soluble receptor in uremic patients</TI>
<SO>Kidney International</SO>
<YR>2000</YR>
<VL>58</VL>
<NO>1</NO>
<PG>417-24</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:18:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:18:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10886590"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Memoli-2002" MODIFIED="2010-05-07 16:24:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Memoli 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-07 16:24:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, Marzano L, et al</AU>
<TI>Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>2</NO>
<PG>266-73</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:24:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:24:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11840366"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Memoli-2003" MODIFIED="2011-06-26 17:23:45 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Memoli 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-06-26 17:23:45 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Memoli B, Bisesti V, Saravo MT, Esposito P, D'Arcangelo R, Nicosia V, et al</AU>
<TI>Cytokine production in standard hemodialysis with a new polyethersulfone membrane: a cross-over study</TI>
<SO>Contributions to Nephrology</SO>
<YR>2003</YR>
<VL>138</VL>
<PG>80-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:24:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:24:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12463149"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merello-Godino-2002" MODIFIED="2010-05-07 16:25:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Merello Godino 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-07 16:25:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C</AU>
<TI>Results from EuCliD (European Clinical Dialysis Database): impact of shifting treatment modality</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1049-60</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:25:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:25:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12487392"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mioli--1994" MODIFIED="2010-05-07 16:27:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mioli  1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:27:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mioli VA, Balestra E, Bibiano L, Dellabella S, Fanciulli E, Gaffi,G, et al</AU>
<TI>Behavior of beta 2-microglobulin (B2-m) serum levels in uremic patients</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11</NO>
<PG>576-80</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:27:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:27:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7744516"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishkin-2002" MODIFIED="2011-03-22 18:53:41 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Mishkin 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-03-22 18:53:41 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishkin MA, Mishkin GJ, Lew SQ</AU>
<TI>Solute removal in hemodiafiltration compared to standard high flux dialysis: combined analysis of 2 cross over studies [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>September, Program &amp; Abstracts</NO>
<PG>238a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno-1996" MODIFIED="2010-05-07 16:28:27 +1000" MODIFIED_BY="Narelle S Willis" NAME="Moreno 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 16:28:27 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno F, Lopez Gomez JM, Sanz-Guajardo D, Jofre R, Valderrabano F</AU>
<TI>Quality of life in dialysis patients. A spanish multicentre study. Spanish Cooperative Renal Patients Quality of Life Study Group</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1996</YR>
<VL>11 Suppl 2</VL>
<PG>125-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:28:27 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:28:27 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8804012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moshfegh-2002" MODIFIED="2010-05-07 16:29:15 +1000" MODIFIED_BY="Narelle S Willis" NAME="Moshfegh 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-07 16:29:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moshfegh A, Jacobson SH, Hallden G, Thylen P, Lundahl J</AU>
<TI>Impact of hemodialysis membrane and permeability on neutrophil transmigration in vitro</TI>
<SO>Nephron</SO>
<YR>2002</YR>
<VL>91</VL>
<NO>4</NO>
<PG>659-65</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:29:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:29:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12138270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mudge-2005" MODIFIED="2012-07-11 17:36:30 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Mudge 2005" YEAR="2004">
<REFERENCE MODIFIED="2012-07-11 17:36:30 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mudge D, Rogers R, Hollett P, Law B, Reiger K, Petrie JJP, et al</AU>
<TI>Plasma homocysteine levels with standard high flux haemodialysis compared with fx class dialysers [abstract]</TI>
<SO>Nephrology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>A16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-28 16:53:10 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mudge DW, Rogers R, Hollett P, Law B, Reiger K, Petrie JJ, et al</AU>
<TI>Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>10</NO>
<PG>2178-85</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:53:10 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:53:10 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16030045"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1998" MODIFIED="2012-03-28 16:54:12 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Muller 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-28 16:54:12 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller TF, Seitz M, Eckle I, Lange H, Kolb G</AU>
<TI>Biocompatibility differences with respect to the dialyzer sterilization method</TI>
<SO>Nephron</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>2</NO>
<PG>139-42</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:54:12 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:54:12 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9496728"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munger-2000" MODIFIED="2012-03-28 16:54:19 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Munger 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-28 16:54:19 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH</AU>
<TI>Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2000</YR>
<VL>36</VL>
<NO>1</NO>
<PG>130-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10873882"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro-1994" MODIFIED="2010-07-15 14:43:30 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Navarro 1994" YEAR="1998">
<REFERENCE MODIFIED="2010-05-07 16:31:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro JF, Marcen R, Teruel JL, Martin del Rio R, Gamez C, Mora C, et al</AU>
<TI>Effect of different membranes on amino-acid losses during haemodialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>1</NO>
<PG>113-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:31:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:31:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9481725"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:43:30 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro JF, Marcen R, et al</AU>
<TI>Effect of different membranes on amino-acid (AA) losses during haemodialysis (HD) [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>995</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:43:30 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro-1997" MODIFIED="2010-05-07 16:30:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Navarro 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-07 16:30:22 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro JF, del Castillo N, Fernandez JL, Macia ML, Mendez ML, Chahin J, et al</AU>
<TI>Hemodialysis urea rebound and membrane biocompatibility: accuracy of Kt/V estimations</TI>
<SO>Artificial Organs</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>2</NO>
<PG>91-5</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:30:22 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:30:22 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9028489"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nensel-1994" MODIFIED="2010-05-07 16:32:39 +1000" MODIFIED_BY="Narelle S Willis" NAME="Nensel 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:32:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nensel U, Rockel A, Hillenbrand T, Bartel J</AU>
<TI>Dialyzer permeability for low-molecular-weight proteins. Comparison between polysulfone, polyamide and cuprammonium rayon dialyzers</TI>
<SO>Blood Purification</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>2</NO>
<PG>128-34</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:32:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:32:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7530014"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohi-2001" MODIFIED="2010-05-07 16:33:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ohi 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 16:33:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohi H, Tamano M, Sudo S</AU>
<TI>Cellulose membranes suppress complement activation in patients after hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>2</NO>
<PG>384-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:33:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:33:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11479166"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opatrny-1993" MODIFIED="2011-05-24 14:22:41 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Opatrny 1993" YEAR="1998">
<REFERENCE MODIFIED="2011-05-24 14:22:41 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opatrny K Jr, Krouzecky A, Wirth J, Vit L, Eiselt J</AU>
<TI>The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis</TI>
<SO>Artificial Organs</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>10</NO>
<PG>816-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9790077"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-05-24 14:22:41 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Opatrny K, Sulkova S, Lopot F, Vit L, Valek A, Opatrny K</AU>
<TI>Clinical study of high-flux cuprammonium rayon hemodialysis membranes</TI>
<SO>Artificial Organs</SO>
<YR>1993</YR>
<VL>17</VL>
<NO>12</NO>
<PG>971-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8110071"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opatrny-1995" MODIFIED="2010-05-07 16:34:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Opatrny 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-07 16:34:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opatrny K Jr, Vit L, Opatrna S, Polakovic V, Sefrna F, Sulkova S, et al</AU>
<TI>Hemocompatibility in hemodialysis and erythropoietin therapy</TI>
<SO>Artificial Organs</SO>
<YR>1995</YR>
<VL>19</VL>
<NO>8</NO>
<PG>814-20</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:34:29 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:34:29 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8573001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opatrny-2006" MODIFIED="2012-03-28 16:55:52 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Opatrny 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-03-28 16:55:52 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opatrny K, Krouzzecky A, Polanska K, Mares J, Tomsu M, Bowry SK, et al</AU>
<TI>Does an alteration of dialyzer design and geometry affect biocompatibility parameters?</TI>
<SO>Hemodialysis International</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>201-8</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:55:52 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:55:52 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16623675"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otti-2001" MODIFIED="2010-05-07 16:40:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="Otti 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 16:40:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otti T, Khajehdehi P, Fawzy A, Gellens M, Bastani B</AU>
<TI>Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes</TI>
<SO>American Journal of Nephrology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>16-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:40:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:40:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11275627"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouseph-2008" MODIFIED="2012-07-11 17:33:35 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Ouseph 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-03-28 16:56:47 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouseph R, Hutchison CA, Ward RA</AU>
<TI>Differences in solute removal by two high-flux membranes of nominally similar synthetic polymers. [see comment]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>5</NO>
<PG>1704-12</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:56:47 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:56:47 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18156455"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:33:35 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward RA, Ouseph R, Utz J</AU>
<TI>Comparison of solute removal by high-flux dialyzers containing membranes of nominally similar synthetic polymers [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v118</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panichi-1995" MODIFIED="2010-05-07 16:41:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Panichi 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-07 16:41:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panichi V, Bianchi AM, Cirami C, Parrini M, Andreini B, Finato V, et al</AU>
<TI>Paired filtration dialysis (PFD): Biocompatibility, dialytic efficiency and clinical tolerance in a long-term multicenter trial</TI>
<SO>Journal of Nephrology</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>3</NO>
<PG>155-61</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:41:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:41:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1995200632"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parker-1996" MODIFIED="2010-05-07 16:42:46 +1000" MODIFIED_BY="Narelle S Willis" NAME="Parker 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 16:42:46 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parker TF 3rd, Wingard RL, Husni L, Alp Ikizler T, Parker RA, Hakim RM</AU>
<TI>Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>2</NO>
<PG>551-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:42:46 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:42:46 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8821843"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pellicano-2008" MODIFIED="2012-07-11 17:33:59 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Pellicano 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-07-11 17:33:46 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pellicano R, Polkinghorne K, Tuominen O, Woods F, Kerr P</AU>
<TI>Crossover trial of porous haemodialysis membrane compared to conventional high-flux membrane: assessment of middle molecule clearance and nutritional parameters [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 6</NO>
<PG>vi131</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:33:59 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pellicano R, Polkinghorne K, Tuominen O, Woods F, Kerr PG</AU>
<TI>Improved clearance of beta 2-microglobulin with superflux dialysis membranes: a randomised double-blind crossover trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>248A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-28 16:58:06 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pellicano R, Polkinghorne KR, Kerr PG</AU>
<TI>Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>52</VL>
<NO>1</NO>
<PG>93-101</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:58:06 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:58:06 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18423807"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pengloan-1991" MODIFIED="2010-07-15 14:45:49 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Pengloan 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-02 14:25:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pengloan J, Petit A, Thibaut G, Blanchier D, Bardos P</AU>
<TI>Biocompatibility of dialyser membranes: roles of membranes and of patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1991</YR>
<VL>6 Suppl 2</VL>
<PG>59-60</PG>
<IDENTIFIERS MODIFIED="2010-05-02 14:25:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 14:25:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1866070"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pereira-1996" MODIFIED="2010-05-07 16:44:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Pereira 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-07 16:44:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereira BJ, Natov SN, Sundaram S, Schmid CH, Trabelsi FR, Strom JA, et al</AU>
<TI>Impact of single use versus reuse of cellulose dialyzers on clinical parameters and indices of biocompatibility</TI>
<SO>Journal of American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>6</NO>
<PG>861-70</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:44:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:44:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8793794"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pickett-2002" MODIFIED="2010-05-07 16:45:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Pickett 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-07 16:45:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pickett TM, Cruickshank A, Greenwood RN, Taube D, Davenport A, Farrington K</AU>
<TI>Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients</TI>
<SO>Blood Purification</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>2</NO>
<PG>161-6</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:45:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:45:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11818679"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponikvar-2001" MODIFIED="2012-03-28 16:59:21 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Ponikvar 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-03-22 19:06:35 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buturovic J, Rus R, Ponikvar R, Kremzar B, Horvat M, Muzlovic I, et al</AU>
<TI>Low flux vs high flux synthetic membrane in the patients with acute renal failure and multiorgan failure treated with hemodialysis: prospective randomized study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>128A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 19:06:35 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buturovic J, Rus R, Ponikvar R, Kremzar B, Horvat M, Muzlovic I, et al</AU>
<TI>Low flux vs. high flux synthetic membrane in the patients with acute renal failure and multiorgan failure treated with hemodialysis: Prospective randomized study [abstract]</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>10</NO>
<PG>625</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-28 16:59:21 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponikvar JB, Rus RR, Kenda RB, Bren AF, Ponikvar RR</AU>
<TI>Low-flux versus high-flux synthetic dialysis membrane in acute renal failure: prospective randomized study</TI>
<SO>Artificial Organs</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>12</NO>
<PG>946-50</PG>
<IDENTIFIERS MODIFIED="2012-03-28 16:59:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 16:59:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 11843761"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quellhorst--1979" MODIFIED="2010-05-07 16:46:21 +1000" MODIFIED_BY="Narelle S Willis" NAME="Quellhorst  1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-07 16:46:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quellhorst E</AU>
<TI>Hemofiltration - differential indication for hemodialysis with reference to hemodynamic and metabolic aspects</TI>
<TO>Hamofiltration-Differentialindikation zur hamodialyse unter berucksichtigung hamodynamischer und metabolischer aspekte</TO>
<SO>Klinische Wochenschrift</SO>
<YR>1979</YR>
<VL>57</VL>
<NO>19</NO>
<PG>1061-8</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:46:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:46:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1980037798"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riegel-2001" MODIFIED="2010-05-07 16:47:25 +1000" MODIFIED_BY="Narelle S Willis" NAME="Riegel 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 16:47:25 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riegel W, Ulrich C, Sauernheimer S, Deppisch RM, Kohler H</AU>
<TI>Hepatotoxic substance(s) removed by high-flux membranes enhances the positive acute phase response</TI>
<SO>Kidney International - Supplement</SO>
<YR>2001</YR>
<VL>78</VL>
<PG>S308-14</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:47:25 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:47:25 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11169032"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Risler-1994" MODIFIED="2010-05-07 16:48:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Risler 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:48:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Risler T, Braun N, Hanel KD, Kuhlmann U, Skroch D, Muller GA</AU>
<TI>Do different dialysis-membranes affect beta 2-microglobulin kinetics during chronic hemodialysis?</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11</NO>
<PG>581-4</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:48:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:48:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7744517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritz-1994" MODIFIED="2010-05-07 16:49:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ritz 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:49:04 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritz E</AU>
<TI>Phosphate removal during dialysis - Does the membrane matter?</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>42</VL>
<NO>Suppl 1</NO>
<PG>S57-60</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:49:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:49:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7923986"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robles-1993" MODIFIED="2010-05-07 16:49:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Robles 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-07 16:49:54 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robles NR, Murga L, Galvan S, Esparrago JF, Sanchez-Casado E</AU>
<TI>Hemodialysis with cuprophane or polysulfone: Effects on uremic polyneuropathy</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>3</NO>
<PG>282-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:49:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:49:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8383423"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robles-1995" MODIFIED="2010-05-07 16:51:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="Robles 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-07 16:51:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robles NR, Gomez-Ainsua C, Cruz A</AU>
<TI>Cellulose acetate and cuprophane for hemodialysis: Effects on protein catabolic rate</TI>
<SO>Nephron</SO>
<YR>1995</YR>
<VL>70</VL>
<NO>4</NO>
<PG>508-9</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:51:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:51:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7477664"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ronco-1995" MODIFIED="2011-03-22 19:07:41 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Ronco 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-03-22 19:07:41 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ronco C, Fox K, Curtin C, Heifetz A</AU>
<TI>Evaluation of beta-2-microglobulin (b2m) removal by high flux dialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sa-2002" MODIFIED="2012-07-11 17:34:18 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Sa 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-07-11 17:34:18 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sa HO, Freitas L, Alves V, Manuel R, Mario C</AU>
<TI>Annexin v-affinity assay to study lymphocyte apoptosis during low and high-flux hemodialysis [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 12</NO>
<PG>157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaefer-1987" MODIFIED="2010-05-07 16:52:39 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schaefer 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-07 16:52:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer RM, Horl WH, Kokot K, Heidland A</AU>
<TI>Enhanced biocompatibility with a new cellulosic membrane: Cuprophan versus Hemophan</TI>
<SO>Blood Purification</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>4</NO>
<PG>262-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:52:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:52:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3426830"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaefer-1993" MODIFIED="2010-05-07 16:53:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schaefer 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-07 16:53:30 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer RM, Fink E, Schaefer L, Barkhausen R, Kulzer P, Heidland A</AU>
<TI>Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialyzers</TI>
<SO>American Journal of Nephrology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>6</NO>
<PG>473-7</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:53:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:53:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8141183"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaefer-1994" MODIFIED="2010-05-07 16:54:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schaefer 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-07 16:54:17 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaefer RM, Kulzer P, Gilge U, Schaefer L, Heidland A</AU>
<TI>Clinical evaluation of the new, steam-sterilized polysulfone high-flux dialyzer</TI>
<SO>Clinical Nephrology</SO>
<YR>1994</YR>
<VL>42 Suppl 1</VL>
<PG>S21-5</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:54:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:54:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7923978"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schauer-1991" MODIFIED="2010-05-08 13:17:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schauer 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-08 13:17:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schauer S, Stein G, Suss J, Falkenhagen D, Linss W</AU>
<TI>Phagocytosis activity of polymorphonuclear cells of normal persons and dialysis patients is influenced by different dialysis membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1991</YR>
<VL>6 Suppl 3</VL>
<PG>35-40</PG>
<IDENTIFIERS MODIFIED="2010-05-07 16:55:12 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-07 16:55:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1775265"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffl-2000" MODIFIED="2010-05-08 13:18:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schiffl 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-08 13:18:54 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffl H, Fischer R, Lang SM, Mangel E</AU>
<TI>Clinical manifestations of AB-amyloidosis: Effects of biocompatibility and flux</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>6</NO>
<PG>840-5</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:18:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:18:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10831638"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schindler-2000" MODIFIED="2010-07-15 14:47:06 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Schindler 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-08 13:20:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindler R, Boenisch O, Fischer C, Frei U</AU>
<TI>Effect of the hemodialysis membrane on the inflammatory reaction in vivo</TI>
<SO>Clinical Nephrology</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>6</NO>
<PG>452-9</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:20:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:20:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10879665"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:47:06 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindler R, Boenisch O, Fischer HC, Eckardt KU, Frei U</AU>
<TI>Plasma c-reactive protein (CRP) and cytokine production in chronic dialysis patients is influenced by the dialysis membrane [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>225A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:47:06 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schindler-2003" MODIFIED="2010-05-08 13:21:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schindler 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-08 13:21:09 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S</AU>
<TI>Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens</TI>
<SO>Clinical Nephrology</SO>
<YR>2003</YR>
<VL>59</VL>
<NO>6</NO>
<PG>447-54</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:21:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:21:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12834177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schonermarck-2006" MODIFIED="2012-03-28 17:01:03 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Schonermarck 2006" YEAR="2007">
<REFERENCE MODIFIED="2012-03-28 17:00:24 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schonermarck U, Dengler C, Ebeling F, Heydenreich M, Hillebrand GF, Samtleben W</AU>
<TI>Comparative evaluation of oxidative and antioxidative capacity during high-flux hemodialysis using two different membranes</TI>
<SO>Clinical Nephrology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>5</NO>
<PG>357-63</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:00:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17140165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-22 19:13:18 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schonermarck U, Dengler C, Ebeling F, Heydenreich M, Hillebrand GF, Samtleben W</AU>
<TI>Comparative evaluation of oxidative and antioxidative capacity during high-flux hemodialysis using two different membranes</TI>
<SO>Nieren und Hochdruckkrankheiten</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>4</NO>
<PG>128-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="2007253016"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schouten-1997" MODIFIED="2011-03-22 11:48:35 +1100" MODIFIED_BY="[Empty name]" NAME="Schouten 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-02 14:23:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schouten WE, Grooternan MP, et al</AU>
<TI>Intermittent induction of the acute phase response by clinical hemodialysis: the influence of dialyzer membranes [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>A175</PG>
<IDENTIFIERS MODIFIED="2010-05-02 14:23:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 14:23:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00261424"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schouten-2000" MODIFIED="2010-05-08 13:22:03 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schouten 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-08 13:22:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ</AU>
<TI>Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>3</NO>
<PG>379-84</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:22:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:22:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10692524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schroder-2001" MODIFIED="2010-05-08 13:23:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schroder 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-08 13:23:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W</AU>
<TI>Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes</TI>
<SO>Kidney International - Supplement</SO>
<YR>2001</YR>
<VL>78</VL>
<PG>S19-24</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:23:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:23:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11168977"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schultze-1987" MODIFIED="2010-05-08 13:24:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schultze 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-08 13:24:22 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SchultzecG, Wagner K, Neumayer HH, Fitzner R, Molzahn M</AU>
<TI>Effect of dialyzer membranes on in vitro generation of eicosanoids</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>4</NO>
<PG>275-8</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:24:22 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:24:22 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3478308"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwalbe-1987" MODIFIED="2010-05-08 13:25:34 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schwalbe 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-08 13:25:34 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch KM, Floege J</AU>
<TI>Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis?</TI>
<SO>Kidney International</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>4</NO>
<PG>1077-83</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:25:34 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:25:34 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9328948"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sethi-1988" MODIFIED="2010-05-08 13:27:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sethi 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-08 13:27:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sethi D, Gower PE</AU>
<TI>Dialysis arthropathy, beta 2-microglobulin and the effect of dialyser membrane</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>6</NO>
<PG>768-72</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:27:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:27:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3147418"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sevillano-1990" MODIFIED="2010-05-08 13:28:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sevillano 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-08 13:28:30 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sevillano G, Rodriguez-Puyol M, Martos R, Duque I, Lamas S, DiezMarques ML, et al</AU>
<TI>Cellulose acetate membrane improves some aspects of red blood cell function in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>7</NO>
<PG>497-9</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:28:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:28:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2130294"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2003" MODIFIED="2010-05-08 13:29:39 +1000" MODIFIED_BY="Narelle S Willis" NAME="Singh 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-08 13:29:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh NP, Bansal R, Thakur A, Kohli R, Bansal RC, Agarwal SK</AU>
<TI>Effect of membrane composition on cytokine production and clinical symptoms during hemodialysis: a crossover study</TI>
<SO>Renal Failure</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>3</NO>
<PG>419-30</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:29:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:29:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12803505"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirolli-1999" MODIFIED="2010-05-08 13:30:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sirolli 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-08 13:30:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirolli V, Ballone E, Amoroso L, Di Liberato L, Di Mascio R, Capelli P, et al</AU>
<TI>Leukocyte adhesion molecules and leukocyte-platelet interactions during hemodialysis: effects of different synthetic membranes</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>8</NO>
<PG>536-42</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:30:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:30:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10533909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirolli-2000" MODIFIED="2012-03-28 17:03:31 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Sirolli 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-28 17:03:31 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirolli V, Di Stante S, Stuard S, Di Liberato L, Amoroso L, Cappelli P, et al</AU>
<TI>Biocompatibility and functional performance of a polyethylene glycol acid-grafted cellulosic membrane for hemodialysis</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>6</NO>
<PG>356-64</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10919752"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirolli-2002" MODIFIED="2010-05-08 13:31:25 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sirolli 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-08 13:31:25 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirolli V, Ballone E, Di Stante S, Amoroso L, Bonomini M</AU>
<TI>Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane</TI>
<SO>International Journal Artificial Organs</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>6</NO>
<PG>529-37</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:31:25 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:31:25 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12117292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sklar-1998" MODIFIED="2010-05-08 13:32:54 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sklar 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-08 13:32:54 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sklar AH, Beezhoild DH, Newman N, Hendrickso T, Dreisbach AW</AU>
<TI>Postdialysis fatigue: Lack of effect of a biocompatible membrane</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1007-10</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:32:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:32:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9631846"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sklar-1999" MODIFIED="2010-05-08 13:33:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sklar 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-08 13:33:31 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sklar A, Newman N, Scott R, Semenyuk L, Schultz J, Fiacco V</AU>
<TI>Identification of factors responsible for postdialysis fatigue</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>3</NO>
<PG>464-70</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:33:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:33:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10469856"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skroeder-1990" MODIFIED="2010-05-02 16:41:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Skroeder 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-02 16:41:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skroeder NR, Jacobson SH, Lins L.E, Kjellstrand CM</AU>
<TI>Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis</TI>
<SO>ASAIO Transactions</SO>
<YR>1990</YR>
<VL>36</VL>
<NO>3</NO>
<PG>M637-9</PG>
<IDENTIFIERS MODIFIED="2010-05-02 16:41:27 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 16:41:27 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2252771"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sombolos-1997" MODIFIED="2010-05-08 13:34:39 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sombolos 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-08 13:34:39 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sombolos K, Tsitamidou Z, Kyriazis G, Karagianni A, Kantaropoulou M, Progia E</AU>
<TI>Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo</TI>
<SO>American Journal of Nephrology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>5</NO>
<PG>406-12</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:34:39 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:34:39 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9382156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sreeharan-1982" MODIFIED="2010-05-08 13:35:20 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sreeharan 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-08 13:35:20 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sreeharan N, Crow MJ, Salter MC</AU>
<TI>Membrane effect on platelet function during hemodialysis: a comparison of cuprophan and polycarbonate</TI>
<SO>Artificial Organs</SO>
<YR>1982</YR>
<VL>6</VL>
<NO>3</NO>
<PG>324-7</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:35:20 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:35:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6217802"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stefanovic1998" MODIFIED="2010-05-08 13:36:03 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stefanovic1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-08 13:36:03 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stefanovic V, Vlahovic P, Kostic S, Mitic-Zlatkovic M</AU>
<TI>In vitro blood compatibility evaluation of cuprophan and polyacrylonitrile membranes</TI>
<SO>Nephron</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>3</NO>
<PG>350-1</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:36:03 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:36:03 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9678440"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmayr-1992" MODIFIED="2010-05-08 13:37:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stegmayr 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-08 13:37:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Esbensen K, Gutierrez A, Lundberg L, Nielsen B, Stroemsaeter CE, et al</AU>
<TI>Granulocyte elastase, beta-thromboglobulin, and C3d during acetate or bicarbonate hemodialysis with Hemophan compared to a cellulose acetate membrane</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>1</NO>
<PG>10-8</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:37:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:37:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1532382"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmayr-1998" MODIFIED="2012-07-11 17:34:35 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stegmayr 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-07-11 17:34:35 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Hussain A</AU>
<TI>Serum Beta2- Microglobulin increases during HD with a hemophane but not with a cellulose diacetate dialyzer [abstract]</TI>
<SO>International Journal of Artifical Organs</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>10</NO>
<PG>634</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:39:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:39:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00322004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmayr-1999" MODIFIED="2012-03-27 17:08:02 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Stegmayr 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-08 13:40:52 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Almroth G, Berlin G, Fehrman I, Kurkus J, Norda R, et al</AU>
<TI>Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>2</NO>
<PG>81-7</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:40:49 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:40:49 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10212042"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-27 17:08:02 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stegmayr BG, Almroth G, Kurkus J, Olander R, Sterner G, Thysell H, et al</AU>
<TI>Plasma exchange versus immunoadsorption in the treatment of rapidly progressive glomerulonephritis (rpg). A multi-center study [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>294</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:48:35 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-2001" MODIFIED="2010-05-08 13:41:45 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stein 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-08 13:41:45 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, et al</AU>
<TI>Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>5</NO>
<PG>999-1008</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:41:45 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:41:45 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11328907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stuard-1996" MODIFIED="2010-05-08 13:42:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stuard 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-08 13:42:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stuard S, Bonomini M, Santarelli P, Carreno MP, Settefrati N, Tetta C, et al</AU>
<TI>Cell-associated and soluble adhesion molecules during hemodialysis with synthetic membranes</TI>
<SO>Giornale Italiano Di Nefrologia</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>3</NO>
<PG>175-85</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:42:29 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:42:29 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1996169305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sultan-1990" MODIFIED="2010-05-08 13:43:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Sultan 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-08 13:43:22 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sultan Y, London GM, Goldfarb B, Toulon P, Marchais SJ</AU>
<TI>Activation of platelets, coagulation and fibrinolysis in patients on long-term haemodialysis: influence of cuprophan and polyacrylonitrile membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>5</NO>
<PG>362-8</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:43:22 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:43:22 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2142756"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takenaka-2001a" MODIFIED="2010-05-08 13:44:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="Takenaka 2001a" YEAR="2001">
<REFERENCE MODIFIED="2010-05-08 13:44:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takenaka T, Itaya Y, Tsuchiya Y, Kobayashi K, Suzuki H</AU>
<TI>Fitness of biocompatible high-flux hemodiafiltration for dialysis-related amyloidosis</TI>
<SO>Blood Purification</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:44:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:44:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11114571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takenaka-2001b" MODIFIED="2010-05-08 13:44:40 +1000" MODIFIED_BY="Narelle S Willis" NAME="Takenaka 2001b" YEAR="2001">
<REFERENCE MODIFIED="2010-05-08 13:44:40 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takenaka T, Kobayashi K, Suzuki H</AU>
<TI>Warning of high-flux hemodialysis</TI>
<SO>Renal Failure</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>6</NO>
<PG>819-25</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:44:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:44:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11777321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tayeb-2000" MODIFIED="2010-05-08 13:45:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Tayeb 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-08 13:45:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tayeb JS, Provenzano R, El-Ghoroury M, Bellovich K, Khairullah Q, Pieper D, et al</AU>
<TI>Effect of biocompatibility of hemodialysis membranes on serum albumin levels</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>4</NO>
<PG>606-10</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:45:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:45:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10739779"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1992" MODIFIED="2010-05-08 13:46:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Taylor 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-08 13:46:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor JE, McLaren M, Mactier RA, Henderson IS, Stewart WK, Belch JJ</AU>
<TI>Effect of dialyzer geometry during hemodialysis with cuprophane membranes</TI>
<SO>Kidney International</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>2</NO>
<PG>442-7</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:46:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:46:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1405328"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tessitore-2000" MODIFIED="2011-03-22 19:17:03 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Tessitore 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-03-22 19:17:03 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tessitore N, Lapolla A, Arico N, Gammaro L, Bedogna V, Valenti G, et al</AU>
<TI>Effect of BKF polymethylmethacrylate hemodialysis (hd) on plasma pentosidine (pe) levels [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>Sept</NO>
<PG>178A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tessitore-2004" MODIFIED="2011-03-22 19:17:36 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Tessitore 2004" YEAR="2004 Sep">
<REFERENCE MODIFIED="2011-03-22 19:17:36 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tessitore N, Lapolla A, Arico NC, Poli A, Gammaro L, Bassi A, et al</AU>
<TI>Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels</TI>
<SO>Journal of Nephrology</SO>
<YR>2004 Sep</YR>
<VL>17</VL>
<NO>5</NO>
<PG>707-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15593039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thalhammer-1998" MODIFIED="2010-05-08 13:47:10 +1000" MODIFIED_BY="Narelle S Willis" NAME="Thalhammer 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-08 13:47:10 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thalhammer F, Kletzmayr J, El Menyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, et al</AU>
<TI>Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>32</VL>
<NO>4</NO>
<PG>642-5</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:47:10 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:47:10 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9774127"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thijs-2007" MODIFIED="2012-03-28 17:05:38 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Thijs 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-03-28 17:05:38 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thijs A, Grooteman MP, Zweegman S, Nube MJ, Huijgens PC, Stehouwer CD</AU>
<TI>Platelet activation during haemodialysis: comparison of cuprammonium rayon and polysulfone membranes</TI>
<SO>Blood Purification</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>5-6</NO>
<PG>389-94</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:05:38 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:05:38 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17890860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonelli-2009" MODIFIED="2012-07-11 17:34:53 +1000" MODIFIED_BY="[Empty name]" NAME="Tonelli 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-02 14:03:15 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Tonelli M, Wang W, Hemmelgarn B, Lloyd A, Manns B, Alberta Kidney Disease Network</AU>
<TI>Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>6</NO>
<PG>1108-15</PG>
<IDENTIFIERS MODIFIED="2010-05-02 14:03:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 14:03:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19619920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-15 14:49:51 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang W, Tonelli M, Hemmelgarn B, Gao S, Johnson JA, Taub K, et al</AU>
<TI>The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2008</YR>
<VL>51</VL>
<NO>5</NO>
<PG>796-803</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:49:48 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="18436090"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-07-11 17:34:53 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang W, Tonelli M, Hemmelgarn B, Taub K, Johnson J, Manns BJ</AU>
<TI>Increasing small solute clearance in underdialysed large hemodialysis patients does not improve quality of life: a randomized cross-over study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>867A</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:49:56 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Traut-2007" MODIFIED="2012-03-28 17:06:52 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Traut 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-03-28 17:06:52 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Traut M, Haufe CC, Eismann U, Deppisch RM, Stein G, Wolf G</AU>
<TI>Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study. [see comment]</TI>
<SO>Blood Purification</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>5-6</NO>
<PG>432-40</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:06:52 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:06:52 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17957097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tridon-1987" MODIFIED="2012-07-11 17:36:42 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Tridon 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-07-11 17:36:42 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deteix P, Betail G, Tridon A, Gaillard G, Marques-Verdier A, Cluzel P, et al</AU>
<TI>Histamine release during hemodialysis [abstract]</TI>
<SO>Kidney International</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>427</PG>
<IDENTIFIERS MODIFIED="2010-07-15 14:51:25 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-02 14:19:53 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tridon A, Deteix P, Coves G, Cluzel P, Marqués Verdier A, Wauquier JP, et al</AU>
<TI>Evaluation of the biocompatibility of a new cellulose membrane by studying the complement system and histamine liberation</TI>
<TO>Evaluation de la biocompatibilité d'une nouvelle membrane cellulosique par l'étude du système du complément et de l'histaminolibération</TO>
<SO>Néphrologie</SO>
<YR>1987</YR>
<VL>8</VL>
<NO>4</NO>
<PG>217-21</PG>
<IDENTIFIERS MODIFIED="2010-05-02 14:19:53 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-02 14:19:53 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2447516"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valentijn-1998" MODIFIED="2010-05-08 13:48:43 +1000" MODIFIED_BY="Narelle S Willis" NAME="Valentijn 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-08 13:48:43 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valentijn RM</AU>
<TI>Aluminum removal: AN69-S membrane versus a combined cuprophane and charcoal filter</TI>
<SO>Kidney International</SO>
<YR>1988</YR>
<VL>24</VL>
<NO>Suppl</NO>
<PG>S171</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:48:43 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:48:43 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3163041"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanherweghem-1988" MODIFIED="2010-05-08 13:52:32 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vanherweghem 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-08 13:52:32 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanherweghem JL, Leon M, Goldman M, Lietar N, Gamar N, Thayse C</AU>
<TI>Membrane-related eosinophilia in hemodialysis</TI>
<SO>Kidney International - Supplement</SO>
<YR>1988</YR>
<VL>24</VL>
<PG>S73-4</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:52:32 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:52:32 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3163056"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanholder-1988" MODIFIED="2010-05-08 13:53:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vanholder 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-08 13:53:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanholder RC, Sys E, DeCubber A, Vermaercke N, Ringoir SM</AU>
<TI>Performance of cuprophane and polyacrylonitrile dialyzers during multiple use</TI>
<SO>Kidney International - Supplement</SO>
<YR>1988</YR>
<VL>24</VL>
<PG>S55-6</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:53:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:53:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="3163053"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanholder-1991" MODIFIED="2010-05-08 13:54:26 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vanholder 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-08 13:54:26 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanholder R, Ringoir S, Dhondt A, Hakim R</AU>
<TI>Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>39l</VL>
<NO>2</NO>
<PG>320-7</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:54:26 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:54:26 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2002645"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanholder-1992a" MODIFIED="2012-11-12 15:22:55 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Vanholder 1992a" YEAR="1992">
<REFERENCE MODIFIED="2010-05-08 13:55:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanholder R, Van Haecke E, Veys N, Ringoir S</AU>
<TI>Endotoxin transfer through dialysis membranes: small- versus large-pore membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>4</NO>
<PG>333-9</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:55:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:55:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1317524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanholder-1999" MODIFIED="2010-05-08 13:56:13 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vanholder 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-08 13:56:13 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanholder R, Lameire N</AU>
<TI>Does biocompatibility of dialysis membranes affect recovery of renal function and survival?</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9187</NO>
<PG>1316-8</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:56:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:56:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10533855"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Stone-1995" MODIFIED="2010-05-08 13:49:55 +1000" MODIFIED_BY="Narelle S Willis" NAME="Van Stone 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-08 13:49:55 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Stone JC</AU>
<TI>The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients</TI>
<SO>ASAIO Journal</SO>
<YR>1995</YR>
<VL>41</VL>
<NO>3</NO>
<PG>M713-6</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:49:55 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:49:55 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8573899"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Ypersele-1991a" MODIFIED="2012-07-11 17:24:58 +1000" MODIFIED_BY="Narelle S Willis" NAME="Van Ypersele 1991a" YEAR="1991">
<REFERENCE MODIFIED="2010-05-08 13:50:44 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Ypersele de Strihou C, Jadoul M, Jamart J</AU>
<TI>Highly permeable and biocompatible membranes</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<NO>8754</NO>
<PG>1415-6</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:50:44 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:50:44 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1674789"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Ypersele-1991b" MODIFIED="2012-07-11 17:24:52 +1000" MODIFIED_BY="Narelle S Willis" NAME="Van Ypersele 1991b" YEAR="1991">
<REFERENCE MODIFIED="2010-05-08 13:51:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J</AU>
<TI>Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>5</NO>
<PG>1012-9</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:51:29 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:51:29 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2067196"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varela-2001" MODIFIED="2010-05-08 13:57:01 +1000" MODIFIED_BY="Narelle S Willis" NAME="Varela 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-08 13:57:01 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varela MP, Kimmel PL, Phillips TM, Mishkin GJ, Lew SQ, Bosch JP</AU>
<TI>Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels</TI>
<SO>Blood Purification</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>4</NO>
<PG>370-9</PG>
<IDENTIFIERS MODIFIED="2010-05-08 13:57:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 13:57:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11574733"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaslaki-1998" MODIFIED="2010-05-08 14:01:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vaslaki 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-08 14:01:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaslaki L, Weber C, Mitteregger R, Falkenhagen D</AU>
<TI>No difference in cytokine induction between patients on on-line hemodiafiltration (HDF) and low-flux HD [abstract]</TI>
<SO>International Journal Artificial Organs</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>10</NO>
<PG>609</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:00:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:00:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00321994"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Velasquez-1988" MODIFIED="2010-05-08 14:04:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Velasquez 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-08 14:04:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Velasquez MT, von Albertini B, Lew SQ, Mishkin GJ, Bosch JP</AU>
<TI>Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>4</NO>
<PG>618-23</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:04:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:04:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9531177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verbeelen-1991" MODIFIED="2010-05-08 14:05:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Verbeelen 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-08 14:05:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verbeelen D, Jochmans K, Herman AG, Van der Niepen P, Sennesael J, De Waele M</AU>
<TI>Evaluation of platelets and hemostasis during hemodialysis with six different membranes</TI>
<SO>Nephron</SO>
<YR>1991</YR>
<VL>59</VL>
<NO>4</NO>
<PG>567-72</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:05:29 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:05:29 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1766495"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verresen-1990" MODIFIED="2010-05-08 14:06:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Verresen 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-08 14:06:28 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verresen L, Waer M, Vanrenterghem Y, Michielsen P</AU>
<TI>Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8727</NO>
<PG>1360-2</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:06:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:06:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1978172"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verresen-1994" MODIFIED="2010-05-08 14:07:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="Verresen 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-08 14:07:17 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verresen L, Fink E, Lemke HD, Vanrenterghem Y</AU>
<TI>Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes</TI>
<SO>Kidney International</SO>
<YR>1994</YR>
<VL>45</VL>
<NO>5</NO>
<PG>1497-503</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:07:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:07:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8072263"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wakasa-1995" MODIFIED="2010-05-08 14:08:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Wakasa 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-08 14:08:11 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wakasa M, Akizawa T, Kinugasa E, Koshikawa S</AU>
<TI>Plasma bradykinin levels during hemodialysis with PAN DX and polysulfone membranes with and without concurrent ACE inhibitor</TI>
<SO>Clinical Nephrology</SO>
<YR>1995</YR>
<VL>44 Suppl 1</VL>
<PG>S29-32</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:08:06 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:08:06 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8608658"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wanner-2004" MODIFIED="2012-03-28 17:09:20 +1100" MODIFIED_BY="[Empty name]" NAME="Wanner 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-03-28 17:09:20 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J</AU>
<TI>Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>10</NO>
<PG>2570-5</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:09:20 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:09:20 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15280524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-1993" MODIFIED="2012-03-28 17:09:29 +1100" MODIFIED_BY="[Empty name]" NAME="Ward 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-03-28 17:09:29 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward RA, Schaefer RM, Falkenhagen D, Joshua MS, Heidland A, Klinkmann H, et al</AU>
<TI>Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>1</NO>
<PG>47-53</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:09:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="8381935"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-1997" MODIFIED="2010-05-08 14:09:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ward 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-08 14:09:16 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward RA, Buscaroli A, Schmidt B, Stefoni S, Gurland HJ, Klinkmann H</AU>
<TI>A comparison of dialysers with low-flux membranes: significant differences in spite of many similarities</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>5</NO>
<PG>965-72</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:09:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:09:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9175051"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-2000" MODIFIED="2010-05-08 14:10:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ward 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-08 14:10:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W</AU>
<TI>A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>12</NO>
<PG>2344-50</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:10:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:10:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11095657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-2003" MODIFIED="2010-05-08 14:10:40 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ward 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-08 14:10:40 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward RA, Ouseph R, McLeish KR</AU>
<TI>Effects of high-flux hemodialysis on oxidant stress</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>1</NO>
<PG>353-9</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:10:40 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:10:40 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12472803"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-1994" MODIFIED="2010-05-08 14:11:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Wei 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-08 14:11:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei SS, Paganini EP, Cressman, Wright E</AU>
<TI>Use of hemodiafiltration to enhance delivered dialysis</TI>
<SO>ASAIO Journal</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>4</NO>
<PG>977-80</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:11:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:11:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7858335"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wens-1992" MODIFIED="2010-05-08 14:12:29 +1000" MODIFIED_BY="Narelle S Willis" NAME="Wens 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-08 14:12:29 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wens R, Dratwa M</AU>
<TI>Intact parathormone (PTH) clearance with high-flux HD membranes [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>166</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:12:29 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:12:29 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00260683"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woffindin-1992" MODIFIED="2010-05-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Woffindin 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woffindin C, Hoenich NA, Matthews JN</AU>
<TI>Cellulose-based haemodialysis membranes: biocompatibility and functional performance compared</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>4</NO>
<PG>340-5</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1317525"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woo-_x0028_Tx_x0029_-2002" MODIFIED="2012-11-12 15:25:15 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Woo (Tx) 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-08 14:14:19 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo YM, Craig AM, King BB, Junor BJ, McMillan MA, Briggs JD, et al</AU>
<TI>Biocompatible membranes do not promote graft recovery following cadaveric renal transplantation</TI>
<SO>Clinical Nephrology</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>1</NO>
<PG>38-44</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:14:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:14:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1841067"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-19 11:12:47 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woo YM</AU>
<TI>Dialysis with biocompatible membranes may delay recovery of graft function following renal transplantation [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>719A</PG>
<IDENTIFIERS MODIFIED="2010-07-19 11:12:47 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woods-2000" MODIFIED="2012-03-28 17:10:00 +1100" MODIFIED_BY="Narelle S Willis" NAME="Woods 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-08 14:15:01 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woods HF, Nandakumar M</AU>
<TI>Improved outcome for haemodialysis patients treated with high-flux membranes</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15 Suppl 1</VL>
<PG>36-42</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:14:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:14:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10737165"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-1999a" MODIFIED="2012-11-12 15:25:40 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Wright 1999a" YEAR="1999">
<REFERENCE MODIFIED="2010-05-08 14:16:58 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright MJ, Woodrow G, Umpleby S, Hull S, Brownjohn AM, Turney JH</AU>
<TI>Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:16:58 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:16:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10401013"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wright-2000" MODIFIED="2012-03-28 17:12:13 +1100" MODIFIED_BY="Narelle S Willis" NAME="Wright 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-28 17:12:13 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright MJ, Woodrow G, Young G, Brownjohn AM, Turney JH</AU>
<TI>Biocompatible dialysis membranes do not reduce plasma leptin levels</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>6</NO>
<PG>925-6</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:12:13 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2012-03-28 17:12:13 +1100" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="10831667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuhiro-1998" MODIFIED="2010-05-08 14:18:38 +1000" MODIFIED_BY="Narelle S Willis" NAME="Yasuhiro 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-08 14:18:38 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yasuhiro I, Eiichi N, Mineo O, Muneto Y, Toshihiro I, Masahiro F, et al</AU>
<TI>Removal of serum beta-2 microglobulin using high-performance membranes and analysis of changes in serum BMG levels after dialysis</TI>
<SO>American Journal of Nephrology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>228-32</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:18:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:18:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9627039"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaoui-1990" MODIFIED="2010-05-08 14:20:13 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zaoui 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-08 14:20:13 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaoui PM, Stone WJ, Hakim RM</AU>
<TI>Effects of dialysis membranes on beta 2-microglobulin production and cellular expression</TI>
<SO>Kidney International</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>5</NO>
<PG>962-8</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:20:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:20:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2266681"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaoui-1991" MODIFIED="2010-05-08 14:20:50 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zaoui 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-08 14:20:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaoui P, Green W, Hakim RM</AU>
<TI>Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>5</NO>
<PG>1020-6</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:20:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:20:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2067197"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaoui-1993" MODIFIED="2010-05-08 14:21:47 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zaoui 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-08 14:21:47 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaoui P, Hakim RM</AU>
<TI>Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane</TI>
<SO>Kidney International</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1298-305</PG>
<IDENTIFIERS MODIFIED="2010-05-08 14:21:47 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-08 14:21:47 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8315942"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2011" MODIFIED="2012-07-18 17:26:31 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-18 17:26:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhang DL, Liu J, Cui WY, Ji DY, Zhang Y, Liu WH</AU>
<TI>Differences in bio-incompatibility among four biocompatible dialyzer membranes using in maintenance hemodialysis patients</TI>
<SO>Renal Failure</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>7</NO>
<PG>682-91</PG>
<IDENTIFIERS MODIFIED="2012-07-18 17:26:21 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-18 17:26:21 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21787159"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-03-22 19:20:57 +1100" MODIFIED_BY="Suetonia Palmer"/>
<ONGOING_STUDIES MODIFIED="2012-11-12 15:27:51 +1100" MODIFIED_BY="Suetonia Palmer">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00004285" MODIFIED="2012-11-12 15:27:51 +1100" MODIFIED_BY="Suetonia Palmer" NAME="NCT00004285" YEAR="2002">
<REFERENCE MODIFIED="2012-11-12 15:27:38 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00004285</AU>
<TI>Phase II randomized study of standard vs high amount of hemodialysis using low vs high flux dialyzer membranes for end stage renal disease</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00004285</SO>
<YR>(accessed 10 Nov 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-11-12 15:27:51 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2012-11-12 15:27:51 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00004285 "/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-06-26 18:31:32 +1000" MODIFIED_BY="Suetonia Palmer">
<ADDITIONAL_REFERENCES MODIFIED="2012-06-26 18:31:32 +1000" MODIFIED_BY="Suetonia Palmer">
<REFERENCE ID="REF-_x0034_D-2005" MODIFIED="2012-03-28 17:15:43 +1100" MODIFIED_BY="Suetonia Palmer" NAME="4D 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Krane V, März W, Olschewski M, Mann J F, Ruf G et a l</AU>
<TI>Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>3</NO>
<PG>238-48</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:15:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:15:43 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16034009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-AURORA-2009" MODIFIED="2012-03-28 17:16:38 +1100" MODIFIED_BY="Suetonia Palmer" NAME="AURORA 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al</AU>
<TI>Rosuvastatin and cardiovascular events in patients undergoing hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>14</NO>
<PG>1395-407</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:16:38 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:16:38 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19332456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Besarab-1998" MODIFIED="2012-03-28 17:17:56 +1100" MODIFIED_BY="[Empty name]" NAME="Besarab 1998" TYPE="JOURNAL_ARTICLE">
<AU>Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al</AU>
<TI>The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>9</NO>
<PG>584-90</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:17:56 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:17:56 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9718377"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CARI-2005" MODIFIED="2012-06-26 18:31:32 +1000" MODIFIED_BY="Suetonia Palmer" NAME="CARI 2005" TYPE="OTHER">
<AU>CARI Guidelines</AU>
<TI>Caring for Australasians with Renal Impairment</TI>
<SO>http://www.cari.org.au/DIALYSIS_adequacy_published/dialysis_membranes_jul-2005.pdf</SO>
<YR>Accessed 28 February 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chertow-2010" MODIFIED="2012-03-28 17:18:56 +1100" MODIFIED_BY="[Empty name]" NAME="Chertow 2010" TYPE="JOURNAL_ARTICLE">
<AU>Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al</AU>
<TI>In-center hemodialysis six times per week versus three times per week</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>24</NO>
<PG>2287-300</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:18:56 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:18:56 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21091062"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clark-1999" MODIFIED="2012-03-28 17:19:49 +1100" MODIFIED_BY="[Empty name]" NAME="Clark 1999" TYPE="JOURNAL_ARTICLE">
<AU>Clark WR, Hamburger RJ, Lysaght MJ</AU>
<TI>Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis</TI>
<SO>Kidney International</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>6</NO>
<PG>2005-15</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:19:49 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:19:49 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10594776"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Jager-2009" MODIFIED="2012-03-28 17:21:06 +1100" MODIFIED_BY="[Empty name]" NAME="de Jager 2009" TYPE="JOURNAL_ARTICLE">
<AU>de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al</AU>
<TI>Cardiovascular and noncardiovascular mortality among patients starting dialysis</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>16</NO>
<PG>1782-9</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:20:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:20:50 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19861670"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2012-03-28 17:22:06 +1100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:22:06 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:22:06 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="3802833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EBPG-2002" MODIFIED="2012-06-26 18:31:13 +1000" MODIFIED_BY="Suetonia Palmer" NAME="EBPG 2002" TYPE="JOURNAL_ARTICLE">
<AU>European Best Practice Guidelines Group</AU>
<TI>II.2 Haemodialysis dose quantification: middle molecules (MM)</TI>
<SO>Nephrology Dialysis and Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 7</NO>
<PG>21-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-1998" MODIFIED="2012-03-28 17:24:10 +1100" MODIFIED_BY="Narelle S Willis" NAME="FDA 1998" TYPE="OTHER">
<AU>US Food and Drug Administration</AU>
<TI>Guidance for the industry and CDRH reviewers on the content of premarket notifications for conventional and high permeability hemodialyzers</TI>
<SO>http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080165.htm</SO>
<YR>Accessed 7 May 2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2010-05-04 22:35:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS MODIFIED="2010-05-04 22:35:09 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-04 22:35:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="12111919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-03-27 13:49:53 +1100" MODIFIED_BY="Ann Jones" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaber-1998" MODIFIED="2011-06-09 18:25:56 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Jaber 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jaber BL, Gonski JA, Cendoroglo M, Balakrishnan VS, Razeghi P, Dinarello CA, et al</AU>
<TI>New polyether sulfone dialyzers attenuate passage of cytokine-inducing substances from pseudomonas aeruginosa contaminated dialysate</TI>
<SO>Blood Purification</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>4</NO>
<PG>210-9</PG>
<IDENTIFIERS MODIFIED="2011-06-09 18:25:41 +1000" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER TYPE="PUBMED" VALUE="9736790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDOQI-2006" MODIFIED="2012-03-16 12:47:27 +1100" MODIFIED_BY="Suetonia Palmer" NAME="KDOQI 2006" TYPE="OTHER">
<AU>National Kidney Foundation</AU>
<TI>Kidney Disease Outcomes Quality Initiative 2006 Updates Clinical Practice Guidelines and Recommendations Hemodialysis Adequacy</TI>
<SO>http://www.kidney.org/professionals/kdoqi/pdf/12-50-0210_JAG_DCP_Guidelines-HD_Oct06_SectionA_ofC.pdf</SO>
<YR>Accessed 19 March 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lonnemann-1992" MODIFIED="2011-06-09 18:29:25 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Lonnemann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Lonnemann G, Behme TC, Lenzner B, Floege J, Schulze M, Colton CK, et al</AU>
<TI>Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria</TI>
<SO>Kidney international</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>1</NO>
<PG>61-8</PG>
<IDENTIFIERS MODIFIED="2011-06-09 18:29:24 +1000" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER TYPE="PUBMED" VALUE="1635355"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-MacLeod-2005" MODIFIED="2012-04-24 16:01:44 +1000" MODIFIED_BY="Suetonia Palmer" NAME="MacLeod 2005" TYPE="COCHRANE_REVIEW">
<AU>MacLeod AM, Campbell M, Cody JD, Daly C, Donaldson C, Grant A, et al</AU>
<TI>Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-03-27 17:12:32 +1100" MODIFIED_BY="Ann Jones">
<IDENTIFIER MODIFIED="2012-03-27 17:12:32 +1100" MODIFIED_BY="Ann Jones" TYPE="DOI" VALUE="10.1002/14651858.CD003234.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miskulin-2009" MODIFIED="2012-03-28 17:26:40 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Miskulin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Miskulin D, Bragg-Gresham J, Gillespie BW, Tentori F, Pisoni RL, Tighiouart H, et al</AU>
<TI>Key comorbid conditions that are predictive of survival among hemodialysis patients</TI>
<SO>Clinical Journal of the American Society of Nephrologists</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>11</NO>
<PG>1818-26</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:26:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:26:40 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19808231"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Port-2001" MODIFIED="2012-03-28 17:27:45 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Port 2001" TYPE="JOURNAL_ARTICLE">
<AU>Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, et al</AU>
<TI>Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>2</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:27:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:27:45 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11157367"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rabindranath-2005" MODIFIED="2012-04-24 09:46:32 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Rabindranath 2005" TYPE="JOURNAL_ARTICLE">
<AU>Rabindranath KS, Strippoli GFM, Roderick P, Wallace SA, MacLeod AM, Daly C</AU>
<TI>Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>3</NO>
<PG>437-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Renal-Association-2009" MODIFIED="2012-03-28 17:35:06 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Renal Association 2009" TYPE="OTHER">
<AU>Renal Association Clinical Practice Guidelines</AU>
<TI>Haemodialysis membranes (Guidelines 4.1 to 4.5)</TI>
<SO>http://www.renal.org/clinical/GuidelinesSection/Haemodialysis.aspx</SO>
<YR>Accessed 19 March 2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schiffl-2011" MODIFIED="2012-03-28 17:36:17 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Schiffl 2011" TYPE="JOURNAL_ARTICLE">
<AU>Schiffl H</AU>
<TI>High-flux dialyzers, backfiltration, and dialysis fluid quality</TI>
<SO>Seminars in Dialysis</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:36:17 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:36:17 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21299628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schwarz-1984" MODIFIED="2010-05-04 23:00:19 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schwarz 1984" TYPE="JOURNAL_ARTICLE">
<AU>Schwarz A, Keller F, Seyfert S, Poll W, Molzahn M, Distler A</AU>
<TI>Carpal tunnel syndrome: a major complication in long-term hemodialysis patients</TI>
<SO>Clinical Nephrology</SO>
<YR>1984</YR>
<VL>22</VL>
<NO>3</NO>
<PG>133-7</PG>
<IDENTIFIERS MODIFIED="2010-05-04 23:00:19 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-04 23:00:19 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6488595"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tattersall-2010" MODIFIED="2011-06-09 18:32:30 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Tattersall 2010" TYPE="JOURNAL_ARTICLE">
<AU>Tattersall J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van Biesen W</AU>
<TI>High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome study</TI>
<SO>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>4</NO>
<PG>1230-2</PG>
<IDENTIFIERS MODIFIED="2011-06-09 18:32:29 +1000" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER TYPE="PUBMED" VALUE="20028829"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-USRDS-Annual-Report-2010" MODIFIED="2012-03-16 12:01:47 +1100" MODIFIED_BY="[Empty name]" NAME="USRDS Annual Report 2010" TYPE="OTHER">
<TI>United States Renal Data System Annual Data Report 2010</TI>
<SO>www.usrds.org</SO>
<YR>Accessed 21 February 2011</YR>
<VL>Volume 2 Atlas of ESRD</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Ypersele-de-Strihou-1991" MODIFIED="2012-03-28 17:38:59 +1100" MODIFIED_BY="[Empty name]" NAME="van Ypersele de Strihou 1991" TYPE="JOURNAL_ARTICLE">
<AU>van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J</AU>
<TI>Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>5</NO>
<PG>1012-9</PG>
<IDENTIFIERS MODIFIED="2012-03-28 17:38:59 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-28 17:38:59 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2067196"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Woffindin-1988" MODIFIED="2011-06-09 18:22:27 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Woffindin 1988" TYPE="JOURNAL_ARTICLE">
<AU>Woffindin C, Hoenich NA</AU>
<TI>Blood-membrane interactions during haemodialysis with cellulose and synthetic membranes</TI>
<SO>Biomaterials</SO>
<YR>1988</YR>
<VL>9</VL>
<NO>1</NO>
<PG>53-7</PG>
<IDENTIFIERS MODIFIED="2011-06-09 18:22:24 +1000" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER TYPE="PUBMED" VALUE="3126842"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-05-04 23:08:34 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Rabindranath-2004" MODIFIED="2010-05-04 23:08:34 +1000" MODIFIED_BY="Narelle S Willis" NAME="Rabindranath 2004" TYPE="COCHRANE_PROTOCOL">
<AU>Rabindranath KS, Strippoli GFM, Daly C, Roderick PJ, Wallace SA, MacLeod AM</AU>
<TI>High-flux versus low-flux haemodialysis membranes for end-stage renal disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-05-04 23:08:32 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2010-05-04 23:08:32 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005016"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-05-02 14:04:02 +1000" MODIFIED_BY="Narelle S Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-08-09 11:09:15 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-08-09 11:09:15 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-06-26 19:08:37 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Acchiardo-1989">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:23 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 9 months</LI>
<LI>Lost to follow-up: 2/20</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:24:38 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: USA</LI>
<LI>Setting: University, single centre</LI>
<LI>Patients: Prevalent haemodialysis</LI>
<LI>Duration on dialysis</LI>
<UL>
<LI>Treatment group: 76.5 ± 48 months</LI>
<LI>Control group: 39.7 ± 30 months</LI>
</UL>
</UL>
<UL>
<LI>Number (treatment/control): 11/9</LI>
<LI>Mean age (treatment/control): 48.6 (29 to 72) to 49.5 (36 to 70)</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 8/3</LI>
<LI>Control group: 6/3</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Severe organ involvement, active haemolysis, or gastrointestinal bleeding; aluminium intoxication</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:26:01 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polysulphone high-flux dialysis: (Hemoflux F60 or F80)</LI>
<LI>Blood flow rate 469 ± 3 mL/min</LI>
<LI>Dialysate flow rate 800 mL/min</LI>
<LI>Time 126.9 ± 10 min</LI>
<LI>Kt/V 1.01 ± 0.1</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Regenerated cellulosic membranes (C-DAK; 90 SCE or 135 SCE)</LI>
<LI>Blood flow rate 297 ± 10 mL/min</LI>
<LI>Dialysate flow rate 500 mL/min</LI>
<LI>Time 193.2 ± 39 min</LI>
<LI>Kt/V 1.05 ± 0.1</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 14:48:40 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Haematocrit</LI>
<LI>Blood urea nitrogen</LI>
<LI>Biochemistry</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:36:25 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Imbalance in time on dialysis at baseline</LI>
<LI>Exclusions post-randomisation but pre-intervention: 0</LI>
<LI>Stop or end point/s: Nil</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-26 11:02:09 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ayli-2005">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:44 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: 0/48</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 14:51:21 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Turkey</LI>
<LI>Setting: University hospital</LI>
<LI>Patients on chronic HD; could not achieve Hb &gt; 11 g/dL despite EPO of at least 200 IU/kg/wk in 3 divided doses/wk for 6 months</LI>
<LI>Duration on dialysis (median)</LI>
<UL>
<LI>Treatment group: 48 months (range 20 to 96)</LI>
<LI>Control group: 44 months (range 18 to 96)</LI>
</UL>
<LI>Number (treatment/control): 24/24</LI>
<LI>Mean age (treatment/control): 58.3/59.9 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 14/10</LI>
<LI>Control group: 12/12</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Iron deficiency; chronic blood loss; acute or chronic infection; malignancy; haemoglobinopathies; malnutrition; B&#8321;&#8322; or folate deficiency; patients on ACEi or ARB</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:14 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux polysulfone membrane (Fresenius F60)</LI>
<LI>Blood flow: 300 mL/min</LI>
<LI>Dialysate: 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux polysulfone membrane (Fresenius F6)</LI>
<LI>Blood flow: 300 mL/min</LI>
<LI>Dialysate: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-26 11:02:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Kt/V</LI>
<LI>URR</LI>
<LI>Predialysis beta-2 microglobulin levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:36:31 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation; details regarding blinding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:36:38 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Blankestijn-1995">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:47 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 weeks</LI>
<LI>Lost to follow-up: 0/28</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:30:49 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: The Netherlands</LI>
<LI>Setting: University hospital</LI>
<LI>Chronic, stable HD patients</LI>
<LI>Median duration on HD: 24 months (range 6 to 176 months)</LI>
<LI>Number: 28</LI>
<LI>Median age: 63 years (range 22 to 80 years)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Diabetes; on drugs that affect cholesterol levels</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:26:38 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux polysulfone membrane (Fresenius F60)</LI>
<LI>Bicarbonate dialysate containing 11 mmol/L glucose</LI>
<LI>Time 11 ± 1.4 h/wk</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux cuprophan membrane</LI>
<LI>Bicarbonate dialysate containing 11 mmol/L glucose</LI>
<LI>Time 11 ± 1.4 h/wk</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 15:56:03 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Lipid profile including: total cholesterol, VLDL cholesterol, LDL cholesterol, HDL cholesterol, triglycerides</LI>
<LI>Kt/V</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:36:38 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation, blinding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-26 11:02:27 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Brown-1989">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:25 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: Unclear</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 11:02:27 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: United Kingdom</LI>
<LI>Setting: Charing Cross Hospital</LI>
<LI>Patients: Patients requiring haemodialysis with dialysis arthropathy</LI>
<LI>Duration on dialysis: 12.3 ± 3 years</LI>
<LI>Number: 18</LI>
<LI>Mean age: 55 ± 10 years</LI>
<LI>Sex (M/F):14/4</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:17 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polyacrylonitrile or polysulphone</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Cuprophane</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:45:27 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Predialysis beta-2 microglobulin</LI>
<LI>Dialysis arthropathy</LI>
<LI>C-reactive protein</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:36:48 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: Unclear</LI>
<LI>Stop or end point/s: Unclear</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Abstract publication only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:36:55 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Chu-2006">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:25 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 months</LI>
<LI>Lost to follow-up: 2/40 (5%)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:32:02 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Taiwan</LI>
<LI>Setting: Single centre</LI>
<LI>Patients: Individuals on maintenance HD &gt; 6 months and &gt; 20 years</LI>
<LI>Duration on dialysis</LI>
<UL>
<LI>Treatment group: 82.2 ± 125 months</LI>
<LI>Control group: 69.1 ± 87.6 months</LI>
</UL>
</UL>
<UL>
<LI>Number (treatment/control): 21</LI>
<LI>Mean age (treatment/control): 19</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 11/9</LI>
<LI>Control group: 9/9</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Active infection, obvious inflammation, malignancy, or intolerance to dialysers</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:28:41 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>FX80 (KUF 59 mL/h/mm Hg)</LI>
<LI>Inline steam sterilisation</LI>
<LI>Surface area 1.8 m²</LI>
<LI>Minimum blood flow rate 250 mL/min</LI>
<LI>Dialysate flow rate 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>F8 HPS (KUF 18 mL/h/mm Hg)</LI>
<LI>Inline steam sterilisation</LI>
<LI>Surface area 1.8 m²</LI>
<LI>Minimum blood flow rate 250 mL/min</LI>
<LI>Dialysate flow rate 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-24 14:47:39 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Oxidative stress</LI>
<LI>Insulin resistance</LI>
<LI>Inflammation</LI>
<LI>Dialysis efficiency</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:36:55 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post randomisation but pre-intervention: 2/40</LI>
<LI>Stop or end point/s: None reported</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:37:02 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Churchill-1993">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:51 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 months</LI>
<LI>Lost to follow-up: 8/30</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 15:57:55 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Canada</LI>
<LI>Setting: University hospital</LI>
<LI>Patients on chronic HD for at least 3 months</LI>
<LI>Number (enrolled/reported): 30/24</LI>
<LI>Age (mean): 52 years (range: 21 to 72 years)</LI>
<LI>Sex (M/F): 13/9</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Inability to complete the QoL tests; inability to complete the neuropsychological evaluation; allergy to ethylene oxide; elective live donor transplant within 8 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:20 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux cellulose acetate (UFR15 mL/h/mm Hg)</LI>
<LI>Beta-2 microglobulin clearance: -11.4 mL/min</LI>
<LI>Bicarbonate dialysis</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux cellulose acetate (UFR: 3.5 to 5 mL/h/mm Hg)</LI>
<LI>Beta-2 microglobulin clearance: No clearance at all</LI>
<LI>Bicarbonate dialysis</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 14:59:17 +1100" MODIFIED_BY="Narelle S Willis">
<P>Quality of life measures including:</P>
<UL>
<LI>HD-QOL</LI>
<LI>TTO index</LI>
<LI>SIP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:37:02 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: 8 patients, no details of dropouts given</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:37:14 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Collins-1993">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:52 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: 5/40</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:10:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: University hospital</LI>
<LI>Patients on chronic HD using CU membranes</LI>
<LI>Number (treatment/control): 17/18</LI>
<LI>Mean age (treatment/control): 50/55 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 7/10</LI>
<LI>Control group: 3/14</LI>
</UL>
<LI>Race (Blacks/other)</LI>
<UL>
<LI>Treatment group: 16/1</LI>
<LI>Control group: 15/3</LI>
</UL>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:21 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux PAN membrane (Hospal F16, 1.55 m²; Kuf-44 mL/mm Hg/h) 3 times/wk</LI>
<LI>Dialysate flow: 500 mL/min</LI>
<LI>Blood flow rate: 300 to 400 mL/min</LI>
<LI>Dialysis duration: 3.25 hours</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux cuprophan membrane (Gambro 9, 1.6 m²; Kuf-8 mL/mm Hg/h) 3 times/wk</LI>
<LI>Dialysate flow: 500 mL/min</LI>
<LI>Blood flow rate: 300 to 400 mL/min</LI>
<LI>Dialysis duration: 3.3 hours</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 15:00:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>Quality of life measures including:</P>
<UL>
<LI>HD-QOL</LI>
<LI>TTO index</LI>
<LI>SIP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:37:14 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 16:11:13 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-De-Vriese-2003">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:10 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 month (first cross-over phase)</LI>
<LI>Lost to follow-up: 2 patients withdrew (1 had presumed reaction to superflux membrane; 1 received a kidney transplant during the study)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:30:11 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Belgium</LI>
<LI>Setting: AZ Sint-Jan AV haemodialysis unit (single unit)</LI>
<LI>Patients: Haemodialysis</LI>
<LI>Duration on dialysis: NS</LI>
<LI>Number (treatment/control): 15/15</LI>
<LI>Mean age: 69.0 ± 18 years (range 36 to 89)</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Acute illness, life expectancy &lt; 3 months, problems with vascular access, excessive interdialytic weight gains requiring regular addition dialyses and inability to provide informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-18 16:11:13 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Triacetate dialyser (FB-150U, Nipro)</LI>
<LI>UF coefficient 29.8 mL/h/mm Hg</LI>
<LI>Sieving coefficient beta-2 microglobulin 0.88</LI>
<LI>Treatment duration, blood flow, dialysate flow and ultrafiltration determined by attending nephrologist</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Triacetate dialyser (Sureflux-150L, Nipro)</LI>
<LI>UF coefficient 12.8 mL/h/mm Hg</LI>
<LI>Sieving coefficient beta-2 microglobulin 0.36</LI>
<LI>Treatment duration, blood flow, dialysate flow and ultrafiltration determined by attending nephrologist</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-24 18:44:52 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Plasma homocysteine</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:37:29 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Had a superflux treatment arm (Sureflux-150FH, ultrafiltration coefficient 66.9 ml/L/mm Hg)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-09 11:09:15 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Fishbane-1997">
<CHAR_METHODS MODIFIED="2012-03-23 16:02:27 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: Unclear</LI>
<LI>Follow-up period: 2 months</LI>
<LI>Lost to follow-up: 5/30 (2/16 high-flux and 3/14 low-flux)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-09 11:09:15 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: USA</LI>
<LI>Setting: Winthrop-University Hospital Dialysis Center</LI>
<LI>Patients: Long term haemodialysis &gt; 6 months with diabetes</LI>
<LI>Duration on dialysis</LI>
<UL>
<LI>Treatment group: 17.4 (4.0) months</LI>
<LI>Control group: 18.0 (4.0) months</LI>
</UL>
</UL>
<UL>
<LI>Number (treatment/control): 13</LI>
<LI>Mean age (treatment/control): 12</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 8/5</LI>
<LI>Control group: 6/6</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Lack of stable dialysis access, URR &lt; 60%, hospitalisation within one month for marked changes in metabolic control and concomitant treatment with an angiotensin converting enzyme inhibitor or lipid lowering medication</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:24 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>AN69 Fitral 16 Dialyzer (Hospal Inc, Lyon, France)</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>F8 dialysis membrane (Fresenius Inc, Germany)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-24 18:46:09 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Advanced glycation end products</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:37:34 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: None</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:37:47 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Gardinali-1994">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:12 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 months</LI>
<LI>Lost to follow-up: 0/36</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:30:13 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: University hospital</LI>
<LI>Patients undergoing regular HD</LI>
<LI>Number: 36</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Recurrent bacterial infections; diabetes; autoimmune diseases and/or myeloma</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:25 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, polysulfone and polyacrylonitrile membranes</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux, cuprophan membranes</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 13:06:16 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Predialysis beta-2 microglobulin values</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:37:47 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:37:55 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Goldberg-1996">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:16 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 1 month</LI>
<LI>Lost to follow-up: 0/29</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:30:18 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: University hospital</LI>
<LI>Patients undergoing regular HD</LI>
<LI>Number: 29</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:27 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, polysulfone membrane (Fresenius F-80)</LI>
<LI>Duration: 3 months</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux, polysulfone membrane (Fresenius F8)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 13:12:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Lipid profiles</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:37:55 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:38:01 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Hartmann-1997">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:21 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 months</LI>
<LI>Lost to follow-up: 0/20</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:20:46 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: University hospital</LI>
<LI>Tubulo-interstitial disease as cause for ESKD; CrCl (10 to 15 mL/min); no previous RRT; repeatedly recorded normotensive values (BP consistently &lt; 140/90 mm Hg, no antihypertensive medication); no comorbidity and no drugs other than for the prevention of secondary hyperparathyroidism or water soluble vitamins</LI>
<LI>Number (treatment/control): 10/10</LI>
<LI>Mean age (treatment/control): 52/51 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 7/3</LI>
<LI>Control group: 7/3</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Already on RRT; presence of comorbidity; on drugs for indications other than hyperparathyroidism and water soluble vitamins</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:28 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux biocompatible polysulfone membrane (Fresenius F 60, UF coefficient 40 mL/mm Hg/h), 3 times/wk for 4 to 5 hours</LI>
<LI>Blood pump speed: 200 to 250 mL/min</LI>
<LI>Dialysate flow speed: 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux cellulose acetate membrane (CT-130 Baxter, UF coefficient 5.6 mL/mm Hg), 3 times/wk for 4 to 5 hours</LI>
<LI>Blood pump speed: 200 to 250 mL/min</LI>
<LI>Dialysate flow speed: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 17:39:59 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Death</LI>
<LI>Number hospitalised</LI>
<LI>Number hospitalised for infection</LI>
<LI>Hypotensive episodes</LI>
<LI>Kt/V</LI>
<LI>RRF</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:38:01 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation, blinding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 16:14:07 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-HEMO-2002">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:22 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 years</LI>
<LI>Lost to follow-up: 0/1846</LI>
<UL>
<LI>392 patients did not continue the study, of whom 194 received a transplant and 198 switched to other methods of dialysis or moved to non-participating dialysis centres</LI>
</UL>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-18 16:14:07 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: USA</LI>
<LI>Setting: Multicentre study</LI>
<LI>Adults (18 to 80 years); in-centre HD thrice weekly; on dialysis for &gt; 3 months; achieve equilibrated Kt/V of 1.3 within 4.5 hours on 2/3 consecutive attempts during baseline to be randomised</LI>
<LI>Number (treatment/control): 921/925</LI>
<LI>Mean age (treatment/control): 57.7/57.6 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 43.3%/56.7%</LI>
<LI>Control group: 44.2%/55.8%</LI>
</UL>
<LI>Race (Blacks/other)</LI>
<UL>
<LI>Treatment group: 62.6%/37.4%</LI>
<LI>Control group: 62.6%/37.4%</LI>
</UL>
<LI>Diabetics (treatment/control): 44.7%/44.7%</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Currently in acute care or chronic care at time of randomisation; interdialytic 24 h urine collection with a urea clearance &gt; 1.5 mL/min/35 L urea volume; current pregnancy; scheduled living donor transplant within period of study; returned to HD after kidney transplantation within 6 months; active malignancies requiring current chemo or radiotherapy; severe CCF (NYHA Class IV) after maximal therapy; unstable angina, new onset angina, recent exacerbation of frequency, duration, or severity of angina pectoris; symptomatic AIDS according to CDC classification; active systemic infections such as TB or systemic fungal infection; CPD requiring supplemental oxygen; cirrhosis with encephalopathy or abnormal PT; severe malnutrition (serum albumin &lt; 2.6 g/dL for 2/3 baseline measurements); expected geographic unavailability for &gt; 20 dialysis treatments/y; use of investigational drugs or involvement in other interventional protocols; unable to follow protocol due to mental incompetence or other reason; unwillingness to participate in the procedures of the protocol</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:45:30 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux HD thrice weekly; 17 types of high-flux dialysers used, most common were Fresenius F80 (43% of sessions) and Baxter CT190 (48%). Reprocessing methods included Renalin without bleach, formaldehyde, or glutaraldehyde, with bleach, or heated citric acid</LI>
<LI>Two-by-two factorial design target equilibrated Kt/V achieved by manipulating duration of treatment session</LI>
<LI>UF coefficient &gt;14 ml/h/mm Hg, mean beta-2 microglobulin clearance &gt; 20 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux HD thrice weekly; 8 types of low-flux dialysers used, most common were Fresenius F8 (46% of sessions) and Baxter CT 210 (43%). To possibly eliminate bio-incompatibility confounding flux, the authors excluded unsubstituted cellulose membranes from the study</LI>
<LI>Reprocessing methods included Renalin without bleach, formaldehyde, or glutaraldehyde, with bleach, or heated citric acid</LI>
<LI>Two-by-two factorial design target equilibrated Kt/V achieved by manipulating duration of treatment session</LI>
<LI>Ultrafiltration coefficient &gt; 14 mL/h/mm Hg, mean beta-2 microglobulin clearance &gt; 20 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 17:21:41 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Mortality (all-cause, cardiovascular, infectious)</LI>
<LI>Beta-2 microglobulin clearance rate</LI>
<LI>Hospitalisation (all-cause, cardiovascular, infectious)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:38:15 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:38:22 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-House-1999">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:25 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 3 months</LI>
<LI>Lost to follow-up: 3/48</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 15:12:56 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Canada</LI>
<LI>Setting: University Hospital</LI>
<LI>Adults (18 to 80 years); HD duration &#8805; 3 but &#8804; 18 months</LI>
<LI>Time on dialysis (mean)</LI>
<UL>
<LI>Treatment group: 9.1 months</LI>
<LI>Control group: 9.8 months</LI>
</UL>
<LI>Number: 48</LI>
<LI>Mean age (treatment/control): 56.7/55.7 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 70.8%/21.2%</LI>
<LI>Control group: 66.7%/33.3%</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Diabetes mellitus; use of lipid lowering drugs; recent coronary artery syndrome; adverse reaction to polysulfone; life expectancy &lt; 6 months; imminent kidney transplantation or major surgery; hypercoagulable state; malabsorption; refusal or inability to provide informed consent</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:33 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux polysulfone (Fresenius F80)</LI>
<LI>Bicarbonate-based dialysate was used and dialysis was carried out 3 times/wk</LI>
<LI>Dialysis membranes were single use only</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux polysulfone (Fresenius F8)</LI>
<LI>Bicarbonate based dialysate was used and dialysis was carried out 3 times/wk</LI>
<LI>Dialysis membranes were single use only</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 17:33:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Lipid profiles</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:38:22 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:47:47 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-INFLUX-2008">
<CHAR_METHODS MODIFIED="2012-03-23 15:13:38 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: Unclear</LI>
<LI>Follow-up period: 4 weeks</LI>
<LI>Lost to follow-up: Unclear</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:35:01 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: France</LI>
<LI>Setting: Multicentre</LI>
<LI>Patients: Regular HD &#8805;12 hours/wk, Kt/V 1.2, no reuse for &#8805; 6 months and CRP levels 5 to 50 mg/L confirmed twice within 4 week inclusion period (HD low permeability membrane, Polyflux L)</LI>
<LI>Duration on dialysis: NS</LI>
</UL>
<UL>
<LI>Number (treatment/control): 79/72</LI>
<LI>Mean age (treatment/control): 60.3 ± 14.5 years/65.5 ± 10.1 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 49/30</LI>
<LI>Control group: 41/31</LI>
</UL>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:34 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polyflux H membrane</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Polyflux L membrane</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:47:47 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Beta-2 microglobulin</LI>
<LI>CRP</LI>
<LI>Prealbumin</LI>
<LI>Advanced glycation end-products</LI>
<LI>Asymmetric dimethyl arginine</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:39:00 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post randomisation but pre-intervention: Not clear</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Number of patients randomised was not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 16:16:06 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Jeloka-2001">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:30 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-18 16:16:06 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: India</LI>
<LI>Setting: Maulana Azad Medical College, New Delhi</LI>
<LI>Patients: 20</LI>
<LI>Duration on dialysis: 7.1 ± 2.57 years (range 3 to 12 years)</LI>
<LI>Number (treatment/control): 10/10</LI>
<LI>Mean age (treatment/control): 49.1 ± 15.44 years/ 45 ± 9.28 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 3:2 ratio</LI>
<LI>Control group: 3:2 ratio</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>AIDS; lymphoproliferative disorders; inflammatory disorders such as systemic lupus erythematous, rheumatoid arthritis, Crohn's disease; viral hepatitis; cirrhosis of the liver; tuberculosis; chronic osteomyelitis; primary amyloidosis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:15:37 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polysulphone membranes</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Cuprophane membrane</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:47:53 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Beta-2 microglobulin</LI>
<LI>Arthritis like symptoms</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:39:12 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: Unclear</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:39:24 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Klemm-2004">
<CHAR_METHODS MODIFIED="2012-03-23 15:18:37 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Cross-over RCT</LI>
<LI>Time frame: Unclear</LI>
<LI>Follow-up period: 6 weeks</LI>
<LI>Lost to follow-up: 3/29 (10%)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:17:35 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: Friedrich Schiller University and Fresenius Medical Care</LI>
<LI>Patients: Stable chronic HD</LI>
<LI>Duration on dialysis: NS</LI>
<LI>Number (treatment/control): NS</LI>
<LI>Mean age (treatment/control): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:16:09 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>FX60 Helixone</LI>
<LI>Surface area of 1.4 m²</LI>
<LI>Haemodialysis 3 times weekly</LI>
<LI>4 to 5.5 hours/session</LI>
<LI>Blood flow rate 500 mL/min</LI>
<LI>Dialysate flow rate and ultrafiltration determined by attending nephrologist</LI>
<LI>Ultrafilter U 8000S</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>F 6 HPS polysulfone</LI>
<LI>Surface area 1.3 m²</LI>
<LI>Haemodialysis 3 times weekly</LI>
<LI>4 to 5.5 hours/session</LI>
<LI>Blood flow rate 500 mL/min</LI>
<LI>Dialysate flow rate and ultrafiltration determined by attending nephrologist</LI>
<LI>Ultrafilter U 8000S</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-24 19:09:14 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Oxidative stress</LI>
<LI>Homocysteine metabolism</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:39:24 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 14:39:35 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Krieter-2002">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:38 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 4 weeks</LI>
<LI>Lost to follow-up: 4/12 (33%)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 16:11:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Stable HD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:36 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polyethersulfone membranes (DIAPES(R) HF8 surface area 1.4 m²; Arylane H4, 1.35 m²</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Hemophan (1.3 m²)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 16:11:26 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Inflammatory markers</LI>
<LI>CRP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:39:35 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Abstract report only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kuchle-1996">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 years</LI>
<LI>Lost to follow-up: 0/30</LI>
<UL>
<LI>2 patients received kidney transplants; 2 died</LI>
</UL>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 11:00:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: University Hospital</LI>
<LI>Patients on long-term haemodialysis</LI>
<LI>Number (treatment/control): 12/12</LI>
<LI>Mean age (treatment/control): 50/52</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 6/4</LI>
<LI>Control group: 6/4</LI>
</UL>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 10:59:08 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, polysulfone (Fresenius F60S, 1.2 m²)</LI>
<LI>Blood flow rate: 200 to 250 mL/min</LI>
<LI>Dialysate flow rate: 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux (Disscap 160E, 1.0-1.2 m²)</LI>
<LI>Blood flow rate: 200 to 250 mL/min</LI>
<LI>Dialysate flow rate: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-26 10:59:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI/>
<LI>Mortality</LI>
<LI>Beta-2 microglobulin</LI>
<LI>Carpal tunnel syndrome; arthropathy</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:36:15 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation, blinding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lang-2001">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:28 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
<LI>Lost to follow-up: 0/30</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 10:59:19 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: University Hospital</LI>
<LI>Patients started on HD electively; stable clinical condition</LI>
<LI>Number (treatment/control):15/15</LI>
<LI>Mean age (treatment/control): 45/43 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 10/5</LI>
<LI>Control group: 9/6</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Severe comorbidity; on nephrotoxic drugs; rapidly progressive GN; RRF &lt; 2 mL/min; predictable follow-up of &lt; 24 months in the same dialysis facility</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-26 10:59:22 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, polysulfone (Fresenius F60, UF coefficient 40 mL/mm Hg /h, 1.3 m²)</LI>
<LI>Blood flow rate: 200 to 280 mL/min</LI>
<LI>Dialysate flow rate: 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux (Disscap 160E, UF coefficient 6.25 mL/mm Hg/h, 1.22 m²)</LI>
<LI>Blood flow rate: 200 to 280 mL/min</LI>
<LI>Dialysate flow rate: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-26 10:59:25 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>RRF</LI>
<LI>Mortality</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:39:48 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation, blinding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:48:20 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Li-2007a">
<CHAR_METHODS MODIFIED="2012-03-23 15:24:33 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: September 2004 to January 2005</LI>
<LI>Follow-up period: 5 months</LI>
<LI>Lost to follow-up: Unclear</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 15:25:01 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: China</LI>
<LI>Setting: University Hospital, Shanghai</LI>
<LI>Patients: Maintenance haemodialysis 1.5 to 5 years</LI>
<LI>Duration on dialysis: 3.2 ± 1.1 years (1.5 to 5.0 years)</LI>
<LI>Number (treatment/control): 23/20</LI>
<LI>Mean age (treatment/control): 55.4 ± 9.7 years (29 to 75 years)</LI>
<LI>Sex (M/F): 25/18</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Lung, liver, neurological disease, malignant tumour</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:20:47 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>F60 polysulfone dialyser</LI>
<LI>Ultrafiltrate coefficient 40 mL/h/mm Hg</LI>
<LI>Surface area 1.3 m²</LI>
<LI>Fresenius 4008S capacity controlled dialyser</LI>
<LI>Bicarbonate dialysate</LI>
<LI>4 hours 3 times per week</LI>
<LI>Dialysate flow rate 500 mL/min</LI>
<LI>Blood flow 190 to 250 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>F6 polysulphone dialyser</LI>
<LI>ultrafiltrate coefficient 5.5 mL/h/mm Hg</LI>
<LI>Surface area 1.3 m²</LI>
<LI>Fresenius 4008S capacity controlled dialyser</LI>
<LI>Bicarbonate dialysate</LI>
<LI>4 hours 3 times per week</LI>
<LI>Dialysate flow rate 500 mL/min</LI>
<LI>Blood flow 190 to 250 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:48:20 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Beta-2 microglobulin</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:40:18 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: Unclear</LI>
<LI>Stop or end point/s: Unclear</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Reported in Chinese</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Li-2010">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:08 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 24 weeks</LI>
<LI>Lost to follow-up: 0%</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-28 15:48:37 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Hong Kong, China</LI>
<LI>Setting: Prince of Wales Hospital (Hong Kong China) and Alice Ho Miu Ling Nethersole Hospital (Hong Kong China)</LI>
<LI>Patients: Stable anuric maintenance HD patients who were on a dialyser reuse program using low-flux polysulfone membrane (F6HPS) and bicarbonate dialysate for &#8805; 3 months and had satisfactory vascular access</LI>
<LI>Duration on dialysis</LI>
<UL>
<LI>Treatment group: 4.2 ± 3.7 years</LI>
<LI>Control group: 5.1 ± 3.1 years</LI>
</UL>
</UL>
<UL>
<LI>Number (treatment/control): 19/23</LI>
<LI>Mean age (treatment/control): 57 ± 11 years/55.7 ± 13.8 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 8/11</LI>
<LI>Control group: 8/15</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients &gt; 75 years; those with a history of active infection, inflammatory disease, ongoing malignancy, active phase immune disease, immunosuppressive drugs, planned renal transplantation in the subsequent year, baseline measured CRP &gt; 50 mg/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:45:36 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polyamide membrane (Polyflux 14S)</LI>
<LI>Surface area 1.4 m²</LI>
<LI>Ultrafiltration coefficient 62 mL/h/mm Hg</LI>
<LI>Vitamin B&#8321;&#8322; clearance 125 mL/min</LI>
<LI>Sterilised using Puristeril 340</LI>
<LI>All individuals underwent their usual protocol (blood flow, dialysate flow, dialysis treatment time, anticoagulation type, dosage)</LI>
<LI>Sieving coefficient for beta-2 microglobulin &gt; 0.6 and UF coefficient &#8805; 20 mL/mm Hg/h</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Polyamide membrane (Polyflux 6L)</LI>
<LI>Surface area 1.4 m²</LI>
<LI>Ultrafiltration coefficient 8.6 mL/h/mm Hg</LI>
<LI>Vitamin B&#8321;&#8322; clearance 85 mL/min</LI>
<LI>Sterilised using Puristeril 340</LI>
<LI>All individuals underwent their usual protocol (blood flow, dialysate flow, dialysis treatment time, anticoagulation type, dosage)</LI>
<LI>Sieving coefficient for beta-2 microglobulin &gt;0 and UF coefficient &#8804; 10 mL/mm Hg/h</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-25 06:49:52 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Mortality; cardiovascular mortality</LI>
<LI>Cholesterol; triglycerides</LI>
<LI>Inflammatory response</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:40:42 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: 0</LI>
<LI>Stop or end point/s: None reported</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Data for first phase of cross-over provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 16:19:15 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Locatelli-1996">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 2 years</LI>
<LI>Lost to follow-up: 0/155</LI>
<UL>
<LI>Patient numbers in the high-flux, low-flux bioincompatible membrane and low-flux biocompatible membrane arms of the study given</LI>
<LI>Numbers of patients who left the study: 24 for kidney transplant, 5 for acute clinical reasons, 4 for fistula related problems, 12 for treatment inadequacy and 50 for technical reasons</LI>
</UL>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 15:31:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: Multicentre study</LI>
<LI>Adults (18 to 70 years); RRT for at least 2 months; on dialysis for &gt; 3 months; regular thrice weekly HD; stable clinical condition</LI>
<LI>Number (treatment/control): 51/104</LI>
<LI>Mean age (treatment/control): 56/52.1 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 70.6%/29.4%</LI>
<LI>Control group: 69.1%/30.9%</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Presence of malignant disease; myocardial Infarction in the previous 12 months; stroke or TIA in the previous 6 months; severe heart failure (NYHA Class III or IV)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-18 16:19:15 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, polysulfone</LI>
<LI>3 times/wk</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux, polysulfone or cuprophane</LI>
<LI>3 times/wk</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 18:02:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Mortality</LI>
<LI>Kt/V</LI>
<LI>Hospital admission</LI>
<LI>Days spent in hospital</LI>
<LI>Beta-2 microglobulin values</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:41:49 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Locatelli-2000">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:32 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 0/84</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:42:54 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: Multicentre study</LI>
<LI>Adult (&gt; 18 years); conventional thrice weekly HD for at least 6 months with cellulose dialyser; negligible RRF (average estimated urea and CrCl &lt; 1 mL/min/1.73 m²); no change in EPO, iron, folic acid, vit B&#8321;&#8322;, ACEi in the previous 3 months; dialysis dosage &gt; 1.2 or &gt; 1.4 (respectively estimated by means of equilibrated or non-equilibrated Kt/V)</LI>
<LI>Number (treatment/control): 35/39</LI>
<LI>Mean age (treatment/control): 64/65 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 19/16</LI>
<LI>Control group: 20/19</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients whose clinical condition had been unstable during the previous 3 months; patients on treatment with erythropoiesis related drugs (steroids, cyclophosphamide, azathioprine, or androgen hormones); severe cardiac, hepatic, bone marrow, connective tissue or neoplastic diseases; plasma transferrin saturation &lt; 25% or serum ferritin &lt; 200 ng/mL; MCV &lt; 83 m³ or &gt; 100 m³; hyperparathyroidism defined as n-amino terminal PTH &gt; 500 mU/mL, with ionised Ca 1.15 to 1.37 mmol/L; use of aluminium based binders at a dose of &gt; 2 g/d for at least 1 year before study entry; clinical or laboratory findings of aluminium toxicity; use of a dialyser with a synthetic membrane or use of a convective dialyser technique in the previous 6 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>High-flux</P>
<UL>
<LI>High-flux BK-F PMMA membrane</LI>
<LI>3 times/wk</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux cellulose-based membrane</LI>
<LI>3 times/wk</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-26 11:00:05 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Mortality</LI>
<LI>Intradialytic hypo- and hypertension</LI>
<LI>Equilibrated Kt/V</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 14:43:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: 10</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:07:54 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Mohini-1989">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:10 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: NS</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:07:38 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: USA</LI>
<LI>Setting: Henry Ford Hospital, Detroit, MI</LI>
<LI>Patients: Clinical stable patients treated with recombinant human EPO and on HD</LI>
<LI>Duration on dialysis: NS</LI>
<LI>Number (treatment/control): 16/18</LI>
<LI>Mean age (treatment/control): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:43 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polysulfone</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Cellulosic</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-24 19:30:41 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Haematocrit</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:07:54 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post randomisation but pre-intervention: NS</LI>
<LI>Stop or end point/s: None reported</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Abstract presentation only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 16:20:14 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-MPO-2009">
<CHAR_METHODS MODIFIED="2012-06-26 15:08:20 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: December 1998 to June 2006</LI>
<LI>Follow-up period: Mean observation time (3.0 years); maximum (7.5 years)</LI>
<LI>Lost to follow-up: 191/738</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-18 16:20:14 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: Multicentre study</LI>
<LI>All new ESKD patients of both sexes, admitted for dialysis, willing to cooperate, gave informed consent and fulfil the following inclusion criteria: aged 18 to 75 years; RRT &lt; 1 month; at risk, originally defined as serum albumin &lt; 4.0 g/dL (subsequently changed to include those with albumin &gt; 4.0 g/dL as the investigators could not find sufficient numbers of patients with the lower albumin level (&lt; 4.0 g/dL)</LI>
<LI>Mean time on dialysis prior to enrolment: 31 days</LI>
<LI>Number (treatment/control): 360/378</LI>
<LI>Mean age (treatment/control): 59.4/60.2 years</LI>
<LI>% Male (treatment/control): 62.9/65.3</LI>
<LI>% Diabetic (Treatment/control): 26.1/22.5</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>AKI; pregnancy; previous leg amputation; scheduled for kidney transplantation from a living donor within the study period; HD after kidney transplantation; nephrotic syndrome (proteinuria &gt; 6 g/24 h/1.73 m²); active malignancies; current therapy with immunosuppressive agents; severe CHF after maximal therapy (NYHA class IV); unstable angina pectoris; active systemic infections (TB, systemic fungal infection, AIDS, hepatitis with ALT &gt; twice the upper normal value); CPD requiring supplementary oxygen; cirrhosis with encephalopathy; CVC as intended permanent vascular access; involvement in other intervention protocols; inability to follow the main requirements of the present protocol; unwillingness to undergo the protocol procedures</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:10:20 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux synthetic or substituted cellulose membranes</LI>
<LI>High-flux was defined as sieving coefficient  beta-2 microglobulin &gt; 0.6 and ultrafiltration coefficient &#8805; 20 mL/mm Hg/h</LI>
<LI>Haemodialysis 3 times per week with bicarbonate haemodialysis with a minimum treatment time of 180 minutes and a minimum spKt/V of 1.2</LI>
<LI>Dialyser reuse was not allowed</LI>
<LI>Treatment parameters (treatment time, blood flow rate, dialysis fluid flow rate, dialyser surface area) adjusted locally by the investigator to reach the Kt/V target</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux synthetic, substituted cellulose or unsubstituted cellulose membranes</LI>
<LI>Haemodialysis 3 times/wk with bicarbonate haemodialysis with a minimum treatment time of 180 minutes and a minimum spKt/V of 1.2</LI>
<LI>Dialyser reuse was not allowed</LI>
<LI>Treatment parameters (treatment time, blood flow rate, dialysis fluid flow rate, dialyser surface area) adjusted locally by the investigator to reach the Kt/V target</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 20:32:02 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Mortality</LI>
<LI>Hospitalisation</LI>
<LI>Beta-2 microglobulin levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:23:38 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: 91</LI>
<LI>Stop or end point/s: End of study period was set to be 3 years from the date of last patient recruitment</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:24:36 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Opatrny-2002">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:33 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 8 weeks</LI>
<LI>Lost to follow-up: 0/25</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 16:18:52 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Czech Republic</LI>
<LI>Setting: University hospital</LI>
<LI>Patients on HD for ESKD</LI>
<LI>Mean time on dialysis (treatment/control): 28/19 months</LI>
<LI>Number (treatment/control): 12/13</LI>
<LI>Mean age (treatment/control): 71/69 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 6/6</LI>
<LI>Control group: 7/6</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Diabetes mellitus; active liver disease; manifest signs of bleeding; clinical or laboratory signs of infection; received blood transfusions</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:50 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, polysulfone (Fresenius F60S, UF coefficient 40 mL/mm Hg /h, 1.3 m²)</LI>
<LI>Blood flow rate: 200 to 350 mL/min</LI>
<LI>Dialysate flow rate: 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux, polysulfone (Fresenius 7HPS, UF coefficient 9.8 mL/mm Hg/h, 1.6 m²)</LI>
<LI>Blood flow rate: 200 to 350 mL/min</LI>
<LI>Dialysate flow rate: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 20:51:27 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Kt/V</LI>
<LI>Beta-2 microglobulin levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:24:36 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: Method of randomisation</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-18 16:21:17 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ottosson-2001">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 12 weeks</LI>
<LI>Lost to follow-up: 3/42</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-25 20:57:00 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Sweden</LI>
<LI>Setting: Multicentre</LI>
<LI>Patients on chronic stable HD for at least 3 months</LI>
<LI>Mean time on dialysis (treatment/control): 16.6/20.4 months</LI>
<LI>Number (treatment/control): 19/23</LI>
<LI>Mean age (treatment/control): 67.9/70.2 years</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 9/10</LI>
<LI>Control group: 15/8</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>ACEi; lipid lowering therapy; oestrogen therapy; planned major surgery; kidney transplantation within the study follow-up period</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-18 16:21:17 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>High-flux, PAN (AN-69, 1.65 m², B&#8321;&#8322; clearance: 115 mL/min)</LI>
<LI>Blood flow: 200 to 300 mL/min</LI>
<LI>Dialysate flow: 500 mL/min</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Low-flux, cellulose diacetate (FB170T, NISSHO Corp, Japan, 1.7 m². B&#8321;&#8322; clearance 77 mL/min)</LI>
<LI>Blood flow: 200 to 300 mL/min</LI>
<LI>Dialysate flow: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 20:59:06 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:26:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:26:48 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Rizvi-1995">
<CHAR_METHODS MODIFIED="2012-03-23 15:46:15 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Cross-over RCT</LI>
<LI>Time frame: Unclear</LI>
<LI>Follow-up period: 1 month</LI>
<LI>Lost to follow-up: 0%</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:26:29 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: India</LI>
<LI>Setting: Single medical college centre</LI>
<LI>Patients: Stable adult individuals with ESKD aged 18 to 61 years</LI>
<LI>Duration on dialysis: Unclear</LI>
<LI>Number (treatment/control): 10/10</LI>
<LI>Mean age (treatment/control): 34.5 ± 11.6 years</LI>
<LI>Sex (M/F)</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:53 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polysulphone (Fresenius)</LI>
<LI>UF rate 15 mL/h/mm Hg</LI>
<LI>Time 2 hours/session</LI>
<LI>Acetate dialysis</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Polysulphone (Fresenius)</LI>
<LI>Ultrafiltration rate 4.0 mL/h/mm Hg</LI>
<LI>Time 4 hours/session</LI>
<LI>Acetate dialysis</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-25 07:59:56 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Serum creatinine, blood urea, calcium, alkaline phosphatase, electrolytes</LI>
<LI>Complications and intradialytic symptoms</LI>
<LI>Cost</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:26:48 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: Unclear</LI>
<LI>Stop or end point/s: None reported</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Abstract only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:27:28 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Sawaya-1989">
<CHAR_METHODS MODIFIED="2012-03-23 15:47:38 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: Unclear</LI>
<LI>Follow-up period: 18 months</LI>
<LI>Lost to follow-up: Unclear</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:27:07 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: USA</LI>
<LI>Setting: Single hospital centre</LI>
<LI>Patients: Stable haemodialysis patients</LI>
<LI>Duration on dialysis: NS</LI>
<LI>Number (treatment/control): NS</LI>
<LI>Mean age (treatment/control): NS</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:55 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polysulfone</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>Saponified cellulose ester</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-25 08:04:14 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Visual evoked potentials</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:27:28 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: Unclear</LI>
<LI>Stop or end point/s: None reported</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:28:11 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Simon-1993">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:35 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 48 months</LI>
<LI>Lost to follow-up: 0/54</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 14:30:36 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: France</LI>
<LI>Setting: University teaching hospital</LI>
<LI>HD 3 times/ wk, 4 hours/session; agree to blood sample collection every month; agree to have treatment in the dialysis centre conducting the study</LI>
<LI>Number (treatment/control): 32/22</LI>
<LI>Age: NS</LI>
<LI>Sex (M/F)</LI>
<UL>
<LI>Treatment group: 13/19</LI>
<LI>Control group: 14/8</LI>
</UL>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Systemic disease; chronic respiratory failure; hepatic dysfunction; neoplasm; chronic infectious disease; uncontrolled hypertension</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-28 07:41:20 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Treatment group</P>
<UL>
<LI>High-flux, polysulfone (AN 69)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Low-flux, cuprophane</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 21:14:25 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Hospitalisation (all-cause, infectious, cardiac)</LI>
<LI>Mortality (all-cause, infectious, cardiac)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:28:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:28:40 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Skroeder-1993">
<CHAR_METHODS MODIFIED="2012-06-26 14:30:37 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Design: Cross-over RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 84 HD sessions</LI>
<LI>Lost to follow-up: 4/20</LI>
<UL>
<LI>The authors mention that only 16/20 completed the study, and that 4 did not complete &lt; 40% of planned treatment sessions and 13 randomly selected patients underwent some duplicate treatments to increase statistical validity</LI>
</UL>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-23 15:50:44 +1100" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Sweden</LI>
<LI>Setting: University hospital</LI>
<LI>Patients on maintenance HD; stable condition for at least 3 months</LI>
<LI>Mean time on dialysis: 1.7 years</LI>
<LI>Number: 20</LI>
<LI>Sex (M/F): 16/4</LI>
<LI>Mean age: 61 years (range 40 to 80)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Signs of inflammatory disease; liver disease; myeloproliferative or lymphoproliferative disease; diabetes mellitus; immunosuppressive therapy; anticoagulants; signs of acute infection or malignancy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-04 21:45:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>High-flux polyamide membranes (Polyflux, area 1.0 or 1.6 m²)</LI>
<LI>Blood flow: 200 or 400 mL/min</LI>
<LI>Dialysis duration: 2 or 4 hours</LI>
<LI>Dialysate flow: 500 mL/min</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Low-flux hemophane (GF 120 Plus, are 1.2 or 2 m²)</LI>
<LI>Blood flow: 200 or 400 mL/min</LI>
<LI>Dialysis duration: 2 or 4 hours</LI>
<LI>Dialysate flow: 500 mL/min</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-02 16:39:26 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Intradialytic symptoms (headache, pruritus, hypotension)</LI>
<LI>Dialysate beta-2 microglobulin concentration</LI>
<LI>Post-dialysis serum beta-2 microglobulin concentration</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:28:40 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: None</LI>
<LI>Stop or end point/s: NS</LI>
<LI>Additional data requested from authors: None</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-26 15:49:19 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Takasawa-2005">
<CHAR_METHODS MODIFIED="2012-06-26 14:17:18 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: Parallel RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
<LI>Lost to follow-up: Unclear</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-26 15:29:06 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: Three hospitals</LI>
<LI>Patients: Stable HD</LI>
<LI>Duration on dialysis: NS</LI>
<LI>Number (treatment/control): 9/10</LI>
<LI>Sex (M/F): NS</LI>
</UL>
<P>Exclusion criteria: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 14:22:56 +1000" MODIFIED_BY="Suetonia Palmer">
<P>High-flux</P>
<UL>
<LI>Polysulfone (APS-E) membrane</LI>
</UL>
<P>Low-flux</P>
<UL>
<LI>FPS-16M membrane</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:49:19 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Haematocrit</LI>
<LI>Beta-2 microglobulin</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-26 15:29:22 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Exclusions post-randomisation but pre-intervention: Unclear</LI>
<LI>Stop or end point/s: None reported</LI>
<LI>Additional data requested from authors: Clinical outcomes, risks of bias</LI>
<LI>Abstract only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin converting enzyme inhibitor; AIDS - acquired immunodeficiency syndrome; AKI - acute kidney injury; ALT - alanine aminotransferase; ARB - angiotensin receptor blocker; BP - blood pressure; Ca - calcium; CCF - congestive cardiac failure; CHF - chronic heart failure; CPD - cardiopulmonary disease; CrCl - creatinine clearance; CRP - C-reactive protein; CVC - central venous catheter; EPO - erythropoietin; ESKD - end-stage kidney disease; GN - glomerulonephritis; Hb - haemoglobin; HD - haemodialysis; HDL - high density lipoprotein; HD-QoL - Haemodialysis Quality of Life Questionnaire; ITT - intention-to-treat; MCV - mean corpuscular volume; NS - not stated; LDL - low density lipoprotein; NYHA - New York Heart Association; PT - prothrombin time; PTH - parathyroid hormone; QoL - quality of life; RCT - randomised controlled trial; RRF - residual renal function; RRT - renal replacement therapy; TB - tuberculosis; TIA - transient ischaemic attack; TTO - time trade-off; UF - ultrafiltration; UFR - ultrafiltration rate; URR - urea reduction rate; VLDL - very low density lipoprotein</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="Suetonia Palmer" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Abe-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing 3 high-flux membranes in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:20 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Abe-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing 2 high-flux membranes in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Alarcon-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Albertazzi-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:29 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Amadori-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:24 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Andreoli-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:24 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:30 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Arakawa-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:27:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arnadottir-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:27:46 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:34 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Becker-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:34 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not CKD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:50:43 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Bergamo-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:50:43 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Short duration (&lt; 1 month exposure)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bonomini-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:50:47 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Bonomini-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:50:47 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Short duration (&lt; 1 month exposure)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-24 14:22:33 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Bordoni-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-24 14:22:33 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:44 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bosc-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Boudville-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:31 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Branger-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:20:07 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Campbell-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:20:07 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caramelo-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:04 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cases-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 11:41:25 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chanard-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 11:41:25 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:54 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Chaveau-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 5 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 11:41:29 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 11:41:29 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Churchill-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Civati-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Combe-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:05 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:55:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-CONTRAST-_x0028_Dutch_x0029_-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:55:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing online HF with low-flux HD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:48:50 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Danielson-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:48:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Interventions not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daugirdas-1994a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Francisco-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:06 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:31 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-De-Precigout-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:20:26 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Dellanna-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:20:26 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:32 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Demirtas-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Descamps_x002d_Latscha-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:07 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Dhakal-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:17:14 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ding-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:17:14 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Diop-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Docci-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:08 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Docci-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Domrongkitchaiporn-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donovan-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:08 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Falkenhagen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferreira-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:09 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fourtunas-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:09 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fox-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:10 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:17:39 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Franke-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:17:39 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:18:01 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Gasc_x00a2_n-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:18:01 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Girndt-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:11 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonella-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:11 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grekas-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:13 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grooteman-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:13 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:56:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Grooteman-1995b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:56:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grooteman-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:14 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:21:31 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Grooteman-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:21:31 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:21:11 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Grooteman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:21:11 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haag_x002d_Weber-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hakim-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hakim-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haque-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:14 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:37 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hardouin-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haufe-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:15 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:52:13 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Heisel-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:52:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:21:52 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Hernandez-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:21:52 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Himmelfarb-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:56:26 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Himmelfarb-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:56:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:56:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hoenich-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:56:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 3 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:38 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hoenich-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoenich-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:56:38 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hoenich-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:56:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:20:55 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Hoenich-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:20:55 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Review, commentary, or editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:38 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hornberger-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hornych-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:17 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huraib-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:17 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:56:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ingram-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:56:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Iorio-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ivanovich-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Josephson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasama-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:20 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:41 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kato-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:56:55 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kim-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:56:55 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing HDF with online endogenous perfusion with low-flux HD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kino-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:42 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kirschbaum-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klemm-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:57:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Klinkmann-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:57:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 4 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:42 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Koda-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:57:15 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kramer-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:57:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 4 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:57:29 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Krieter-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:57:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:57:37 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Krieter-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:57:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing high-flux HD and online post-dilution HDF</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:57:44 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lee-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:57:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing high cut-off versus high-flux dialysis membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:22:14 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Leitienne-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:22:14 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate exposure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:43 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Levin-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:44 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linnenweber-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-1996b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article and protocol of future trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:53:26 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Locatelli-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:53:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Design of ongoing study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-2000b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Locatelli-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lonnenmann-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:58:11 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lundberg-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:58:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:50 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-MacGinley-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:50 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mahuet-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:51:36 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-MAMHEBI-Study-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:51:36 +1000" MODIFIED_BY="Suetonia Palmer">
<P>FX high-flux versus standard high-flux</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 16:24:00 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Mandolfo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 16:24:00 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Haemodiafiltration versus high-flux dialysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mann-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Martin_x002d_Malo-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:52 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Martin_x002d_Malo-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinez-Ara-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martos-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matthews-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Matzkies-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-McCarthy-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:58:24 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mehrotra-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:58:24 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing high-normal with low-normal arterial pH</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Memoli-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Memoli-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Memoli-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:54 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Merello-Godino-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:55 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mioli--1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:55 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 16:24:38 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Mishkin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 16:24:38 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Haemodiafiltration versus high-flux dialysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:55 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Moreno-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:55 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moshfegh-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:01:45 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Mudge-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:01:45 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Superflux versus high flux</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:01:15 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Muller-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:01:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Comparison of sterilization techniques</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:51:47 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Munger-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:51:47 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Short duration (&lt; 1 month)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Navarro-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:56 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Navarro-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nensel-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-24 14:23:05 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Opatrny-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-24 14:23:05 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:49:58 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Opatrny-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:49:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:52:19 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Opatrny-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:52:19 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Otti-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:52:29 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ouseph-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:52:29 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Panichi-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:52:45 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Parker-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:52:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:58:42 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Pellicano-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:58:42 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Super-flux versus high-flux</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pengloan-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-08 14:54:16 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Pereira-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-08 14:54:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>Interventions not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pickett-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Interventions not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:58:56 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ponikvar-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:58:56 +1000" MODIFIED_BY="Suetonia Palmer">
<P>AKI patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quellhorst--1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riegel-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Risler-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritz-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robles-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robles-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:01 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ronco-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:01 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:10:15 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Sa-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:10:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaefer-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schaefer-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Schaefer-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 3 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schauer-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schiffl-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schindler-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schindler-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:17 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Schonermarck-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:17 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schouten-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schouten-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schroder-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schultze-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwalbe-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sethi-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sevillano-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:29 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Singh-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sirolli-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:33 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Sirolli-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:33 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Short duration (&lt; 1 month)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sirolli-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sklar-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:44 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sklar-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Skroeder-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sombolos-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sreeharan-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stefanovic1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stegmayr-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:53:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Stegmayr-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:53:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stegmayr-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Interventions not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stein-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stuard-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sultan-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takenaka-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takenaka-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tayeb-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taylor-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:18:07 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Tessitore-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:18:07 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not high flux versus low flux</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:18:11 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Tessitore-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:18:11 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thalhammer-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:19:42 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Thijs-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:19:42 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not high flux versus low flux</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 16:26:58 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tonelli-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 16:26:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Cross-over RCT comparing 2 high-flux dialysers in parallel to 3 other dialysis modalities (4 hours of standard HD, 4.5 hours of HD, and 4 hours of HD with increased dialysate flow)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 19:21:49 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Traut-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 19:21:49 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Irrelevant outcomes - not clearly RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tridon-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valentijn-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Stone-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Ypersele-1991a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Ypersele-1991b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanherweghem-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanholder-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vanholder-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Interventions not relevant to review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanholder-1992a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:22 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vanholder-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Varela-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaslaki-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Velasquez-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verbeelen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Verresen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verresen-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wakasa-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:16:14 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Wanner-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:16:14 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not high flux versus low flux intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-26 17:16:50 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Ward-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-26 17:16:50 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:54:24 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ward-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:54:24 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 4 low-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:54:29 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ward-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:54:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Compared 2 high-flux membranes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ward-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wei-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Interventions not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wens-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Woffindin-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 15:59:16 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Woo-_x0028_Tx_x0029_-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 15:59:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>AKI patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Woods-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wright-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:28:23 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:27:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wright-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:27:26 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yasuhiro-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:27:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zaoui-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:27:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:27:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zaoui-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:27:19 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zaoui-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-18 17:27:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-18 17:27:07 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes not relevant to the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AKI - acute kidney injury; CKD - chronic kidney disease; HD - haemodialysis; HDF - haemodiafiltration; HF - haemofiltration</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-03-22 19:20:57 +1100" MODIFIED_BY="Suetonia Palmer" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-NCT00004285">
<CHAR_STUDY_NAME MODIFIED="2012-06-26 15:36:43 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Phase II Randomized Study of Standard vs High Amount of Hemodialysis Using Low vs High Flux Dialyzer Membranes for End Stage Renal Disease. <A HREF="http://www.clinicaltrials.gov/ct2/show/NCT00004285">http://www.clinicaltrials.gov/ct2/show/NCT00004285</A>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-26 15:36:43 +1000" MODIFIED_BY="Narelle S Willis"/>
<CHAR_PARTICIPANTS MODIFIED="2012-07-26 10:59:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Disease Characteristics</P>
<UL>
<LI>End stage renal disease that requires in-centre hemodialysis 3 times/week On hemodialysis for at least 3 months (6 months following renal transplant)</LI>
<LI>No scheduled renal transplant from living donor</LI>
</UL>
<P>Prior/Concurrent Therapy</P>
<UL>
<LI>No concurrent intervention studies unless ancillary to this protocol No concurrent investigational drugs</LI>
</UL>
<P>Patient Characteristics</P>
<UL>
<LI>Hepatic: Albumin at least 2.6 g/dL by nephelometry No cirrhosis with encephalopathy or abnormal PT</LI>
<LI>Renal: Urea clearance (interdialytic) no greater than 1.5 mL/min per 35 litres total urea volume</LI>
<LI>Cardiovascular: No New York Heart Association class IV congestive heart failure despite maximal therapy No unstable angina No new onset angina No recent exacerbation of frequency, duration, or severity of angina</LI>
<LI>Pulmonary: No chronic pulmonary disease requiring supplemental oxygen</LI>
<LI>Other: Not hospitalised in acute or long term care facility at entry No active malignancy requiring chemotherapy or radiotherapy No AIDS No active systemic infection, e.g., tuberculosis or fungal infection No mental incompetence or other contraindication to protocol therapy Not pregnant Geographically available for treatment at participating institution No more than 20 missed treatments/year</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-26 15:36:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>Patients are randomly assigned to 1 of 4 groups: moderate dose dialysis, low flux membrane; high dose dialysis, low flux membrane; moderate dose dialysis, high flux membrane; or high dose dialysis, high flux membrane. Moderate dose is a target eKt/V of 1.05 and high dose is 1.45. The dose and delivery of dialysis are measured monthly by the equilibrated fractional clearance of urea (eKt/V) calculated with double pool kinetics.</P>
<P>Patients are dialyzed 3 times a week in the shortest possible time (minimum 2.5 hours), adjusted for adequate fluid removal. General medical care, protein and calorie intake, and dialyzer reuse and other aspects of dialysis therapy are standardized. The protocol document lists approved dialyzers; no unsubstituted cellulosic membranes are permitted.</P>
<P>The intervention phase of this study is 5 years.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-26 15:36:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Patients are followed for survival</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-06-26 15:36:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>October 1992</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-06-26 15:37:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Study Chair: Daniel B Ornt, University of Rochester</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-06-26 15:30:49 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Available at <A HREF="http://www.clinicaltrials.gov/ct2/show/NCT00004285">http://www.clinicaltrials.gov/ct2/show/NCT00004285</A> Accessed 26 June 2012. Study completed, no publications identified</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-07-26 10:59:14 +1000" MODIFIED_BY="Suetonia Palmer">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-06-20 17:30:57 +1000" MODIFIED_BY="Suetonia Palmer" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:30:57 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:29:27 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:29:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:30:12 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:30:29 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:30:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:31:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:31:47 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:32:04 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:32:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:32:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 17:23:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>Performed centrally using random permuted blocks, with stratification according to clinical centre, age and diabetic status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:33:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 18:56:30 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>Random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:33:59 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 19:04:04 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>Computer generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:34:36 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 12:48:46 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:35:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 19:14:52 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>Alternate order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:36:04 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:37:05 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>Randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:38:40 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 12:36:38 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:00:04 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>Centralised randomisation using a separate list for each participating centre divided into blocks of eight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:40:24 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:42:51 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>Provided by authors - record of method not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 20:52:39 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:15 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:28 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:43 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:44:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:44:11 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-26 14:08:51 +1000" MODIFIED_BY="Suetonia Palmer" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 14:08:51 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:29:31 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-21 17:45:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>Adequate, sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:30:13 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:30:30 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:30:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:31:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:31:48 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:32:05 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:32:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:32:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 17:07:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:33:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:33:46 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:34:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:34:21 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:34:37 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:35:12 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>Drawn by lots</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:35:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 19:15:08 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>Alternate order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:36:05 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:37:08 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>Consecutively numbered sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:39:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>Centralized at the Nephrology department in Lecce - not otherwise described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:40:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 19:34:09 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>Centralised randomisation using a separate list for each participating centre divided into blocks of eight</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:40:25 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-24 19:42:05 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>Patients names were written in a piece of paper put in a bag and taken out without looking at the names (information obtained by contacting the authors)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:02 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:15 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:29 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:43:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:44:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-24 08:44:12 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-06-20 17:35:37 +1000" MODIFIED_BY="Suetonia Palmer" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Were investigators blinded?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Were outcome assessors blinded?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Where participants blinded?</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-20 17:29:08 +1000" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 21:50:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 21:58:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 21:58:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 22:00:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 22:07:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 22:29:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 22:39:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 22:51:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-19 22:52:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:00:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:03:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:09:22 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:05:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:11:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:55:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 15:58:39 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:02:27 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>Participants: not blinded</P>
<P>Investigators: not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:06:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:11:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:30:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:33:52 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:41:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>Not blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:46:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:50:51 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:00:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 16:52:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:03:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:06:02 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:08:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:19:17 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>Participants not blinded</P>
<P>Investigators blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:22:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:25:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 17:29:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2012-06-20 17:31:08 +1000" MODIFIED_BY="Narelle S Willis" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:31:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 21:57:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 21:58:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 22:00:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 22:08:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 22:29:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>Blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 22:39:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 22:42:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-19 22:52:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:00:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:03:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:09:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>Blinded to allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:05:25 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:11:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:55:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 15:58:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:02:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:06:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:12:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:30:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:33:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:41:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:46:17 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>Not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:50:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:00:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 16:53:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:03:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:05:47 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:08:19 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:19:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:21:39 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:26:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-06-20 17:29:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-07-26 10:59:14 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-25 06:23:27 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>Enrolled/randomised (20); analysed (18); 90% followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:13:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>Enrolled/randomised (48); analysed (48); 100% followed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:46:54 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>Enrolled/randomised (28); analysed (28); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:32:41 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>Enrolled/randomised (18); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:48:52 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>Enrolled/randomised (40); analysed (38); followed (95%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:49:22 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>Enrolled/randomised (30); analysed (22); followed (73.3%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:50:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>Enrolled/randomised (40); analysed (35); followed (87.5%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:51:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>Enrolled/randomised (30); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-19 22:53:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>Enrolled/randomised (30); analysed (25); followed (83%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 15:01:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>Enrolled/randomised (36); analysed (36); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-25 06:24:22 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>Enrolled/randomised (29); analysed (29); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 15:10:27 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>Enrolled/randomised (1846); analysed (1846); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 15:06:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>Enrolled/randomised (20); analysed (20); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 15:12:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>Enrolled/randomised (48); analysed (45); followed (93.75%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-25 06:25:33 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>Enrolled/randomised (not reported); analysed (151); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 15:59:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>Enrolled/randomised (20); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:03:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>Enrolled/randomised (29); analysed (26); followed (90%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:06:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>Enrolled/randomised (12); analysed (8); followed (66%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-26 10:59:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>Enrolled/randomised (24); analysed (20); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-25 06:49:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>Enrolled/randomised (30); analysed (30); followed (100)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:33:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>Enrolled/randomised (43); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:42:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>Enrolled/randomised (46); analysed (45); followed (98%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:45:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>Enrolled/randomised (155); analysed (83); followed (53.5%). Patients were accounted for (24 for kidney transplant, 5 for acute clinical reasons, 4 for fistula related problems, 12 for treatment inadequacy and 50 for technical reasons).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:50:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>Enrolled/randomised (84); analysed (74); followed (88.09%). All patients accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:01:53 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>Enrolled/randomised (738); analysed (647); followed (86.31%). All patients accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 16:54:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>Enrolled/randomised (34); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:03:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>Enrolled/randomised (25); analysed (25); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:06:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>Enrolled/randomised (42); analysed (39); followed (92.58%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:08:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>Enrolled/randomised (20); analysed (20); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:17:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>Enrolled/randomised (8); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:22:05 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>Enrolled/randomised (54); analysed (54); followed (100%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:25:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>Enrolled/randomised (20); analysed (16); followed (80%). The authors mention that only 16/20 completed the study, and that 4 did not complete &lt; 40% of planned treatment sessions and 13 randomly selected patients underwent some duplicate treatments to increase statistical validity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 17:28:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>Enrolled/randomised (19); analysed (unclear); followed (unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-07-18 16:18:29 +1000" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:31:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>Primary and secondary outcomes were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 21:54:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>Primary outcome (mortality) some secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:48:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>Only some secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:32:59 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>Only some secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:49:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>Only some secondary outcomes reported; unable to meta-analyse</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:49:52 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>Only one secondary outcome reported; unable to meta-analyse</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:50:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to meta-analyse</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:51:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>Primary and secondary outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:54:03 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>Primary and secondary outcomes not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:02:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>Only one secondary outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:04:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>Only one secondary outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:10:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>Primary and secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:06:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>Primary and secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:13:21 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>Only one secondary outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:57:24 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:01:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:03:56 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 16:18:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:13:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>Primary (mortality) and secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:32:10 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>One primary outcome and 1 secondary outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:36:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>Only one secondary outcome reported; data unable to be meta-analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:42:49 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>Primary and some secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:46:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>Primary and secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 14:43:40 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>Only 1 primary outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:01:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>Primary and one secondary outcome reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:54:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>No primary or secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:04:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>Secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:07:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>Only secondary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:09:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:19:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>No relevant outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:22:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>Primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:27:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>Only secondary outcomes reported; unable to include in meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:29:58 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>Only one secondary outcome reported; unable to include in meta-analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-06-26 15:28:48 +1000" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 21:49:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Acchiardo-1989">
<DESCRIPTION>
<P>ITT not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:31:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2005">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:33:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Blankestijn-1995">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:33:23 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Brown-1989">
<DESCRIPTION>
<P>ITT not clearly described; study reported in abstract form only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:33:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2006">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:33:50 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Churchill-1993">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:50:12 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Collins-1993">
<DESCRIPTION>
<P>ITT: All participants not included in analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:34:07 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-De-Vriese-2003">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-19 22:52:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fishbane-1997">
<DESCRIPTION>
<P>ITT: All participants not included in analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:34:20 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Gardinali-1994">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:34:26 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1996">
<DESCRIPTION>
<P>ITT not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:09:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-HEMO-2002">
<DESCRIPTION>
<P>ITT analysis performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:05:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Hartmann-1997">
<DESCRIPTION>
<P>ITT analysis performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:12:06 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-House-1999">
<DESCRIPTION>
<P>ITT analysis not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:57:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-INFLUX-2008">
<DESCRIPTION>
<P>ITT : not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 15:59:00 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Jeloka-2001">
<DESCRIPTION>
<P>ITT: not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:04:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Klemm-2004">
<DESCRIPTION>
<P>ITT: randomised participants not all included in analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:06:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Krieter-2002">
<DESCRIPTION>
<P>ITT: not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:12:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kuchle-1996">
<DESCRIPTION>
<P>ITT: not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:31:01 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Lang-2001">
<DESCRIPTION>
<P>ITT: not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:34:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Li-2007a">
<DESCRIPTION>
<P>ITT: not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:42:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Li-2010">
<DESCRIPTION>
<P>ITT: patients randomised not all included in analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:46:46 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Locatelli-1996">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:50:42 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Locatelli-2000">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:58:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-MPO-2009">
<DESCRIPTION>
<P>ITT performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 16:55:08 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mohini-1989">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:03:15 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Opatrny-2002">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:05:55 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Ottosson-2001">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:08:27 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rizvi-1995">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:18:14 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Sawaya-1989">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:21:23 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Simon-1993">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 15:28:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Skroeder-1993">
<DESCRIPTION>
<P>ITT not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 17:28:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Takasawa-2005">
<DESCRIPTION>
<P>ITT not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2012-06-20 17:35:37 +1000" MODIFIED_BY="Suetonia Palmer" NO="7">
<NAME>Intention-to-treat analysis</NAME>
<DESCRIPTION>
<P>Was ITT analysis performed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-06-09 19:15:13 +1000" MODIFIED_BY="Suetonia Palmer"/>
<ADDITIONAL_TABLES MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-07-18 16:27:33 +1000" MODIFIED_BY="Suetonia Palmer" NO="1">
<TITLE MODIFIED="2011-03-23 17:55:24 +1100" MODIFIED_BY="Suetonia Palmer">Current guidelines on membrane flux for individuals requiring haemodialysis</TITLE>
<TABLE COLS="4" ROWS="6">
<TR>
<TH VALIGN="TOP">
<P>
<B>Guideline</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Country</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Year</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Recommendation/suggestion</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>
</P>
</TD>
<TD>
<P>USA</P>
</TD>
<TD>
<P>2003; 2006</P>
</TD>
<TD>
<P>The use of poorly biocompatible, unmodified cellulose dialyser membranes for haemodialysis is discouraged. In patients with evidence of, or at risk for beta-2 microglobulin amyloidosis, non-cuprophane (EVIDENCE), high-flux dialysers (OPINION) should be used</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-CARI-2005" TYPE="REFERENCE">CARI 2005</LINK>
</P>
</TD>
<TD>
<P>Australia</P>
</TD>
<TD>
<P>2005</P>
<P>(being updated)</P>
</TD>
<TD>
<P>No recommendations possible based on Level I or II evidence (Level I evidence is a systematic review of randomised controlled trials and Level II evidence is evidence from randomised controlled trials)</P>
</TD>
</TR>
<TR>
<TD>
<P>Kidney Disease Improvement Global Outcomes</P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P> </P>
</TD>
<TD>
<P>No recommendation</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-EBPG-2002" TYPE="REFERENCE">EBPG 2002</LINK>
</P>
</TD>
<TD>
<P>Europe</P>
</TD>
<TD>
<P>2007</P>
</TD>
<TD>
<P>The use of synthetic high-flux membranes should be considered to delay long-term complications of haemodialysis therapy. Specific indications include: to reduce dialysis-related amyloidosis; to improve control of hyperphosphataemia; to reduce the increased cardiovascular risk; to improve control of anaemia.</P>
<P>
<I>Position statement from the European Renal Best Practice Advisory Board (2009)</I>: Strong recommendation that high-flux dialysis should be used in the case of high-risk patients (comparable to the low-albumin group in <LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>). In view of the small incremental extra cost of high-flux filters, the high prevalence of albumin &lt; 40 g/L at the start of dialysis, and the substantial improvement in an intermediate marker (beta-2 microglobulin) in the high-flux group of the MPO, expanding the use of high-flux to all patients makes sense. The recommendation to use high-flux in all patients remains at 2B (weak recommendation, based on moderate quality evidence)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="REF-Renal-Association-2009" TYPE="REFERENCE">Renal Association 2009</LINK>
</P>
</TD>
<TD>
<P>United Kingdom</P>
</TD>
<TD>
<P>2009</P>
</TD>
<TD>
<P>Suggest that high-flux dialysers should be used instead of low-flux dialysers to provide haemodialysis (weak recommendation, based on moderate quality evidence). Evidence of improved patient survival with the use of high-flux membranes is restricted to incident patients, who have lower serum albumin concentrations (&lt; 40 g/L) or have diabetes mellitus, and prevalent patients, who have been on haemodialysis &gt; 3.7 years</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins" NO="2">
<TITLE MODIFIED="2012-03-28 15:47:26 +1100" MODIFIED_BY="Suetonia Palmer">Characteristics of included studies categorised according to type of high-flux membrane</TITLE>
<TABLE COLS="13" ROWS="32">
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>No. of patients</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Age</B>
</P>
<P>
<B>(years)</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Sex</P>
<P>
<B>(% men)</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Diabetes mellitus</B>
</P>
<P>
<B>(%)</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Time on dialysis (months)</B>
</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Membrane type</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Membrane reuse</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Study design</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Kt/V urea</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Follow-up</B>
</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Primary outcome</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>High-flux</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Low-flux</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="13">
<P>
<B>Polysulphone</B> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>
</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>48.6 to 49.5</P>
</TD>
<TD>
<P>70</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>39.7 to 76.5</P>
</TD>
<TD>
<P>Polysulphone</P>
</TD>
<TD>
<P>Regenerated cellulose</P>
</TD>
<TD>
<P>Reuse</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>1.01 to 1.05</P>
</TD>
<TD>
<P>9 mo</P>
</TD>
<TD>
<P>Haematocrit</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>
</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cellulose</P>
</TD>
<TD>
<P>Reuse</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>6 mo</P>
</TD>
<TD>
<P>Haematocrit</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>
</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cellulose</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>18 mo</P>
</TD>
<TD>
<P>Visual evoked potentials</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>
</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>63 (22 to 80)</P>
</TD>
<TD>
<P>35.7</P>
</TD>
<TD>
<P>0<SUP>&#8224;</SUP>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>2.73 to 2.95/wk</P>
</TD>
<TD>
<P>1.5 mo</P>
</TD>
<TD>
<P>Lipids</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>
</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>34.5 ± 11.6</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1 mo</P>
</TD>
<TD>
<P>Biochemistry, complications and intradialytic symptoms</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>
</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cellulose acetate</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1 mo</P>
</TD>
<TD>
<P>Lipids</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>
</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>50 to 52</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>40 to 42</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>6 y</P>
</TD>
<TD>
<P>Dialysis-related arthropathy</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>
</P>
</TD>
<TD>
<P>155</P>
</TD>
<TD>
<P>50.5 to 56.0</P>
</TD>
<TD>
<P>69.6</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
<P>Cuprophane</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>1.21 to 1.26</P>
</TD>
<TD>
<P>24 mo</P>
</TD>
<TD>
<P>Dialysis tolerance</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>
</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>51 to 52</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>0<SUP>&#8224;</SUP>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cellulose acetate</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>1.65</P>
</TD>
<TD>
<P>12 mo</P>
</TD>
<TD>
<P>Residual renal function</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>
</P>
</TD>
<TD>
<P>48</P>
</TD>
<TD>
<P>55.7 to 56.7</P>
</TD>
<TD>
<P>68.8</P>
</TD>
<TD>
<P>0<SUP>&#8224;</SUP>
</P>
</TD>
<TD>
<P>9.1 to 9.8</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3 mo</P>
</TD>
<TD>
<P>Plasma homocysteine</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>
</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>45 to 49.1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>85.2 ± 30.8</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3 mo</P>
</TD>
<TD>
<P>beta-2 microglobulin</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>
</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>43 to 45</P>
</TD>
<TD>
<P>63.3</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>24 mo</P>
</TD>
<TD>
<P>Residual renal function</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>
</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>63 ± 15</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>0<SUP>&#8224;</SUP>
</P>
</TD>
<TD>
<P>19.0 to 28.0</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>1.5 ± 0.3</P>
</TD>
<TD>
<P>2 mo</P>
</TD>
<TD>
<P>Anaemia</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>
</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>57 to 64</P>
</TD>
<TD>
<P>73.1</P>
</TD>
<TD>
<P>30.8</P>
</TD>
<TD>
<P>39 to 58</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>6 wk</P>
</TD>
<TD>
<P>Oxidative stress</P>
<P>Homocysteine metabolism</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>
</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>6 mo</P>
</TD>
<TD>
<P>Haematocrit</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>
</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>55.4 ± 9.7</P>
</TD>
<TD>
<P>58.1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>18-60</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>5 mo</P>
</TD>
<TD>
<P>beta-2 microglobulin</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>54.4 to 60.4</P>
</TD>
<TD>
<P>52.6</P>
</TD>
<TD>
<P>39.5</P>
</TD>
<TD>
<P>69.1 to 82.2</P>
</TD>
<TD>
<P>Modified polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Reuse</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>1.33 to 1.40</P>
</TD>
<TD>
<P>2 mo</P>
</TD>
<TD>
<P>Oxidative stress, insulin resistance, inflammation, and dialysis efficiency</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>
</P>
</TD>
<TD>
<P>151</P>
</TD>
<TD>
<P>60.3 to 65.5</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>5 mo</P>
</TD>
<TD>
<P>C-reactive protein</P>
</TD>
</TR>
<TR>
<TD COLSPAN="13">
<P>
<B>Polyacrylonitrile</B> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>
</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>50 to 55</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>42.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polyacrylonitrile</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3 mo</P>
</TD>
<TD>
<P>Dialysis tolerance</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>
</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polyacrylonitrile</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>1.05 to 1.30</P>
</TD>
<TD>
<P>12 mo</P>
</TD>
<TD>
<P>Mortality or first hospitalisation</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>
</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>54 to 55</P>
</TD>
<TD>
<P>56</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>17.4 to 18.0</P>
</TD>
<TD>
<P>Polyacrylonitrile</P>
</TD>
<TD>
<P>Polysulfone</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>2 mo</P>
</TD>
<TD>
<P>Advanced glycation end product (AGE) peptide clearance</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>
</P>
</TD>
<TD>
<P>42</P>
</TD>
<TD>
<P>69 (39 to 85)</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>18 (3 to 107)</P>
</TD>
<TD>
<P>Polyacrylonitrile</P>
</TD>
<TD>
<P>Cellulose diacetate</P>
</TD>
<TD>
<P>Single use</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3 mo</P>
</TD>
<TD>
<P>Lipids</P>
</TD>
</TR>
<TR>
<TD COLSPAN="13">
<P>
<B>Polysulphone or polyacrylonitrile</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>
</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>55 ± 10</P>
</TD>
<TD>
<P>77.7</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>151.2 ± 36</P>
</TD>
<TD>
<P>Polyacrylonitrile or polysulfone</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Parallel</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>6 mo</P>
</TD>
<TD>
<P>Dialysis arthropathy, beta-2 microglobulin and C-reactive protein</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>
</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>27 to 72</P>
</TD>
<TD>
<P>63.9</P>
</TD>
<TD>
<P>0<SUP>&#8224;</SUP>
</P>
</TD>
<TD>
<P>77 ± 69</P>
</TD>
<TD>
<P>Polyacrylonitrile or polysulfone</P>
</TD>
<TD>
<P>Cuprophane</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3 mo</P>
</TD>
<TD>
<P>Anaphylotoxins</P>
</TD>
</TR>
<TR>
<TD COLSPAN="13">
<P>
<B>Polyamide</B> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>
</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>59 ± 13</P>
</TD>
<TD>
<P>80</P>
</TD>
<TD>
<P>0<SUP>&#8224;</SUP>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Polyamide</P>
</TD>
<TD>
<P>Hemophane or cuprophane</P>
</TD>
<TD>
<P>Reuse</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>18 to 24 sessions</P>
</TD>
<TD>
<P>Beta-2 microglobulin clearance</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>
</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>57 to 60</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>16.6</P>
</TD>
<TD>
<P>91.2 to 98.4</P>
</TD>
<TD>
<P>Polyamide</P>
</TD>
<TD>
<P>Polyamide</P>
</TD>
<TD>
<P>Reuse</P>
</TD>
<TD>
<P>Cross-over</P>
</TD>
<TD>
<P>1.48 to 1.51</P>
</TD>
<TD>
<P>6 mo</P>
</TD>
<TD>
<P>Inflammatory response</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Data are mean ± SD, mean (range) or proportion. Where baseline values were not reported for the entire cohort but for separate subgroups (e.g., high-flux or low-flux groups) the mean value for each treatment group is provided.</P>
<P>&#8224;Patients with diabetes mellitus were excluded.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins" NO="3">
<TITLE MODIFIED="2012-07-11 14:11:45 +1000" MODIFIED_BY="Suetonia Palmer">Dialysis prescription details in the included studies</TITLE>
<TABLE COLS="3" ROWS="35">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>High-flux haemodialysis</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Low-flux haemodialysis</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone membranes (F60 or F80). Blood flow rate 469 ± 3 mL/min, dialysate flow rate 800 mL/min, time 126.9 ± 10 min, Kt/V 1.01 ± 0.1</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulosic membranes (C-DAK: 90 SCE or 135 SCE). Blood flow rate 297 ± 10 mL/min, dialysate flow rate 500 mL/min, time 193.2 ± 39 minutes, Kt/V 1.05 ± 0.1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polyacrylonitrile or polysulfone</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophane</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulfone membrane (Kd-urea 277 ± 13 mL/min, dialysis times 133 ± 4.8 min)</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose membrane (Kd-urea 186 ± 8 mL/min, dialysis time 170 ± 7.8 min)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulfone</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose ester</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose acetate sterilised with ethylene oxide. Dialysate glucose-bicarbonate. Kt/V urea &#8805; 1.0. Dialyzer Duoflux High Performance Artificial Kidney. Beta-2 microglobulin clearance 11.4 mL/min. In vivo ultrafiltration rate 15 mL/h/mm Hg. Dialysis delivery system Cobe Centry 2000 Rx retrofitted to accommodate higher ultrafiltration requirements</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose acetate sterilised with ethylene oxide. Dialysate glucose-bicarbonate. Kt/V urea &#8805; 1.0. Dialyzer CD3500 or CD4000. Beta-2 microglobulin clearance 0 mL/min. In vitro ultrafiltration rate 3.5 to 5.0 mL/h/mm Hg. Dialysis delivery system Cobe Centry 2000 Rx</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Non-cellulosic AN69 membrane (Hospal F16 hollow fibre). Dialyzer CGH Medical, Lakewood, CO. Surface area 1.55 m². C<SUB>urea</SUB> 269 mL/min, ultrafiltration coefficient 44 mL/h/mm Hg. Blood flow 400 ml/min, dialysis flow 500 mL/min. Volumetrically controlled machines (Fresenius 2008D)</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophane membrane (Gambro 6N plate). Dialyzer CGH Medical, Lakewood, CO. Surface area 1.6 m². C<SUB>urea</SUB> 272 mL/min, ultrafiltration coefficient 8 mL/h/mm Hg. Blood flow 400 mL/min, dialysis flow 500 mL/min. Volumetrically controlled machines (Fresenius 2008D)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>AN69 membrane</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophan</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polyamine (Polyflux, area 1.0 or 1.6 m²). Volume monitored bicarbonate haemodialysis 2 to 4 hours. Ethylene oxide sterilisation. Dialysate flow 500 mL/min. Blood flow 200 mL/min for 4 hours or 400 mL/min for 2 hours. Sterilised with ethylene oxide</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophan (GF 120 H, area 1.2 or 2 m²), hemophan (GF 120 Plus, area 1.2 or 2 m²). Volume monitored bicarbonate haemodialysis 2 to 4 hours. Ethylene oxide sterilisation. Dialysate flow 500 mL/min. Blood flow 200 mL/min for 4 hours or 400 mL/min for 2 hours. Sterilised with ethylene oxide</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone or polyacrylonitrile</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophane</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone. Bicarbonate dialysate containing 11 mmol/L glucose. Time 11 ± 1.4 h/wk</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophane. Bicarbonate dialysate containing 11 mmol/L glucose. Time 11 ± 1.4 h/wk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone (Fresenius). Ultrafiltration rate 15 mL/h/mm Hg. Time 2 hours/session. Acetate dialysis</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone (Fresenius). Ultrafiltration rate 4.0 mL/h/mm Hg. Time 4 hours/session. Acetate dialysis</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F80 (Fresenius)</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose acetate (Terumo 220)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F60 surface area 1.2 m² 3 times/wk for 4 to 5 hours, MTS A 2008 C delivery system (Fresenius), dialysate flow rate 500 mL/min, blood flow rates 200 to 250 mL/min, acetate and bicarbonate dialysate</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophane membrane, surface areas 1.0 to 1.2 m² (Hospal Germany), 3 times/wk for 4 to 5 hours, MTS A 2008 C delivery system (Fresenius), dialysate flow rate 500 mL/min, blood flow rates 200 to 250 mL/min, acetate and bicarbonate dialysate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulfone, bicarbonate dialysate, Kt/V &#8805;1</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulfone or cuprophane, bicarbonate dialysate, Kt/V &#8805;1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>AN69 Fitral 16 dialyser</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F8 dialyser</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F60 hollow fibre 1.25 m² surface area, 3 times/wk for 4 to 5 hours (MTS 2008 C delivery system, blood pump speed 200 to 250 mL/min and the dialysate flow rate 500 mL/min, bicarbonate dialysate. Ultrafiltration coefficient 40 mL/h/mm Hg</P>
</TD>
<TD VALIGN="TOP">
<P>CA-130 cellulose acetate hollow fibre 1.3 m² surface area, 3 times/wk for 4 to 5 hours (MTS 2008 C delivery system, blood pump speed 200 to 250 mL/min and the dialysate flow rate 500 mL/min, bicarbonate dialysate. Ultrafiltration coefficient 5.6 mL/h/mm Hg</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone. Prescription defined by nephrologist. Bicarbonate dialysate</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone. Prescription defined by nephrologist. Bicarbonate dialysate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>BK-F polymethyl methacrylate (PMMA)</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone</P>
</TD>
<TD VALIGN="TOP">
<P>Cuprophane</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F 60 hollow fibre, ultrafiltration coefficient 40 mL/mm Hg/h, surface area 1.3 m², urea clearance 185 mL/min at a blood flow rate of 200 mL/min, dialysis 3 times/ wk for 4 to 5 hours (MTS 4008 delivery system). Blood pump speed 200 to 280 mL/min and dialysate flow rate 500 mL/min</P>
</TD>
<TD VALIGN="TOP">
<P>Disscap 160 E, ultrafiltration coefficient 6.25 mL/mm Hg/h, surface area 1.22 m², urea clearance 189 mL/min at a blood flow rate of 200 mL/min, dialysis 3 times/wk for 4 to 5 hours (MTS 4008 delivery system). Blood pump speed 200 to 280 mL/min and dialysate flow rate 500 mL/min</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polyacrylonitrile AN69 membrane, surface area 1.65 m² and urea clearance 190 mL/min. Prescribed blood flow set at 200 to 300 mL/min and dialysate flow set at 500 mL/min</P>
</TD>
<TD VALIGN="TOP">
<P>Cellulose diacetate FB170T, surface area 1.7 m², urea clearance 190 mL/min. Prescribed blood flow set at 200 to 300 mL/min and dialysate flow set at 500 mL/min</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polyethersulfone DIAPES HF800 (1.4 m²), Arylane H4 (1.35 m²)</P>
</TD>
<TD VALIGN="TOP">
<P>Hemophan (1.3 m²)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Most commonly Fresenius F80 (43% of sessions) and Baxter CT190 (used in 48%). Reprocessing methods included Renalin without bleach, formaldehyde or glutaraldehyde, with bleach, or heated citric acid. Two-by-two factorial design target equilibrated Kt/V achieved by manipulating duration of treatment session. Ultrafiltration coefficient &gt; 14 mL/mm Hg/h, mean beta-2 microglobulin clearance &gt; 20 mL/min</P>
</TD>
<TD VALIGN="TOP">
<P>Most commonly Fresenius F8 (46% of sessions) and Baxter CA210 (used in 43%). Reprocessing methods included Renalin without bleach, formaldehyde or glutaraldehyde, with bleach, or heated citric acid. Two-by-two factorial design target equilibrated Kt/V achieved by manipulating duration of treatment session. Ultrafiltration coefficient &lt; 10 mL/mm Hg/h</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Steam sterilised F60S dialyser with surface area 1.3 m² and urea clearance 185 mL/min. Blood flow rates 200 to 350 mL/min. Dialysate flow 500 mL/min. Dialysis 3 times/wk</P>
</TD>
<TD VALIGN="TOP">
<P>Steam sterilised F7HPS dialyser with surface area 1.6 m² and urea clearance 186 mL/min. Blood flow rates 200 to 350 mL/min. Dialysate flow 500 mL/min. Dialysis 3 times/wk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Triacetate (FB-150U), surface area 1.5 m², ultrafiltration coefficient 29.8 mL/mm Hg/h, sieving coefficient beta-2 microglobulin 0.88. Treatment duration, blood flow, dialysate flow and ultrafiltration determined by attending nephrologist</P>
</TD>
<TD VALIGN="TOP">
<P>Triacetate (Sureflux-150 L), surface area 1.5 m², ultrafiltration coefficient 12.8 mL/mm Hg/h, sieving coefficient beta-2 microglobulin 0.36. Treatment duration, blood flow, dialysate flow and ultrafiltration determined by attending nephrologist</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>FX 60, Helixone, surface area 1.4 m², 3 times/wk for 4 to 5.5 hours, blood flow rate 500 mL/min, dialysate flow rate 500 mL/min, ultrafilter U 8000S</P>
</TD>
<TD VALIGN="TOP">
<P>F 6 HPS polysulfone, surface area 1.3 m², 3 times/wk for 4 to 5.5 hours, blood flow rate 500 mL/min, dialysate flow rate 500 mL/min, ultrafilter U 8000S</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayli-2005" TYPE="STUDY">Ayli 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F60 for 4 hours, 3 times/wk, blood flow 300 mL/min, dialysate flow rate 500 mL/min</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone F6 HPS for 4 hours, 3 times/wk, blood flow 300 mL/min, dialysate flow rate 500 mL/min</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulfone (APS-E) membrane</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulfone (F7HPS) membrane</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bordoni-2006" TYPE="STUDY">Bordoni 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone and cellulose triacetate</P>
</TD>
<TD VALIGN="TOP">
<P>Polysulphone and cellulose triacetate</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>F60 polysulphone dialyser, ultrafiltration coefficient 40 mL/mm Hg/h, Fresenius 4008S capacity-controlled dialyser and bicarbonate dialysate for 4 hours, 3 times/wk, dialysate flow 500 mL/min, blood flow 190 to 250 mL/min</P>
</TD>
<TD VALIGN="TOP">
<P>F6 polysulphone dialyser, ultrafiltration coefficient 5.5 mL/mm Hg/h, Fresenius 4008S capacity-controlled dialyser and bicarbonate dialysate for 4 hours 3 times/wk, dialysate flow 500 mL/min, blood flow 190 to 250 mL/min</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>FX80 helixone, ultrafiltration coefficient 59 mL/mm Hg/h, inline steam sterilisation, surface area 1.8 m², minimum blood flow rate 250 mL/min and dialysate flow rate 500 mL/min</P>
</TD>
<TD VALIGN="TOP">
<P>F8 HPS polysulphone, ultrafiltration coefficient 18 mL/mm Hg/h, inline steam sterilisation, surface area 1.8 m², minimum blood flow rate 250 mL/min and dialysate flow rate 500 mL/min</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Polyflux H membrane</P>
</TD>
<TD VALIGN="TOP">
<P>Polyflux L membrane</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Synthetic (99%) or substituted cellulose membranes. Haemodialysis 3 times/wk with bicarbonate haemodialysis for a minimum treatment time of 180 minutes and a minimum spKt/V of 1.2. Treatment parameters (treatment time, blood flow rate, dialysis fluid flow rate, and dialyser surface area) were adjusted locally by the investigator to reach the spKt/V target</P>
</TD>
<TD VALIGN="TOP">
<P>Synthetic (75%), substituted cellulose (22%) or unsubstituted cellulose membranes. Haemodialysis 3 times/wk with bicarbonate haemodialysis for a minimum treatment time of 180 minutes and a minimum spKt/V of 1.2. Treatment parameters (treatment time, blood flow rate, dialysis fluid flow rate, and dialyzer surface area) were adjusted locally by the investigator to reach the spKt/V target</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>High-flux polyamide membrane (Polyflux 14S) made of Polyamide S, surface area 1.4 m². Ultrafiltration coefficient 62 mL/h/mm Hg and vitamin B&#8321;&#8322; clearance 125 mL/min. Sterilised using Puristeril 340. All individuals underwent their usual prescriptions (blood flow, dialysate flow, dialysis treatment time, anticoagulation type, and dosage). Sieving coefficient for beta-2 microglobulin &gt; 0.6 and ultrafiltration coefficient &#8805; 20 mL/mm Hg/h</P>
</TD>
<TD VALIGN="TOP">
<P>High-flux polyamide membrane (Polyflux 6L) made of Polyamide S, surface area 1.4 m². Ultrafiltration coefficient 8.6 mL/h/mm Hg and vitamin B&#8321;&#8322; clearance 85 mL/min. Sterilised using Puristeril 340. All individuals underwent their usual prescriptions (blood flow, dialysate flow, dialysis treatment time, anticoagulation type, and dosage). Sieving coefficient for beta-2 microglobulin &gt; 0 and ultrafiltration coefficient &#8804;10 mL/mm Hg/h</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-07-11 14:13:33 +1000" MODIFIED_BY="Suetonia Palmer" NO="4">
<TITLE MODIFIED="2011-03-23 17:58:32 +1100" MODIFIED_BY="Suetonia Palmer">Summary of reported quality of life outcomes</TITLE>
<TABLE COLS="6" ROWS="3">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Quality of life instrument</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Time of assessment</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Method of reporting</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Domains reported</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>TTO index</LI>
<LI>HQL</LI>
<LI>SIP</LI>
</OL>
<P/>
</TD>
<TD VALIGN="TOP">
<P>During the final 2 weeks of each treatment period (total 4 months treatment). If an acute event occurred, measurement was delayed until after 1 month of clinical stability</P>
</TD>
<TD VALIGN="TOP">
<P>Compared scores for individual domains at beginning and end of treatment</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>TTO</LI>
<LI>SIP: physical; psychological; total</LI>
<LI>HQL intradialytic symptoms (fatigue, washed out, thirst, boredom, pruritus, muscle cramps, back pain, dizziness, hypotension, muscle twitching, headache, nausea, irritability, chest pain)</LI>
<LI>HQL interdialytic symptoms (lack of energy, weakness, thirst, muscle loss, insomnia, easy bruising, aches in bones, dry mouth, restless, joint pain, inability to concentrate, dry skin, leg cramps, dyspnoea, nausea, pruritus, headache, drowsiness, poor appetite, skin colour)</LI>
</OL>
<P/>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>TTO &#8211; no statistical difference</LI>
<LI>SIP &#8211; no statistical difference</LI>
<LI>HQL &#8211; intradialytic &#8211; dizziness, nausea and chest pain statistically better with high-flux dialysis (not statistically difference at the P &lt; 0.01 level)</LI>
<LI>HQL &#8211; interdialytic &#8211; no statistical difference between groups</LI>
</OL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>IWB</LI>
<LI>KDQOL-LF</LI>
<LI>SF-36</LI>
</OL>
<P/>
</TD>
<TD VALIGN="TOP">
<P>At baseline, and yearly at 1, 2, and 3 years of follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>Mean change in scores compared with baseline. Mean differences between high- and low-flux groups adjusted for baseline covariates</P>
</TD>
<TD VALIGN="TOP">
<P>IWB, physical functioning, role (physical), bodily pain, general health, vitality, social functioning, role (emotional), mental health, physical component summary score, mental component score, symptom/problem (effects, burden, cognitive function, sleep, social support, staff encouragement, patient satisfaction)</P>
</TD>
<TD VALIGN="TOP">
<P>High-flux membranes were not associated with statistically significant differences in health-related quality of life</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>HQL, Haemodialysis Quality of Life questionnaire; IWB, Index of Well-Being; KDQOL-LF, Kidney Disease Quality of Life-Long Form; SF-36, Short Form-36 Health Survey; SIP, Sickness Impact Profile; TTO, time trade-off</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2016-01-20 15:31:53 +1100" MODIFIED_BY="Gail Y Higgins" NO="5">
<TITLE MODIFIED="2012-03-27 17:02:36 +1100" MODIFIED_BY="Suetonia Palmer">Adverse events</TITLE>
<TABLE COLS="2" ROWS="34">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Study</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Adverse events reported in studies</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Acchiardo-1989" TYPE="STUDY">Acchiardo 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Hypertension, seizures, and clotted vascular access</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brown-1989" TYPE="STUDY">Brown 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mohini-1989" TYPE="STUDY">Mohini 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>&#8220;Adverse reactions were not greater with high flux dialysis&#8221;</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawaya-1989" TYPE="STUDY">Sawaya 1989</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Churchill-1993" TYPE="STUDY">Churchill 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Reported in quality of life analyses</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Collins-1993" TYPE="STUDY">Collins 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Hypotensive events, saline administration, emesis, cramping, symptom index reported. Cramping increased in high-flux group (P &lt; 0.05). No significant differences in the occurrence of hospital admissions, infections, and graft thrombosis between groups</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Simon-1993" TYPE="STUDY">Simon 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Skroeder-1993" TYPE="STUDY">Skroeder 1993</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gardinali-1994" TYPE="STUDY">Gardinali 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blankestijn-1995" TYPE="STUDY">Blankestijn 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rizvi-1995" TYPE="STUDY">Rizvi 1995</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>No statistically significant difference was observed as regards to frequency of complications and intradialytic symptoms during both therapies</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Goldberg-1996" TYPE="STUDY">Goldberg 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuchle-1996" TYPE="STUDY">Kuchle 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported other than complications of dialysis-related arthropathy</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Locatelli-1996" TYPE="STUDY">Locatelli 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Drop-outs due to technical reasons, acute clinical reason, fistula-related, treatment inadequacy, transplant, death, and dialysis sessions with hypotension reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fishbane-1997" TYPE="STUDY">Fishbane 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hartmann-1997" TYPE="STUDY">Hartmann 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Hospitalisation and hypotensive episodes</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-House-1999" TYPE="STUDY">House 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Reaction to dialysis membrane spontaneous rupture of oesophagus</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Locatelli-2000" TYPE="STUDY">Locatelli 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>No major side-effects. No differences in blood pressure values during follow-up</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jeloka-2001" TYPE="STUDY">Jeloka 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Arthritis-like symptoms on direct questioning</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lang-2001" TYPE="STUDY">Lang 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Hypotension</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ottosson-2001" TYPE="STUDY">Ottosson 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Krieter-2002" TYPE="STUDY">Krieter 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-HEMO-2002" TYPE="STUDY">HEMO 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Opatrny-2002" TYPE="STUDY">Opatrny 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-Vriese-2003" TYPE="STUDY">De Vriese 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Klemm-2004" TYPE="STUDY">Klemm 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayli-2005" TYPE="STUDY">Ayli 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Takasawa-2005" TYPE="STUDY">Takasawa 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-INFLUX-2008" TYPE="STUDY">INFLUX 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-MPO-2009" TYPE="STUDY">MPO 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Vascular access failure, myocardial infarction, intracranial haemorrhage</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-07-26 11:16:02 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2012-07-26 11:16:02 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>High-flux versus low-flux membranes</NAME>
<DICH_OUTCOME CHI2="4.130707328392716" CI_END="1.0352772384748057" CI_START="0.8662606377956441" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9470057660312836" ESTIMABLE="YES" EVENTS_1="519" EVENTS_2="552" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.015056665751264738" LOG_CI_START="-0.062351419153492085" LOG_EFFECT_SIZE="-0.023647376701113682" METHOD="IV" MODIFIED="2012-03-16 14:12:54 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.5307551408510189" P_Q="1.0" P_Z="0.2311125964332016" Q="0.0" RANDOM="YES" SCALE="107.6" SORT_BY="WEIGHT" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1425" TOTAL_2="1490" WEIGHT="100.00000000000001" Z="1.1974978251964548">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="153" O_E="0.0" SE="0.0" STUDY_ID="STD-Hartmann-1997" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="152" O_E="0.0" SE="0.0" STUDY_ID="STD-Jeloka-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="155" O_E="0.0" SE="0.0" STUDY_ID="STD-Lang-2001" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="154" O_E="0.0" SE="0.0" STUDY_ID="STD-Locatelli-2000" TOTAL_1="35" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.82976889241327" CI_START="0.0162496050423134" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9459493366395004" LOG_CI_START="-1.7891571903791628" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="156" O_E="0.0" SE="1.6066151129664257" STUDY_ID="STD-Li-2010" TOTAL_1="21" TOTAL_2="24" VAR="2.581212121212121" WEIGHT="0.08009845778145101"/>
<DICH_DATA CI_END="14.207980025005401" CI_START="0.07038298183415555" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.152532337860481" LOG_CI_START="-1.152532337860481" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="157" O_E="0.0" SE="1.3540064007726602" STUDY_ID="STD-Kuchle-1996" TOTAL_1="12" TOTAL_2="12" VAR="1.8333333333333335" WEIGHT="0.11277333279047928"/>
<DICH_DATA CI_END="3.4002745598295228" CI_START="0.04891840987518968" EFFECT_SIZE="0.40784313725490196" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.5315139861612825" LOG_CI_START="-1.3105276684316323" LOG_EFFECT_SIZE="-0.3895068411351748" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="158" O_E="0.0" SE="1.0820243861611256" STUDY_ID="STD-Locatelli-1996" TOTAL_1="51" TOTAL_2="104" VAR="1.1707767722473605" WEIGHT="0.1765931089656061"/>
<DICH_DATA CI_END="1.0428285722355026" CI_START="0.39482626586311886" EFFECT_SIZE="0.6416666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.01821292180030007" LOG_CI_START="-0.40359396355058585" LOG_EFFECT_SIZE="-0.19269052087514293" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="159" O_E="0.0" SE="0.24777145243286736" STUDY_ID="STD-Simon-1993" TOTAL_1="32" TOTAL_2="22" VAR="0.06139069264069265" WEIGHT="3.3677924327381565"/>
<DICH_DATA CI_END="1.1373550023764873" CI_START="0.6654870503542333" EFFECT_SIZE="0.8699971412235563" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="88" LOG_CI_END="0.05589604209254801" LOG_CI_START="-0.17686039099984968" LOG_EFFECT_SIZE="-0.06048217445365082" MODIFIED="2011-05-10 13:24:15 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="64" O_E="0.0" SE="0.13672228096140004" STUDY_ID="STD-MPO-2009" TOTAL_1="318" TOTAL_2="329" VAR="0.018692982111288014" WEIGHT="11.060359919299833"/>
<DICH_DATA CI_END="1.0736127626084695" CI_START="0.8850882701855415" EFFECT_SIZE="0.9748036022226481" ESTIMABLE="YES" EVENTS_1="429" EVENTS_2="442" LOG_CI_END="0.030847665546124163" LOG_CI_START="-0.05301341479049205" LOG_EFFECT_SIZE="-0.011082874622183943" MODIFIED="2011-03-23 13:36:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="151" O_E="0.0" SE="0.04926041370877099" STUDY_ID="STD-HEMO-2002" TOTAL_1="921" TOTAL_2="925" VAR="0.0024265883587592726" WEIGHT="85.20238274842448"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9011530093308684" CI_END="1.139608651030042" CI_START="0.7068010721231158" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8974834908502838" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="128" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.056755737408742804" LOG_CI_START="-0.15070280039787118" LOG_EFFECT_SIZE="-0.0469735314945642" METHOD="IV" MODIFIED="2012-06-26 18:20:31 +1000" MODIFIED_BY="Suetonia Palmer" NO="2" P_CHI2="0.6372606902148881" P_Q="1.0" P_Z="0.37477499739657705" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1271" TOTAL_2="1276" WEIGHT="100.0" Z="0.8875646278951895">
<NAME>Death due to infection</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0806595113679043" CI_START="0.12778118628848004" EFFECT_SIZE="0.515625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.3182010160921352" LOG_CI_START="-0.8935330843041346" LOG_EFFECT_SIZE="-0.28766603410599967" MODIFIED="2011-03-23 13:37:15 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="168" O_E="0.0" SE="0.7117786087533032" STUDY_ID="STD-Simon-1993" TOTAL_1="32" TOTAL_2="22" VAR="0.5066287878787878" WEIGHT="2.9312169640895425"/>
<DICH_DATA CI_END="1.4885387238157883" CI_START="0.4044826946819112" EFFECT_SIZE="0.7759433962264151" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.17276013714919436" LOG_CI_START="-0.39310005443471113" LOG_EFFECT_SIZE="-0.11016995864275836" MODIFIED="2011-05-24 14:32:21 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="121" O_E="0.0" SE="0.33238907758950925" STUDY_ID="STD-MPO-2009" TOTAL_1="318" TOTAL_2="329" VAR="0.1104824989008048" WEIGHT="13.44139490237044"/>
<DICH_DATA CI_END="1.216326775747257" CI_START="0.7214242353012849" EFFECT_SIZE="0.9367430886160528" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="104" LOG_CI_END="0.08505026723819664" LOG_CI_START="-0.14180927221890025" LOG_EFFECT_SIZE="-0.0283795024903518" MODIFIED="2011-03-23 13:37:15 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="166" O_E="0.0" SE="0.13325841644993006" STUDY_ID="STD-HEMO-2002" TOTAL_1="921" TOTAL_2="925" VAR="0.017757805554742993" WEIGHT="83.62738813354002"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7444882820339199" CI_END="0.9869856377111713" CI_START="0.6990067017063468" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8306079552039104" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="235" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.005689166994160964" LOG_CI_START="-0.15551866044869128" LOG_EFFECT_SIZE="-0.08060391372142613" METHOD="IV" MODIFIED="2012-07-26 11:16:02 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.8626932863882055" P_Q="1.0" P_Z="0.03496121463886637" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1302" TOTAL_2="1310" WEIGHT="100.0" Z="2.1088073417923225">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-23 13:37:05 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="165" O_E="0.0" SE="0.0" STUDY_ID="STD-Jeloka-2001" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.82976889241327" CI_START="0.0162496050423134" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9459493366395004" LOG_CI_START="-1.7891571903791628" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2011-03-23 13:37:05 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="164" O_E="0.0" SE="1.6066151129664257" STUDY_ID="STD-Li-2010" TOTAL_1="21" TOTAL_2="24" VAR="2.581212121212121" WEIGHT="0.30008627365743756"/>
<DICH_DATA CI_END="1.6460672658962456" CI_START="0.19940467424685032" EFFECT_SIZE="0.5729166666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.2164475785133461" LOG_CI_START="-0.7002646656039953" LOG_EFFECT_SIZE="-0.2419085435453246" MODIFIED="2011-03-23 13:37:05 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="163" O_E="0.0" SE="0.5384813099933193" STUDY_ID="STD-Simon-1993" TOTAL_1="32" TOTAL_2="22" VAR="0.2899621212121212" WEIGHT="2.6713362550114206"/>
<DICH_DATA CI_END="1.315857589083077" CI_START="0.5593952663455537" EFFECT_SIZE="0.8579536738763615" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="41" LOG_CI_END="0.11920888956511079" LOG_CI_START="-0.2522812129889882" LOG_EFFECT_SIZE="-0.06653616171193873" MODIFIED="2011-05-10 13:25:04 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="65" O_E="0.0" SE="0.21821512514594288" STUDY_ID="STD-MPO-2009" TOTAL_1="318" TOTAL_2="329" VAR="0.04761784084245951" WEIGHT="16.26672510281647"/>
<DICH_DATA CI_END="1.0151409260710629" CI_START="0.6915185773318989" EFFECT_SIZE="0.8378477242244248" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="187" LOG_CI_END="0.006526336994617372" LOG_CI_START="-0.16019614827432468" LOG_EFFECT_SIZE="-0.07683490563985368" MODIFIED="2011-03-23 13:37:05 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="161" O_E="0.0" SE="0.09793361313658873" STUDY_ID="STD-HEMO-2002" TOTAL_1="921" TOTAL_2="925" VAR="0.009590992581987024" WEIGHT="80.76185236851468"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.41658974853597347" CI_END="1.17536374618289" CI_START="0.5291340297100433" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7886221879917183" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07017229087426301" LOG_CI_START="-0.2764343071883155" LOG_EFFECT_SIZE="-0.10313100815702626" METHOD="IV" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.9367945341262687" P_Q="0.8423027692487927" P_Z="0.24347121588319443" Q="0.34323156462943477" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="64" WEIGHT="300.0" Z="1.166354378750653">
<NAME>Hospitalisation</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07335818390653868" CI_END="1.203330703646116" CI_START="0.5191982907066973" DF="1" EFFECT_SIZE="0.7904221938229916" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.08038499810574992" LOG_CI_START="-0.2846667459801665" LOG_EFFECT_SIZE="-0.10214087393720825" MODIFIED="2012-06-26 19:07:56 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.7865085932466369" P_Z="0.2727334999263352" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="32" WEIGHT="99.99999999999999" Z="1.0967893593696023">
<NAME>Any cause</NAME>
<DICH_DATA CI_END="5.772152615091743" CI_START="0.17324559253430377" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7613378052724571" LOG_CI_START="-0.7613378052724571" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-26 19:07:48 +1000" MODIFIED_BY="Narelle S Willis" ORDER="83" O_E="0.0" SE="0.8944271909999159" STUDY_ID="STD-Hartmann-1997" TOTAL_1="10" TOTAL_2="10" VAR="0.8" WEIGHT="5.747699738800582"/>
<DICH_DATA CI_END="1.2012662735116049" CI_START="0.5053839501126887" EFFECT_SIZE="0.7791666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.07963928408839732" LOG_CI_START="-0.2963785544386115" LOG_EFFECT_SIZE="-0.10836963517510705" MODIFIED="2012-06-26 19:07:56 +1000" MODIFIED_BY="Narelle S Willis" ORDER="84" O_E="0.0" SE="0.22087473966908464" STUDY_ID="STD-Simon-1993" TOTAL_1="32" TOTAL_2="22" VAR="0.048785650623885915" WEIGHT="94.25230026119941"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.698950242431829" CI_START="0.22716655340174224" DF="0" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.568078489308735" LOG_CI_START="-0.6436556110875347" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2012-06-26 19:07:16 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="1.0" P_Z="0.9027049877799957" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="22" WEIGHT="100.0" Z="0.12224500135236188">
<NAME>Cardiovascular cause</NAME>
<DICH_DATA CI_END="3.698950242431829" CI_START="0.22716655340174224" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.568078489308735" LOG_CI_START="-0.6436556110875347" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2011-03-23 13:37:42 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="171" O_E="0.0" SE="0.7117786087533032" STUDY_ID="STD-Simon-1993" TOTAL_1="32" TOTAL_2="22" VAR="0.5066287878787878" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-06-26 19:07:15 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118">
<NAME>Infectious cause</NAME>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2012-06-26 19:03:31 +1000" MODIFIED_BY="Narelle S Willis" ORDER="172" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Hartmann-1997" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2012-06-26 19:04:42 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="51" TOTAL_2="54" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Hospital admissions/year</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.030817748122712457" CI_START="-0.3691822518772875" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.3" MODIFIED="2011-03-23 13:38:02 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="181" SD_1="0.2" SD_2="0.6" SE="0.08631906158060838" STUDY_ID="STD-Locatelli-1996" TOTAL_1="51" TOTAL_2="54" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.057156882187805" CI_END="-8.51113747495686" CI_START="-15.8289139144018" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.17002569467933" ESTIMABLE="YES" I2="68.8612371624363" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2012-07-18 14:41:34 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.006682785496709198" P_Q="1.0" P_Z="7.07106659630469E-11" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="11.610072456327767" TOTALS="YES" TOTAL_1="1029" TOTAL_2="1042" UNITS="mg/L" WEIGHT="100.0" Z="6.519142050835265">
<NAME>Predialysis beta-2 microglobulin</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High -flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.693068297675797" CI_START="-27.306931702324203" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="41.1" MEAN_2="57.1" MODIFIED="2011-03-23 13:38:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="183" SD_1="12.4" SD_2="16.7" SE="5.768948711053794" STUDY_ID="STD-Klemm-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="7.763263966717502"/>
<CONT_DATA CI_END="-8.298673229552254" CI_START="-27.701326770447746" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="55.0" MODIFIED="2011-03-23 13:38:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="184" SD_1="14.0" SD_2="7.0" SE="4.949747468305833" STUDY_ID="STD-Kuchle-1996" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.651031692792698"/>
<CONT_DATA CI_END="-6.189350581790693" CI_START="-23.01064941820931" EFFECT_SIZE="-14.600000000000001" ESTIMABLE="YES" MEAN_1="35.1" MEAN_2="49.7" MODIFIED="2011-03-23 13:38:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="185" SD_1="9.3" SD_2="12.5" SE="4.2912265146459" STUDY_ID="STD-Gardinali-1994" TOTAL_1="10" TOTAL_2="16" WEIGHT="11.607092934473949"/>
<CONT_DATA CI_END="-9.936936266833975" CI_START="-19.26306373316602" EFFECT_SIZE="-14.599999999999998" ESTIMABLE="YES" MEAN_1="28.8" MEAN_2="43.4" MODIFIED="2011-03-23 13:38:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="186" SD_1="14.2" SD_2="9.6" SE="2.379157867158618" STUDY_ID="STD-Locatelli-1996" TOTAL_1="51" TOTAL_2="54" WEIGHT="20.178927522244514"/>
<CONT_DATA CI_END="-6.18683717769052" CI_START="-14.613162822309476" EFFECT_SIZE="-10.399999999999999" ESTIMABLE="YES" MEAN_1="31.6" MEAN_2="42.0" MODIFIED="2011-05-25 05:47:21 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="62" SD_1="5.3" SD_2="9.1" SE="2.1496123681569506" STUDY_ID="STD-Ayli-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="21.471349672120585"/>
<CONT_DATA CI_END="-6.876651317722258" CI_START="-8.923348682277739" EFFECT_SIZE="-7.899999999999999" ESTIMABLE="YES" MEAN_1="33.6" MEAN_2="41.5" MODIFIED="2011-03-23 13:38:09 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="188" SD_1="9.1" SD_2="13.0" SE="0.5221262688242152" STUDY_ID="STD-HEMO-2002" TOTAL_1="921" TOTAL_2="925" WEIGHT="29.32833421165075"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.061353696952608" CI_END="0.019903436855860993" CI_START="-0.02918097188957416" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.004638767516856583" ESTIMABLE="YES" I2="2.976378922419282" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-07-18 14:38:52 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.3567655493315677" P_Q="1.0" P_Z="0.7110424400109827" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="7.249764630486612E-5" TOTALS="YES" TOTAL_1="980" TOTAL_2="988" UNITS="" WEIGHT="99.99999999999999" Z="0.37045642386550043">
<NAME>Equilibrated Kt/V<SUB>urea</SUB>
</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>Low-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>High-flux better</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1064943462815127" CI_START="-1.0464943462815126" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="1.24" MEAN_2="1.21" MODIFIED="2011-06-27 09:52:36 +1000" MODIFIED_BY="Narelle S Willis" ORDER="63" SD_1="2.0" SD_2="1.8" SE="0.549241901776136" STUDY_ID="STD-Ayli-2005" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.05196360483107041"/>
<CONT_DATA CI_END="0.023702699421569898" CI_START="-0.16370269942157" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" MEAN_1="1.26" MEAN_2="1.33" MODIFIED="2011-03-23 13:38:33 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="202" SD_1="0.21" SD_2="0.2" SE="0.047808378195050974" STUDY_ID="STD-Locatelli-2000" TOTAL_1="35" TOTAL_2="39" WEIGHT="6.649080854722714"/>
<CONT_DATA CI_END="0.01915942859334964" CI_START="-0.01915942859334964" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.34" MODIFIED="2011-03-23 13:38:33 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="201" SD_1="0.21" SD_2="0.21" SE="0.00977539829531398" STUDY_ID="STD-HEMO-2002" TOTAL_1="921" TOTAL_2="925" WEIGHT="93.2989555404462"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Dialysis-associated amyloid-related complications</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-06-26 18:55:20 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Carpel tunnel syndrome</NAME>
<DICH_DATA CI_END="0.89921265290551" CI_START="0.0038480415075079558" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.046137590733664136" LOG_CI_START="-2.4147602520228837" LOG_EFFECT_SIZE="-1.2304489213782739" MODIFIED="2011-03-23 13:37:42 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="173" O_E="0.0" SE="1.3913406761125573" STUDY_ID="STD-Kuchle-1996" TOTAL_1="10" TOTAL_2="10" VAR="1.9358288770053478" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-06-26 18:56:24 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Dialysis-associated arthropathy</NAME>
<DICH_DATA CI_END="0.89921265290551" CI_START="0.0038480415075079558" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.046137590733664136" LOG_CI_START="-2.4147602520228837" LOG_EFFECT_SIZE="-1.2304489213782739" MODIFIED="2012-06-26 18:56:24 +1000" MODIFIED_BY="Narelle S Willis" ORDER="174" O_E="0.0" SE="1.3913406761125573" STUDY_ID="STD-Kuchle-1996" TOTAL_1="10" TOTAL_2="10" VAR="1.9358288770053478" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2012-06-26 19:04:42 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Intradialytic hypotension</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.6064398572955" CI_START="0.12568701946272015" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8549520819268552" LOG_CI_START="-0.9007095724875305" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-03-23 13:37:55 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="176" O_E="0.0" SE="1.6186892965481947" STUDY_ID="STD-Locatelli-2000" TOTAL_1="42" TOTAL_2="42" VAR="2.6201550387596897" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2012-06-26 19:04:42 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="51" TOTAL_2="104" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to treatment inadequacy</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.705092067075708" CI_START="0.12548973058537316" EFFECT_SIZE="0.5826330532212886" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.43218205078917277" LOG_CI_START="-0.9013918130880361" LOG_EFFECT_SIZE="-0.23460488114943162" MODIFIED="2011-03-23 13:37:42 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="175" O_E="0.0" SE="0.783347888938563" STUDY_ID="STD-Locatelli-1996" TOTAL_1="51" TOTAL_2="104" VAR="0.6136339151045033" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="29.19999285966482" CI_END="0.020356632738371253" CI_START="-0.13701493243248486" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05832914984705681" ESTIMABLE="YES" I2="41.780807681351135" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="Suetonia Palmer" NO="11" P_CHI2="0.03272596272022932" P_Q="0.6379828727685171" P_Z="0.14624989959917378" Q="2.537224718452774" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.016029337262892848" TOTALS="SUB" TOTAL_1="295" TOTAL_2="325" UNITS="mmol/L" WEIGHT="500.0" Z="1.452905838801977">
<NAME>Lipid profile</NAME>
<GROUP_LABEL_1>High-flux better</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.028637072977686" CI_END="0.269010973169889" CI_START="-0.5866776915223416" DF="3" EFFECT_SIZE="-0.15883335917622632" ESTIMABLE="YES" I2="62.63375747675501" ID="CMP-001.11.01" MODIFIED="2012-06-26 18:48:13 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.045423676459327544" P_Z="0.46684685450365004" STUDIES="4" TAU2="0.11513156117804754" TOTAL_1="60" TOTAL_2="64" WEIGHT="100.0" Z="0.7276189959601429">
<NAME>Total cholesterol</NAME>
<CONT_DATA CI_END="0.5447750411961645" CI_START="-0.8247750411961638" EFFECT_SIZE="-0.13999999999999968" ESTIMABLE="YES" MEAN_1="4.49" MEAN_2="4.63" MODIFIED="2011-03-23 13:38:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="208" SD_1="1.21" SD_2="1.13" SE="0.3493814409844172" STUDY_ID="STD-House-1999" TOTAL_1="22" TOTAL_2="23" WEIGHT="20.08919885630142"/>
<CONT_DATA CI_END="1.26644539825004" CI_START="-0.0664453982500407" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="5.34" MEAN_2="4.74" MODIFIED="2011-03-23 13:38:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="209" SD_1="0.92" SD_2="1.12" SE="0.34002941049268076" STUDY_ID="STD-Ottosson-2001" TOTAL_1="16" TOTAL_2="20" WEIGHT="20.650507847478696"/>
<CONT_DATA CI_END="0.09033282055090508" CI_START="-1.0703328205509055" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" MEAN_1="4.71" MEAN_2="5.2" MODIFIED="2011-03-23 13:38:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="210" SD_1="0.95" SD_2="0.57" SE="0.29609361454011224" STUDY_ID="STD-Blankestijn-1995" TOTAL_1="14" TOTAL_2="14" WEIGHT="23.496384007019014"/>
<CONT_DATA CI_END="-0.1262617895599118" CI_START="-0.6537382104400875" EFFECT_SIZE="-0.3899999999999997" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="4.38" MODIFIED="2011-03-23 13:38:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="211" SD_1="0.26" SD_2="0.26" SE="0.1345627840717591" STUDY_ID="STD-Goldberg-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="35.763909289200875"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5019144731470657" CI_END="0.04951988181970062" CI_START="-0.13831099711376973" DF="3" EFFECT_SIZE="-0.04439555764703456" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" MODIFIED="2012-06-26 18:51:50 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.6818285709717147" P_Z="0.3541804591122468" STUDIES="4" TAU2="0.0" TOTAL_1="73" TOTAL_2="81" WEIGHT="100.0" Z="0.926511067358416">
<NAME>HDL cholesterol</NAME>
<CONT_DATA CI_END="0.6325059601446966" CI_START="-0.41250596014469687" EFFECT_SIZE="0.10999999999999988" ESTIMABLE="YES" MEAN_1="1.13" MEAN_2="1.02" MODIFIED="2012-06-26 18:51:50 +1000" MODIFIED_BY="Narelle S Willis" ORDER="212" SD_1="0.34" SD_2="1.13" SE="0.2665895721891612" STUDY_ID="STD-Ottosson-2001" TOTAL_1="16" TOTAL_2="20" WEIGHT="3.230661771340728"/>
<CONT_DATA CI_END="0.10511733329274295" CI_START="-0.3051173332927427" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.4" MODIFIED="2012-06-26 18:51:50 +1000" MODIFIED_BY="Narelle S Willis" ORDER="213" SD_1="0.3" SD_2="0.4" SE="0.10465362369445672" STUDY_ID="STD-Li-2010" TOTAL_1="21" TOTAL_2="24" WEIGHT="20.963764234229977"/>
<CONT_DATA CI_END="0.23288259013886917" CI_START="-0.1528825901388691" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="1.02" MODIFIED="2012-06-26 18:51:50 +1000" MODIFIED_BY="Narelle S Willis" ORDER="215" SD_1="0.33" SD_2="0.33" SE="0.09841129309533359" STUDY_ID="STD-House-1999" TOTAL_1="22" TOTAL_2="23" WEIGHT="23.70761857711006"/>
<CONT_DATA CI_END="0.060114787025266875" CI_START="-0.20011478702526678" EFFECT_SIZE="-0.06999999999999995" ESTIMABLE="YES" MEAN_1="0.81" MEAN_2="0.88" MODIFIED="2012-06-26 18:51:50 +1000" MODIFIED_BY="Narelle S Willis" ORDER="214" SD_1="0.16" SD_2="0.19" SE="0.0663863152851765" STUDY_ID="STD-Blankestijn-1995" TOTAL_1="14" TOTAL_2="14" WEIGHT="52.09795541731923"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.664537051216466" CI_END="0.31143756642853143" CI_START="-0.1952749348803378" DF="3" EFFECT_SIZE="0.05808131577409681" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.03" MODIFIED="2012-06-26 18:51:55 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.44628758802998836" P_Z="0.6532029501177252" STUDIES="4" TAU2="0.0" TOTAL_1="73" TOTAL_2="81" WEIGHT="100.0" Z="0.4493170655860246">
<NAME>LDL cholesterol</NAME>
<CONT_DATA CI_END="1.081344228387989" CI_START="-0.1013442283879894" EFFECT_SIZE="0.48999999999999977" ESTIMABLE="YES" MEAN_1="3.55" MEAN_2="3.06" MODIFIED="2012-06-26 18:51:55 +1000" MODIFIED_BY="Narelle S Willis" ORDER="217" SD_1="0.82" SD_2="0.99" SE="0.301711782998278" STUDY_ID="STD-Ottosson-2001" TOTAL_1="16" TOTAL_2="20" WEIGHT="18.35618905931109"/>
<CONT_DATA CI_END="0.49832549251659486" CI_START="-0.49832549251659486" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.54" MEAN_2="2.54" MODIFIED="2012-06-26 18:51:55 +1000" MODIFIED_BY="Narelle S Willis" ORDER="216" SD_1="0.9" SD_2="0.8" SE="0.2542523722105726" STUDY_ID="STD-House-1999" TOTAL_1="22" TOTAL_2="23" WEIGHT="25.848600684040317"/>
<CONT_DATA CI_END="0.3716680951495286" CI_START="-0.6116680951495288" EFFECT_SIZE="-0.1200000000000001" ESTIMABLE="YES" MEAN_1="2.87" MEAN_2="2.99" MODIFIED="2012-06-26 18:51:55 +1000" MODIFIED_BY="Narelle S Willis" ORDER="219" SD_1="0.73" SD_2="0.59" SE="0.2508556784858007" STUDY_ID="STD-Blankestijn-1995" TOTAL_1="14" TOTAL_2="14" WEIGHT="26.553342180439547"/>
<CONT_DATA CI_END="0.4685210055174613" CI_START="-0.4685210055174613" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.2" MODIFIED="2012-06-26 18:51:55 +1000" MODIFIED_BY="Narelle S Willis" ORDER="218" SD_1="0.8" SD_2="0.8" SE="0.23904572186687875" STUDY_ID="STD-Li-2010" TOTAL_1="21" TOTAL_2="24" WEIGHT="29.24186807620904"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.145183403706791" CI_END="0.16595112209722707" CI_START="-0.3853248905701335" DF="1" EFFECT_SIZE="-0.10968688423645322" ESTIMABLE="YES" I2="53.38393918804145" ID="CMP-001.11.04" MODIFIED="2012-06-26 18:52:01 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.14301801048562346" P_Z="0.43542355974296054" STUDIES="2" TAU2="0.022447946428571425" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.7799444842145985">
<NAME>VLDL cholesterol</NAME>
<CONT_DATA CI_END="0.04858544978504803" CI_START="-0.628585449785048" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="1.04" MEAN_2="1.33" MODIFIED="2012-06-26 18:52:01 +1000" MODIFIED_BY="Narelle S Willis" ORDER="221" SD_1="0.37" SD_2="0.53" SE="0.17275085279921817" STUDY_ID="STD-Blankestijn-1995" TOTAL_1="14" TOTAL_2="14" WEIGHT="37.82306352981145"/>
<CONT_DATA CI_END="0.1896334790727178" CI_START="-0.1896334790727178" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.66" MEAN_2="0.66" MODIFIED="2012-06-26 18:52:01 +1000" MODIFIED_BY="Narelle S Willis" ORDER="220" SD_1="0.27" SD_2="0.31" SE="0.09675355290634036" STUDY_ID="STD-Ottosson-2001" TOTAL_1="16" TOTAL_2="20" WEIGHT="62.17693647018856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.21903172248578" CI_END="0.05395036220101934" CI_START="-0.48187774266802863" DF="3" EFFECT_SIZE="-0.21396369023350464" ESTIMABLE="YES" I2="51.76097929918768" ID="CMP-001.11.05" MODIFIED="2012-06-26 18:52:32 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.10142683242058048" P_Z="0.11751672914428826" STUDIES="4" TAU2="0.03781025302652418" TOTAL_1="59" TOTAL_2="65" WEIGHT="100.0" Z="1.5652823099282636">
<NAME>Triglycerides</NAME>
<CONT_DATA CI_END="-0.13930366261488236" CI_START="-1.1806963373851174" EFFECT_SIZE="-0.6599999999999999" ESTIMABLE="YES" MEAN_1="1.82" MEAN_2="2.48" MODIFIED="2012-06-26 18:52:32 +1000" MODIFIED_BY="Narelle S Willis" ORDER="223" SD_1="0.59" SD_2="0.8" SE="0.26566627830526673" STUDY_ID="STD-Blankestijn-1995" TOTAL_1="14" TOTAL_2="14" WEIGHT="17.238929709259455"/>
<CONT_DATA CI_END="0.5421570026379258" CI_START="-0.3421570026379256" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.4" MODIFIED="2012-06-26 18:52:32 +1000" MODIFIED_BY="Narelle S Willis" ORDER="222" SD_1="0.8" SD_2="0.7" SE="0.22559445281933937" STUDY_ID="STD-Li-2010" TOTAL_1="21" TOTAL_2="24" WEIGHT="21.064732933069468"/>
<CONT_DATA CI_END="0.3918023793514824" CI_START="-0.4318023793514824" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.42" MEAN_2="1.44" MODIFIED="2012-06-26 18:52:32 +1000" MODIFIED_BY="Narelle S Willis" ORDER="224" SD_1="0.58" SD_2="0.68" SE="0.21010711553871755" STUDY_ID="STD-Ottosson-2001" TOTAL_1="16" TOTAL_2="20" WEIGHT="22.79911606698265"/>
<CONT_DATA CI_END="-0.10179360204702873" CI_START="-0.49820639795297095" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.37" MEAN_2="1.67" MODIFIED="2012-06-26 18:52:32 +1000" MODIFIED_BY="Narelle S Willis" ORDER="225" SD_1="0.19" SD_2="0.2" SE="0.10112757148416902" STUDY_ID="STD-Goldberg-1996" TOTAL_1="8" TOTAL_2="7" WEIGHT="38.89722129068843"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2012-06-26 19:04:42 +1000" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="15" UNITS="mL/min" WEIGHT="0.0" Z="0.0">
<NAME>Residual renal function at end of study period</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>Low-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>High-flux better</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3950814575712953" CI_START="0.8049185424287044" EFFECT_SIZE="1.0999999999999999" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.2" MODIFIED="2011-03-23 13:38:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="226" SD_1="0.5" SD_2="0.3" SE="0.1505545305418162" STUDY_ID="STD-Lang-2001" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2012-06-26 19:04:42 +1000" MODIFIED_BY="Suetonia Palmer" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.2" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="10" TOTAL_2="10" UNITS="mL/min/mo" WEIGHT="0.0" Z="0.0">
<NAME>Average rate of loss of residual renal function</NAME>
<GROUP_LABEL_1>High-flux</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux</GROUP_LABEL_2>
<GRAPH_LABEL_1>High-flux better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Low-flux better</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.08530594461496088" CI_START="-0.17469405538503913" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.5" MODIFIED="2011-03-23 13:38:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="227" SD_1="0.06" SD_2="0.04" SE="0.022803508501982758" STUDY_ID="STD-Hartmann-1997" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-08-09 11:21:15 +1000" MODIFIED_BY="Suetonia Palmer">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-08-09 11:21:15 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3wAAALRCAYAAAAA4aGmAACAAElEQVR42uydDaQWzf//vyRJkkiS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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-07-26 10:59:15 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-07-26 10:59:15 +1000" MODIFIED_BY="Suetonia Palmer" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUcAAAUzCAIAAADZ13L4AABFGklEQVR42u3dv44dx9HG4QUMGA42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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-06-19 20:53:11 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-03-22 11:26:25 +1100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2012-06-19 20:53:11 +1000" MODIFIED_BY="Gail Y Higgins">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor Renal Dialysis explode all trees</LI>
<LI>MeSH descriptor Hemofiltration explode all trees</LI>
<LI>MeSH descriptor Kidney Failure, Chronic, this term only</LI>
<LI>(dialysis*):ti,ab,kw in Clinical Trials</LI>
<LI>(hemodialysis or haemodialysis):ti,ab,kw in Clinical Trials</LI>
<LI>(hemofiltration or haemofiltration):ti,ab,kw in Clinical Trials</LI>
<LI>(hemodiafiltration or haemodiafiltration):ti,ab,kw in Clinical Trials</LI>
<LI>(CAPD or CCPD or APD):ti,ab,kw in Clinical Trials</LI>
<LI>("end-stage kidney" or "end-stage renal" or "endstage kidney" or "endstage renal"):ti,ab,kw in Clinical Trials</LI>
<LI>(ESKD or ESKF or ESRD or ESRF):ti,ab,kw in Clinical Trials</LI>
<LI>(1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10)</LI>
<LI>MeSH descriptor Membranes, Artificial explode all trees</LI>
<LI>MeSH descriptor Kidney, Artificial, this term only</LI>
<LI>(high flux* ):ti,ab,kw or (high-flux*):ti,ab,kw in Clinical Trials</LI>
<LI>(low flux* ):ti,ab,kw or (low-flux*):ti,ab,kw in Clinical Trials</LI>
<LI>(membrane*):ti,ab,kw in Clinical Trials</LI>
<LI>(12 OR 13 OR 14 OR 15 OR 16)</LI>
<LI>(11 AND 17)</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>exp Renal Dialysis/</LI>
<LI>exp Hemofiltration/</LI>
<LI>Kidney Failure, Chronic/</LI>
<LI>dialysis.tw.</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>(CAPD or CCPD or APD).tw.</LI>
<LI>(end-stage kidney or end-stage renal or endstage kidney or endstage renal).tw.</LI>
<LI>(ESKD or ESKF or ESRD or ESRF).tw.</LI>
<LI>or/1-10</LI>
<LI>exp Membranes, Artificial/</LI>
<LI>Kidney, Artificial/</LI>
<LI>high-flux$.tw.</LI>
<LI>low-flux$.tw.</LI>
<LI>membrane$.tw.</LI>
<LI>or/12-16</LI>
<LI>and/11,17</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>exp Renal Replacement Therapy/</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>dialysis.tw.</LI>
<LI>(CAPD or CCPD or APD).tw.</LI>
<LI>Chronic Kidney Disease/</LI>
<LI>Kidney Failure/</LI>
<LI>Chronic Kidney Failure/</LI>
<LI>(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.</LI>
<LI>(ESRF or ESKF or ESRD or ESKD).tw.</LI>
<LI>or/1-11</LI>
<LI>dialysis membrane/</LI>
<LI>artificial kidney/</LI>
<LI>(high flux$ and (dialysis$ or membrane$)).tw.</LI>
<LI>(low flux$ and (dialysis$ or membrane$)).tw.</LI>
<LI>or/13-16</LI>
<LI>and/12,17</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-07-26 11:10:46 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-03-28 17:40:38 +1100" MODIFIED_BY="[Empty name]">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-28 17:40:44 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="4552">
<ADDRESS>
<DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451469</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Emergency and Organ Transplantation</DEPARTMENT>
<ORGANISATION>University of Bari</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Medical Scientific Office</DEPARTMENT>
<ORGANISATION>Diaverum</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_3" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Diaverum Academy</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included in meta-analyses: 16 (3221 participants)&lt;/p&gt;&lt;ul&gt;&lt;li&gt;All-cause mortality: 10 (2915 participants)&lt;/li&gt;&lt;li&gt;Cardiovascular mortality: 5 (2612 participants)&lt;/li&gt;&lt;li&gt;Infection-related mortality: 2 (1900 participants)&lt;/li&gt;&lt;li&gt;Hospitalisation: 2 (74 participants)&lt;/li&gt;&lt;/ul&gt;" WIDTH="380">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 33 (81 reports; 3820 participants)&lt;br&gt;Ongoing studies: 1&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full text records screened: 352&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records screened: 1034&lt;br&gt;(title and abstract)&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;Total number of records: 1985&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;CENTRAL: 824 records&lt;/p&gt;" WIDTH="150"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;CRG Specialised Register: 309 records&lt;/p&gt;" WIDTH="250"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;MEDLINE: 782 records&lt;/p&gt;" WIDTH="150"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;EMBASE: 70 records&lt;/p&gt;" WIDTH="150"/>
<OUT TEXT="&lt;p&gt;Duplicates removed: 951&lt;/p&gt;" WIDTH="200"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded: 682&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Not RCT (review or commentary); wrong population (paediatric); wrong intervention&lt;/li&gt;&lt;/ul&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Studies excluded*: 225 (270 records)&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Not RCT (84); wrong intervention (56); Not ESKD (3); not specified outcome/s (75); duration &amp;lt; 1 month (6); duplicates (80)&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;*One study could have multiple reasons for exclusion&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>